<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Psychiatry</journal-id><journal-id journal-id-type="iso-abbrev">Front Psychiatry</journal-id><journal-id journal-id-type="publisher-id">Front. Psychiatry</journal-id><journal-title-group><journal-title>Frontiers in Psychiatry</journal-title></journal-title-group><issn pub-type="epub">1664-0640</issn><publisher><publisher-name>Frontiers Media S.A.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">24478731</article-id><article-id pub-id-type="pmc">3900858</article-id><article-id pub-id-type="doi">10.3389/fpsyt.2014.00003</article-id><article-categories><subj-group subj-group-type="heading"><subject>Psychiatry</subject><subj-group><subject>Original Research</subject></subj-group></subj-group></article-categories><title-group><article-title>Effects of Nicotine on the Neurophysiological and Behavioral Effects of Ketamine in Humans</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Mathalon</surname><given-names>Daniel H.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="corresp" rid="cor1">*</xref><uri xlink:type="simple" xlink:href="http://frontiersin.org/people/u/5890"/></contrib><contrib contrib-type="author"><name><surname>Ahn</surname><given-names>Kyung-Heup</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff4"><sup>4</sup></xref><xref ref-type="aff" rid="aff5"><sup>5</sup></xref></contrib><contrib contrib-type="author"><name><surname>Perry</surname><given-names>Edward B.</given-names><suffix>Jr.</suffix></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff4"><sup>4</sup></xref><xref ref-type="aff" rid="aff5"><sup>5</sup></xref></contrib><contrib contrib-type="author"><name><surname>Cho</surname><given-names>Hyun-Sang</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff6"><sup>6</sup></xref></contrib><contrib contrib-type="author"><name><surname>Roach</surname><given-names>Brian J.</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><uri xlink:type="simple" xlink:href="http://frontiersin.org/people/u/5895"/></contrib><contrib contrib-type="author"><name><surname>Blais</surname><given-names>Rebecca K.</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Bhakta</surname><given-names>Savita</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><uri xlink:type="simple" xlink:href="http://frontiersin.org/people/u/131583"/></contrib><contrib contrib-type="author"><name><surname>Ranganathan</surname><given-names>Mohini</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Ford</surname><given-names>Judith M.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><uri xlink:type="simple" xlink:href="http://frontiersin.org/people/u/5360"/></contrib><contrib contrib-type="author"><name><surname>D&#x02019;Souza</surname><given-names>Deepak Cyril</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff4"><sup>4</sup></xref><xref ref-type="aff" rid="aff5"><sup>5</sup></xref><uri xlink:type="simple" xlink:href="http://frontiersin.org/people/u/10284"/></contrib></contrib-group><aff id="aff1"><sup>1</sup><institution>Department of Psychiatry, University of California San Francisco</institution>, <addr-line>San Francisco, CA</addr-line>, <country>USA</country></aff><aff id="aff2"><sup>2</sup><institution>Mental Health Service (116D), San Francisco VA Medical Center</institution>, <addr-line>San Francisco, CA</addr-line>, <country>USA</country></aff><aff id="aff3"><sup>3</sup><institution>Department of Psychiatry, Yale University School of Medicine</institution>, <addr-line>New Haven, CT</addr-line>, <country>USA</country></aff><aff id="aff4"><sup>4</sup><institution>Schizophrenia Biological Research Center (116A), VA Connecticut Healthcare System</institution>, <addr-line>West Haven, CT</addr-line>, <country>USA</country></aff><aff id="aff5"><sup>5</sup><institution>Abraham Ribicoff Research Facilities, Connecticut Mental Health Center</institution>, <addr-line>New Haven, CT</addr-line>, <country>USA</country></aff><aff id="aff6"><sup>6</sup><institution>Department of Psychiatry, Yonsei University College of Medicine</institution>, <addr-line>Seoul</addr-line>, <country>South Korea</country></aff><author-notes><fn fn-type="edited-by"><p>Edited by: Andr&#x000e9; Schmidt, University of Basel, Switzerland</p></fn><fn fn-type="edited-by"><p>Reviewed by: Kevin M. Spencer, Harvard Medical School, USA; Verner Knott, University of Ottawa Institute of Mental Health Research, Canada</p></fn><corresp content-type="corresp" id="cor1">*Correspondence: Daniel H. Mathalon, Mental Health Service (116D), San Francisco VA Medical Center, 4150 Clement Street, San Francisco, CA 94121, USA e-mail: <email>daniel.mathalon@ucsf.edu</email></corresp><fn fn-type="other" id="fn001"><p>This article was submitted to Schizophrenia, a section of the journal Frontiers in Psychiatry.</p></fn></author-notes><pub-date pub-type="epreprint"><day>19</day><month>11</month><year>2013</year></pub-date><pub-date pub-type="epub"><day>24</day><month>1</month><year>2014</year></pub-date><pub-date pub-type="collection"><year>2014</year></pub-date><volume>5</volume><elocation-id>3</elocation-id><history><date date-type="received"><day>25</day><month>10</month><year>2013</year></date><date date-type="accepted"><day>07</day><month>1</month><year>2014</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2014 Mathalon, Ahn, Perry Jr, Cho, Roach, Blais, Bhakta, Ranganathan, Ford and D&#x02019;Souza.</copyright-statement><copyright-year>2014</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/3.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><abstract><p><bold>Background:</bold>
<italic>N</italic>-methyl-<sc>d</sc>-aspartate (NMDA) receptor hypofunction has been implicated in the pathophysiology of schizophrenia and its associated neurocognitive impairments. The high rate of cigarette smoking in schizophrenia raises questions about how nicotine modulates putative NMDA receptor hypofunction in the illness. Accordingly, we examined the modulatory effects of brain nicotinic acetylcholine receptor (nAChR) stimulation on NMDA receptor hypofunction by examining the interactive effects of nicotine, a nAChR agonist, and ketamine, a non-competitive NMDA receptor antagonist, on behavioral and neurophysiological measures in healthy human volunteers.</p><p><bold>Methods:</bold> From an initial sample of 17 subjects (age range 18&#x02013;55&#x02009;years), 8 subjects successfully completed 4 test sessions, each separated by at least 3&#x02009;days, during which they received ketamine or placebo and two injections of nicotine or placebo in a double-blind, counterbalanced manner. Schizophrenia-like effects Positive and Negative Syndrome Scale, perceptual alterations Clinician Administered Dissociative Symptoms Scale, subjective effects Visual Analog Scale and auditory event-related brain potentials (mismatch negativity, MMN; P300) were assessed during each test session.</p><p><bold>Results:</bold> Consistent with existing studies, ketamine induced transient schizophrenia-like behavioral effects. P300 was reduced and delayed by ketamine regardless of whether it was elicited by a target (P3b) or novel (P3a) stimulus, while nicotine only reduced the amplitude of P3a. Nicotine did not rescue P300 from the effects of ketamine; the interactions of ketamine and nicotine were not significant. While nicotine significantly reduced MMN amplitude, ketamine did not.</p><p><bold>Conclusion:</bold> Nicotine failed to modulate ketamine-induced neurophysiological and behavioral effects in this preliminary study. Interestingly, ketamine reduced P3b amplitude and nicotine reduced P3a amplitude, suggesting independent roles of NMDA receptor and nAChR in the generation of P3b and P3a, respectively.</p></abstract><kwd-group><kwd>schizophrenia</kwd><kwd>nicotine</kwd><kwd>ketamine</kwd><kwd><italic>N</italic>-methyl-<sc>d</sc>-aspartate receptor</kwd><kwd>nicotinic acetylcholine receptor</kwd><kwd>event-related potential</kwd><kwd>mismatch negativity</kwd><kwd>P300</kwd></kwd-group><counts><fig-count count="4"/><table-count count="8"/><equation-count count="0"/><ref-count count="141"/><page-count count="16"/><word-count count="12118"/></counts></article-meta></front><body><sec id="S1"><title>Introduction</title><p>Several lines of evidence support a glutamatergic hypothesis of schizophrenia involving <italic>N</italic>-methyl-<sc>d</sc>-aspartate (NMDA) receptor hypofunction (<xref ref-type="bibr" rid="B1">1</xref>&#x02013;<xref ref-type="bibr" rid="B7">7</xref>). Studies with the NMDA receptor antagonist, ketamine, in healthy human subjects have been a cornerstone of the glutamatergic hypothesis of schizophrenia, producing clinical symptoms and cognitive impairments similar to those observed in schizophrenia (<xref ref-type="bibr" rid="B4">4</xref>, <xref ref-type="bibr" rid="B5">5</xref>, <xref ref-type="bibr" rid="B7">7</xref>&#x02013;<xref ref-type="bibr" rid="B13">13</xref>). Nicotine has been shown to have cognitive enhancing effects in some (<xref ref-type="bibr" rid="B14">14</xref>&#x02013;<xref ref-type="bibr" rid="B16">16</xref>), although not all (<xref ref-type="bibr" rid="B17">17</xref>, <xref ref-type="bibr" rid="B18">18</xref>), studies. It has been suggested that the high rate of cigarette smoking in schizophrenia patients may reflect their efforts to use nicotine to &#x0201c;self-medicate&#x0201d; (<xref ref-type="bibr" rid="B19">19</xref>&#x02013;<xref ref-type="bibr" rid="B21">21</xref>). In the present, exploratory study, we examined the interactive effects of ketamine and nicotine in healthy volunteers in order to determine whether impairments in brain function mediated by NMDA receptor hypofunction can be ameliorated by nicotine.</p><sec id="S1-1"><title>Parallel effects of ketamine and schizophrenia on clinical, cognitive, and neurophysiological function</title><p>When administered at subanesthetic doses, ketamine produces an array of transient effects in healthy humans that resemble the positive and negative symptoms and cognitive deficits of schizophrenia (<xref ref-type="bibr" rid="B4">4</xref>, <xref ref-type="bibr" rid="B7">7</xref>&#x02013;<xref ref-type="bibr" rid="B13">13</xref>, <xref ref-type="bibr" rid="B22">22</xref>&#x02013;<xref ref-type="bibr" rid="B26">26</xref>). Ketamine has also been shown to produce some of the event-related brain potential (ERP) abnormalities observed in schizophrenia including reductions of two ERP components associated with controlled and automatic processing of deviant stimuli, P300 and mismatch negativity (MMN), as described below.</p><p>P300 is a positive voltage ERP component occurring about 300&#x02009;ms following infrequent deviant stimuli interspersed among frequent &#x0201c;standard&#x0201d; stimuli, typically elicited in auditory or visual &#x0201c;oddball&#x0201d; tasks (<xref ref-type="bibr" rid="B27">27</xref>). P300 has been posited to reflect allocation of attentional resources (<xref ref-type="bibr" rid="B28">28</xref>&#x02013;<xref ref-type="bibr" rid="B30">30</xref>), stimulus categorization (<xref ref-type="bibr" rid="B31">31</xref>), and contextual updating of working memory (<xref ref-type="bibr" rid="B32">32</xref>). Multiple brain regions have been implicated as neural generators of the P300, including the temporo-parietal junction and prefrontal cortex (<xref ref-type="bibr" rid="B33">33</xref>, <xref ref-type="bibr" rid="B34">34</xref>). P300 comprises two subcomponents, the P3b and P3a that are differentially present depending on task conditions (<xref ref-type="bibr" rid="B27">27</xref>, <xref ref-type="bibr" rid="B35">35</xref>&#x02013;<xref ref-type="bibr" rid="B38">38</xref>). The P3b is primarily elicited by infrequent target stimuli, reflects top-down allocation of attention, and has a parietal scalp maximum (<xref ref-type="bibr" rid="B27">27</xref>, <xref ref-type="bibr" rid="B36">36</xref>, <xref ref-type="bibr" rid="B37">37</xref>). The P3a is primarily elicited by an infrequent non-target distractor or novel stimuli in an oddball sequence, reflects bottom-up orienting of attention, and has a fronto-central scalp maximum (<xref ref-type="bibr" rid="B27">27</xref>, <xref ref-type="bibr" rid="B38">38</xref>&#x02013;<xref ref-type="bibr" rid="B41">41</xref>).</p><p>P300 amplitude reduction, particularly auditory P3b, is one of the most widely replicated brain abnormalities observed in patients with schizophrenia (<xref ref-type="bibr" rid="B42">42</xref>, <xref ref-type="bibr" rid="B43">43</xref>), although it is also reduced in a number of other psychiatric and neurological disorders (<xref ref-type="bibr" rid="B44">44</xref>, <xref ref-type="bibr" rid="B45">45</xref>). Furthermore, several studies have shown that ketamine reduces P300 amplitude in healthy volunteers (<xref ref-type="bibr" rid="B46">46</xref>&#x02013;<xref ref-type="bibr" rid="B51">51</xref>), consistent with the possibility that NMDA receptor hypofunction contributes to P300 amplitude reduction in schizophrenia. Interestingly, in the Knott et al. (<xref ref-type="bibr" rid="B47">47</xref>) study, the reduction of P300 amplitude by ketamine was only evident in the subgroup of non-smokers, consistent with a possible protective effect of nicotine.</p><p>Mismatch negativity is a negative ERP component elicited automatically by infrequent deviant auditory stimuli randomly interspersed among frequent &#x0201c;standard&#x0201d; stimuli (<xref ref-type="bibr" rid="B52">52</xref>, <xref ref-type="bibr" rid="B53">53</xref>). MMN has been widely interpreted to reflect auditory sensory echoic memory because the detection of deviance requires an online representation of what has recently been &#x0201c;standard&#x0201d; in the auditory stream (<xref ref-type="bibr" rid="B52">52</xref>). More recently, interpretations of the MMN have emphasized its reflection of both short-term (seconds) and long-term (minutes to hours) synaptic plasticity in the service of auditory sensory/perceptual learning since the amplitude of the MMN to a deviant stimulus increases as a function of the number of repetitions of the preceding standard stimulus (<xref ref-type="bibr" rid="B54">54</xref>, <xref ref-type="bibr" rid="B55">55</xref>). From this perspective, memory traces of the recent auditory past code predictions of future auditory events, with the MMN signaling a prediction error, when the auditory expectancy is violated by a deviant stimulus (<xref ref-type="bibr" rid="B54">54</xref>&#x02013;<xref ref-type="bibr" rid="B56">56</xref>). Auditory deviance along a number of dimensions elicits MMN, including pitch, duration, intensity, and location, among others (<xref ref-type="bibr" rid="B52">52</xref>, <xref ref-type="bibr" rid="B57">57</xref>). MMN generators have been localized to the auditory cortex and to the frontal lobes (<xref ref-type="bibr" rid="B52">52</xref>). MMN is considered to be largely pre-attentive (<xref ref-type="bibr" rid="B52">52</xref>), and it is typically elicited while subjects perform a distractor task.</p><p>Mismatch negativity has been shown to be reduced in schizophrenia, particularly the duration-deviant MMN (<xref ref-type="bibr" rid="B58">58</xref>&#x02013;<xref ref-type="bibr" rid="B60">60</xref>). Moreover, MMN abnormalities, relative to P300 abnormalities, appear to be more specific to schizophrenia (<xref ref-type="bibr" rid="B61">61</xref>, <xref ref-type="bibr" rid="B62">62</xref>). Non-competitive NMDA receptor antagonism by phencyclidine (PCP) and ketamine has been shown to reduce MMN in non-human primates (<xref ref-type="bibr" rid="B63">63</xref>, <xref ref-type="bibr" rid="B64">64</xref>) and healthy volunteers (<xref ref-type="bibr" rid="B26">26</xref>, <xref ref-type="bibr" rid="B46">46</xref>, <xref ref-type="bibr" rid="B65">65</xref>&#x02013;<xref ref-type="bibr" rid="B68">68</xref>), respectively. However, some studies failed to find an effect of ketamine on MMN (<xref ref-type="bibr" rid="B50">50</xref>) or showed the effect to depend on the type of auditory deviance or the underlying cortical source examined (<xref ref-type="bibr" rid="B65">65</xref>, <xref ref-type="bibr" rid="B67">67</xref>). Recently, Knott and colleagues (<xref ref-type="bibr" rid="B66">66</xref>) reported that reduction of MMN with ketamine was only seen in people with a predisposition to experience auditory hallucinations and delusions. Moreover, this effect was blocked when these subjects were chewing nicotine gum, consistent with a possible protective effect of nicotine (<xref ref-type="bibr" rid="B66">66</xref>).</p></sec><sec id="S1-2"><title>Effects of nicotine on neurocognitive and neurophysiological function</title><p>Nicotine has been shown to enhance cognitive functions including attention, episodic memory, and working memory in humans in some (<xref ref-type="bibr" rid="B14">14</xref>&#x02013;<xref ref-type="bibr" rid="B16">16</xref>, <xref ref-type="bibr" rid="B69">69</xref>, <xref ref-type="bibr" rid="B70">70</xref>), but not all (<xref ref-type="bibr" rid="B17">17</xref>, <xref ref-type="bibr" rid="B18">18</xref>), studies. The effects of nicotine administration or smoking on neurophysiological measures related to processing of deviant stimuli have been examined in a number of studies (<xref ref-type="bibr" rid="B71">71</xref>, <xref ref-type="bibr" rid="B72">72</xref>). In experienced tobacco users, cigarette smoking or nicotine administration has been shown to increase P300 amplitude (<xref ref-type="bibr" rid="B73">73</xref>&#x02013;<xref ref-type="bibr" rid="B75">75</xref>), especially in non-smokers (<xref ref-type="bibr" rid="B47">47</xref>), and/or to reduce P300 latency (<xref ref-type="bibr" rid="B74">74</xref>, <xref ref-type="bibr" rid="B76">76</xref>, <xref ref-type="bibr" rid="B77">77</xref>). However, some studies have failed to show such effects (<xref ref-type="bibr" rid="B78">78</xref>&#x02013;<xref ref-type="bibr" rid="B81">81</xref>) or have found effects on visual, but not auditory, P300 (<xref ref-type="bibr" rid="B77">77</xref>). In addition, some studies (<xref ref-type="bibr" rid="B75">75</xref>, <xref ref-type="bibr" rid="B82">82</xref>, <xref ref-type="bibr" rid="B83">83</xref>), but not others (<xref ref-type="bibr" rid="B84">84</xref>), have shown reduced P300 amplitudes in chronic smokers, suggesting a distinction between the effects of acute and chronic exposure to nicotine. Indeed, Knott and colleagues reported that the enhancement of P300 produced by nicotine administration was only evident in non-smokers (<xref ref-type="bibr" rid="B47">47</xref>).</p><p>Regarding MMN, some studies have reported that nicotine or nicotinic agonists increase MMN amplitude (<xref ref-type="bibr" rid="B85">85</xref>&#x02013;<xref ref-type="bibr" rid="B88">88</xref>) or shorten MMN latency (<xref ref-type="bibr" rid="B86">86</xref>, <xref ref-type="bibr" rid="B89">89</xref>, <xref ref-type="bibr" rid="B90">90</xref>), whereas others have failed to show such amplitude increases (<xref ref-type="bibr" rid="B89">89</xref>&#x02013;<xref ref-type="bibr" rid="B91">91</xref>) or latency reductions (<xref ref-type="bibr" rid="B66">66</xref>, <xref ref-type="bibr" rid="B88">88</xref>, <xref ref-type="bibr" rid="B91">91</xref>) with nicotine administration.</p></sec><sec id="S1-3"><title>Nicotine and schizophrenia</title><p>There is a high prevalence of cigarette smoking among patients with schizophrenia (<xref ref-type="bibr" rid="B92">92</xref>&#x02013;<xref ref-type="bibr" rid="B95">95</xref>). This may reflect an effort by schizophrenia patients to &#x0201c;self-medicate&#x0201d; clinical symptoms and a number of neurocognitive impairments including deficits in attention and memory (<xref ref-type="bibr" rid="B19">19</xref>) and deficient sensory gating (<xref ref-type="bibr" rid="B96">96</xref>). Thus, there is significant interest in developing nicotinic acetylcholine receptor (nAChR) agonists to target the neurocognitive symptoms of schizophrenia. Indeed, an alpha7 nicotinic agonist, 3-[(2,4-dimethoxy) benzylidene] Anabaseine (DMXAB) has been shown to produce significant improvements in cognitive function and P50 sensory gating in patients with schizophrenia (<xref ref-type="bibr" rid="B97">97</xref>).</p><p>Several studies have examined the effects of nicotine administration on MMN in patients with schizophrenia. Regarding MMN amplitude, a study of schizophrenic smokers showed that nicotine increases the amplitude and the latency of duration-deviant MMN, but shows no effect on frequency-deviant MMN (<xref ref-type="bibr" rid="B98">98</xref>). An earlier study from the same group examined the effects of nicotine on a mixed sample of smoking and non-smoking schizophrenia patients with high levels of auditory hallucinations and found no effects on MMN amplitudes in response to duration, frequency, and intensity deviants, although the latency of the intensity-deviant MMN was shortened by nicotine (<xref ref-type="bibr" rid="B99">99</xref>). Another study of non-smoking schizophrenia patients failed to show any effect of nicotine on a frequency-deviant MMN (<xref ref-type="bibr" rid="B90">90</xref>).</p></sec><sec id="S1-4"><title>Nicotinic receptor modulation of glutamatergic neurotransmission</title><p>One possible mechanism by which nAChR agonists might enhance neurocognitive and neurophysiological function is facilitating glutamatergic neurotransmission via presynaptic nAChR (<xref ref-type="bibr" rid="B100">100</xref>) or via GABA interneurons (<xref ref-type="bibr" rid="B101">101</xref>, <xref ref-type="bibr" rid="B102">102</xref>). Nicotine or nAChR agonists have been shown to facilitate glutamatergic transmission in rat prefrontal cortex (<xref ref-type="bibr" rid="B103">103</xref>, <xref ref-type="bibr" rid="B104">104</xref>) and hippocampus (<xref ref-type="bibr" rid="B105">105</xref>). Specifically relevant to this study, nicotine attenuates or reverses memory and attentional deficits induced by the NMDA receptor antagonist MK-801 (dizocilpine) in rats (<xref ref-type="bibr" rid="B106">106</xref>, <xref ref-type="bibr" rid="B107">107</xref>). Moreover, dizocilpine blocked nicotinic enhancement of memory consolidation in mice (<xref ref-type="bibr" rid="B108">108</xref>). Knott et al. (<xref ref-type="bibr" rid="B47">47</xref>) examined the effects of nicotine and a sub-perceptual dose of ketamine on P300 in men and women, smokers and non-smokers. In non-smokers, ketamine reduced P300, an effect that did not interact with nicotine. However, in the third assessment block, following the drug infusion, nicotine increased P300 amplitude on its own but further reduced P300 when combined with ketamine. In a subsequent study, Knott and colleagues (<xref ref-type="bibr" rid="B66">66</xref>) found that ketamine reduces the amplitude of MMN in healthy individuals with a high propensity toward hallucinatory experiences and/or delusional thinking, an effect that was blocked by nicotine. Similar effects were not evident in individuals with a low propensity toward these psychotic symptoms.</p></sec><sec id="S1-5"><title>The rationale and hypotheses for current study</title><p>It is difficult to isolate and study the NMDA receptor hypofunction and its consequences in schizophrenia. The ketamine paradigm in healthy subjects offers a pharmacological model for investigating nicotine&#x02019;s effect on putative NMDA receptor hypofunction in schizophrenia. Specifically, this study examined the effects of nAChR activation on NMDA receptor hypofunction by investigating the interactions of ketamine, a non-competitive NMDA receptor antagonist, and nicotine, a nAChR agonist, when administered to healthy volunteers in a placebo-controlled study over four test days. The neurophysiological outcome measures, chosen based on their established sensitivity to schizophrenia, consisted of: (1) two variants of the auditory P300, the P3b elicited by target stimuli and the P3a elicited by novel distractor stimuli, and (2) the MMN elicited automatically by a duration-deviant auditory stimulus. The primary and secondary hypotheses were that nicotine would attenuate the neurophysiological abnormalities and schizophrenia-like clinical symptoms induced by ketamine, respectively.</p></sec></sec><sec sec-type="materials|methods" id="S2"><title>Materials and Methods</title><sec id="S2-6"><title>Research participants</title><p>The study was approved by the Institutional Review Boards of VA Connecticut Healthcare System (West Haven, CT, USA) and Yale University School of Medicine (New Haven, CT, USA). Subjects were recruited via public advertisements and were paid for their study participation. Written informed consent was obtained from all subjects. Smokers who were not interested in quitting and lifetime non-smokers who had tried nicotine in the past were both invited to participate. Subjects were medically healthy by physical examination, history, electrocardiography, and laboratory testing. They had no history of a DSM-IV Axis-I disorder (other than nicotine dependence), major current or recent (&#x0003c;6&#x02009;weeks) life stressors, and first-degree relative with a history of psychosis. Screening procedures included the Structured Clinical Interview for DSM-IV, Non-Patient Edition (<xref ref-type="bibr" rid="B109">109</xref>), selected sub-tests from the Wechsler Adult Intelligence Scale (Information, Vocabulary, Block Design, Picture Completion) to provide an estimate of general level of cognitive ability (<xref ref-type="bibr" rid="B110">110</xref>), and the Fagerstr&#x000f6;m Test for Nicotine Dependence (<xref ref-type="bibr" rid="B111">111</xref>) to measure the severity of nicotine dependence in smokers. Subjects were instructed to refrain from consuming psychoactive substances from 1&#x02009;week prior to testing through completion of the study. An outside informant identified by the subject was interviewed to corroborate information provided by potential subjects. Urine toxicology testing was performed at screening and on the morning of each test day to rule out recent illicit substance use. Subjects were instructed to fast overnight and abstain from smoking after 11:00 p.m. prior to arrival for each test day. They were excluded if breath carbon monoxide levels were higher than 10&#x02009;ppm.</p><p>Seventeen subjects participated in at least one test day. Eight of the 17 subjects scheduled for four test days did not complete testing: 3 of 5 (60%) non-smokers and 5 of 12 (42%) smokers. The reasons for discontinuation were mostly related to adverse effects of ketamine or nicotine (<italic>n</italic>&#x02009;=&#x02009;6). Adverse events and study discontinuations were reported to the VA Connecticut Human Studies Subcommittee. As with all of our prior ketamine studies, clinical follow-ups indicated that all adverse events associated with acute ketamine administration resolved spontaneously without any late appearing or persistent adverse effects. There were no significant differences in age, sex, education, smoking status, or Fagerstr&#x000f6;m Nicotine Dependence scores between study completers and non-completers. Only nine subjects completed all four test days. Demographic data for these nine completers are presented in Table <xref ref-type="table" rid="T1">1</xref>. Of the nine completers (five men, four women), one woman was excluded from the ERP analyses because she was too somnolent and impaired to perform the oddball task or the MMN distractor task during the Ketamine Alone test day. In addition, one man was dropped from the ERP MMN analysis because of technical problems running the MMN paradigm during his Nicotine Alone test day.</p><table-wrap id="T1" position="float"><label>Table 1</label><caption><p><bold>Demographic data for study completers (<italic>N</italic>&#x02009;=&#x02009;9)</bold>.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Variable</th><th align="left" rowspan="1" colspan="1">Number of subjects</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Gender (male/female)</td><td align="left" rowspan="1" colspan="1">5/4</td></tr><tr><td align="left" rowspan="1" colspan="1">Smoking status (smoker/non-smoker)</td><td align="left" rowspan="1" colspan="1">7/2</td></tr><tr><td colspan="2" align="left" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><bold>Mean (SD)</bold></td></tr><tr><td colspan="2" align="left" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1">Age (years)</td><td align="left" rowspan="1" colspan="1">29.8 (7.9)</td></tr><tr><td align="left" rowspan="1" colspan="1">Education (years)</td><td align="left" rowspan="1" colspan="1">16.8 (3.0)</td></tr><tr><td align="left" rowspan="1" colspan="1">Fagerstr&#x000f6;m nicotine dependence score</td><td align="left" rowspan="1" colspan="1">1.78 (2.28)</td></tr></tbody></table></table-wrap></sec><sec id="S2-7"><title>Test days</title><p>Across the four test days, subjects received ketamine and nicotine in a double-blind, randomized, 2&#x02009;&#x000d7;&#x02009;2 crossover design. On each test day, subjects received ketamine (a bolus of 0.26&#x02009;mg/kg over 1&#x02009;min, followed by maintenance infusion at 0.65&#x02009;mg/kg/h&#x02009;&#x000d7;&#x02009;2&#x02009;h) or placebo (normal saline). Fifteen minutes after the ketamine bolus, subjects received an intravenous infusion of nicotine (1.0&#x02009;&#x003bc;g/kg/min&#x02009;&#x000d7;&#x02009;10&#x02009;min) or placebo followed by another nicotine or placebo injection 70&#x02009;min later. The reason for two spaced nicotine injections was to attempt to minimize the possibility of desensitization that is known to occur with nicotine exposure. The dose of nicotine administered with each infusion (1.0&#x02009;&#x003bc;g/kg/min&#x02009;&#x000d7;&#x02009;10&#x02009;min)&#x02009;=&#x02009;0.7&#x02009;mg in a 70-kg individual. A regular cigarette contains about 1.2&#x02013;1.4&#x02009;mg nicotine and an average of 0.88&#x02009;mg of nicotine is delivered to a smoker from each cigarette. The timing of procedures is detailed in Table <xref ref-type="table" rid="T2">2</xref>. Behavioral ratings were obtained at baseline and repeated periodically after the administration of ketamine and nicotine, but ERP data were collected only once per test day. Plasma ketamine and nicotine levels were measured after each infusion to rule out any pharmacokinetic interactions.</p><table-wrap id="T2" position="float"><label>Table 2</label><caption><p><bold>Study procedures</bold>.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Time (minutes)</th><th align="left" rowspan="1" colspan="1">Procedure</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">&#x02212;110</td><td align="left" rowspan="1" colspan="1">IV lines and EEG leads placed, PANSS, CADSS, VAS, VS, plasma cotinine level, breath carbon monoxide, urine toxicology, training for AX-CPT</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02212;20</td><td align="left" rowspan="1" colspan="1">Ketamine or placebo bolus plus infusion</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02212;19</td><td align="left" rowspan="1" colspan="1">VS, PANSS, CADSS, VAS</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02212;5</td><td align="left" rowspan="1" colspan="1">VS</td></tr><tr><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">Nicotine or placebo</td></tr><tr><td align="left" rowspan="1" colspan="1">+3</td><td align="left" rowspan="1" colspan="1">VS</td></tr><tr><td align="left" rowspan="1" colspan="1">+5</td><td align="left" rowspan="1" colspan="1">AX-CPT, ERP recording for MMN, periodic VS</td></tr><tr><td align="left" rowspan="1" colspan="1">+35</td><td align="left" rowspan="1" colspan="1">Plasma ketamine and nicotine levels, VS, PANSS, CADSS, VAS</td></tr><tr><td align="left" rowspan="1" colspan="1">+58</td><td align="left" rowspan="1" colspan="1">VS</td></tr><tr><td align="left" rowspan="1" colspan="1">+60</td><td align="left" rowspan="1" colspan="1">Nicotine or placebo</td></tr><tr><td align="left" rowspan="1" colspan="1">+63</td><td align="left" rowspan="1" colspan="1">VS</td></tr><tr><td align="left" rowspan="1" colspan="1">+65</td><td align="left" rowspan="1" colspan="1">ERP recording for P300, periodic VS</td></tr><tr><td align="left" rowspan="1" colspan="1">+98</td><td align="left" rowspan="1" colspan="1">Plasma ketamine and nicotine levels</td></tr><tr><td align="left" rowspan="1" colspan="1">+100</td><td align="left" rowspan="1" colspan="1">VS</td></tr><tr><td align="left" rowspan="1" colspan="1">+110</td><td align="left" rowspan="1" colspan="1">PANSS, CADSS, VAS, VS</td></tr><tr><td align="left" rowspan="1" colspan="1">+180</td><td align="left" rowspan="1" colspan="1">PANSS, CADSS, VAS, VS</td></tr><tr><td align="left" rowspan="1" colspan="1">+240</td><td align="left" rowspan="1" colspan="1">VS, discharge</td></tr></tbody></table><table-wrap-foot><p><italic>PANSS, Positive and Negative Syndrome Scale; CADSS, Clinician Administered Dissociative Symptoms Scale; VAS, Visual Analog Scale; VS, vital signs; MMN, mismatch negativity; AX-CPT, AX-Continuous Performance Test</italic>.</p></table-wrap-foot></table-wrap></sec><sec id="S2-8"><title>Behavioral measures</title><p>The schizophrenia-like clinical symptoms induced by ketamine were assessed using the Positive and Negative Syndrome Scale (PANSS) (<xref ref-type="bibr" rid="B112">112</xref>). Perceptual alterations were assessed using the Clinician Administered Dissociative Symptoms Scale (CADSS) (<xref ref-type="bibr" rid="B113">113</xref>). The following subjective states were rated by participants using 100-mm Visual Analog Scales (VASs) (<xref ref-type="bibr" rid="B10">10</xref>): Talkative, Happy, Drowsy, Tense, Dad, Calm, Depressed, Anxious, Energetic, Fearful, Mellow, High, Angry, Mania, Irritable, Tired, Hungry, and Craving.</p></sec><sec id="S2-9"><title>Analysis of nicotine and ketamine levels</title><p>Plasma ketamine and norketamine were assayed using the identical method as described in detail elsewhere (<xref ref-type="bibr" rid="B114">114</xref>). Plasma nicotine concentrations were assayed using reversed-phase high-performance liquid chromatography (HPLC) based on a modification of a previously described method (<xref ref-type="bibr" rid="B115">115</xref>, <xref ref-type="bibr" rid="B116">116</xref>). The nicotine assay involved HPLC/MS operated in the APCI/SIM mode using deuterated nicotine as an internal standard. After addition of the internal standard the plasma is deproteinized with sulfosalicylic acid and the supernatant made alkaline and extracted with heptane methylene chloride 85:15. This solvent is then dried down via vacuum centrifuge. The residue is redissolved in ethanol and an aliquot is injected into the HPLC. The HPLC column (Nova Pak C18 30&#x02009;cm&#x02009;&#x000d7;&#x02009;3.9&#x02009;mm, 4&#x02009;&#x003bc;m) is run in the isocratic mode using methanol acetonitrile ammonium formate (pH 4.0) 32.5:42.5:35.0 as mobile phase. The standard curve encompassing a range of 1&#x02013;200&#x02009;ng/ml was linear with negligible intercept. Plasma controls containing 4, 40, and 80&#x02009;ng/ml nicotine in six consecutive runs demonstrated an inter-assay relative standard deviation RSD of 8.6, 7.4, and 8.3%, respectively.</p></sec><sec id="S2-10"><title>ERP measures</title><p>Electroencephalography (EEG) data were recorded using a 23-channel Physiometrix electrode cap. The cap included one ground electrode placed on the forehead (FPz), and the mean of freely placed bilateral earlobe electrodes served as the reference channel. Vertical and horizontal electro-oculograms (VEOGs and HEOGs) were recorded and used to correct EEG data for eye blink and eye-movement artifacts. Electrode impedances were maintained at &#x0003c;5&#x02009;k&#x003a9;. The data were recorded using Neuroscan Synamps amplifiers, which were calibrated prior to each session. Data were acquired using a 0.05&#x02013;100-Hz band pass filter, and the sampling rate was 1000&#x02009;Hz.</p><p>P300 was elicited during an auditory oddball target detection task. Three types of stimuli were delivered through Etymotic ER-3A insert earphones: (1) standard tones: 500&#x02009;Hz pure tones (rise/fall 5&#x02009;ms; 50&#x02009;ms duration), (2) target tones: 1000&#x02009;Hz pure tones (rise/fall 5&#x02009;ms; 50&#x02009;ms duration), and (3) novel distractor sounds, selected from a corpus of novel sounds (average duration of 250&#x02009;ms) developed by Friedman et al. (<xref ref-type="bibr" rid="B117">117</xref>). All auditory stimuli were presented at an identical sound pressure level (~80&#x02009;dB SPL C scale). The task was presented in three blocks. Each block comprised of 150 pseudo-randomized stimuli (80% standards, 10% targets, 10% novel distractors) presented with a stimulus onset asynchrony (SOA) of 1250&#x02009;ms. Subjects were instructed to press a response button with the index finger of their dominant hand each time a target tone occurred, giving equal emphasis to speed and accuracy.</p><p>For the MMN paradigm, subjects were presented with a pseudorandom sequence of standard tones (90% probability; 633&#x02009;Hz; 5&#x02009;ms rise/fall time; 50&#x02009;ms duration) and duration-deviant tones (10% probability; 633&#x02009;Hz, 5&#x02009;ms rise/fall time, 100&#x02009;ms duration) presented at 80&#x02009;dB SPL, with a 510-ms SOA. A long duration-deviant MMN paradigm was chosen because of some evidence that it may more sensitive to the effect of schizophrenia than other types of MMN (<xref ref-type="bibr" rid="B58">58</xref>, <xref ref-type="bibr" rid="B60">60</xref>, <xref ref-type="bibr" rid="B61">61</xref>). The MMN paradigm was presented in two blocks, with each block comprising 783 standard tones and 87 deviant tones. These tones were presented binaurally through earphone inserts, while subjects performed a visual AX-Continuous Performance Task (AX-CPT) (<xref ref-type="bibr" rid="B118">118</xref>). Because several of the behavioral performance files from this task were irretrievably corrupted resulting in many subjects with missing behavioral performance data, the AX-CPT performance data were not analyzed in the current study. Thus, the AX-CPT essentially served as the distractor task during MMN recording.</p></sec><sec id="S2-11"><title>ERP data processing</title><p>As the MMN and P300 measures generally achieve their maximum amplitudes along the midline and do not typically show hemispheric lateralization, EEG data from the midline fronto-central sites (Fz, Cz) and fronto-central-parietal sites (Fz, Cz, Pz) were analyzed for the MMN and P300 components, respectively. The processing pipeline for the P300 elicited during the three-stimulus auditory oddball task involved the following steps: continuous data were separated into 1000&#x02009;ms epochs time-locked to stimulus onset, with a 100-ms pre-stimulus baseline. VEOG and HEOG data were used to correct EEG for eye-movements and blinks with a regression-based algorithm (<xref ref-type="bibr" rid="B119">119</xref>). After baseline correction, epochs containing artifacts (voltages exceeding &#x000b1;100&#x02009;&#x003bc;V) were rejected. P300 was identified as the most positive peak in a 235- to 400-ms time window following stimulus onset; however, because target P3b and novelty P3a have different topographies, different rules were used for identifying their peaks. The target P3b peak was first identified at Pz, then a 50-ms window (&#x000b1;25&#x02009;ms) surrounding this peak&#x02019;s latency was used to identify target P3b peaks at other sites. Novelty P3a showed more scalp variability in peak latency than target P3b, particularly at frontal sites, leading us to adopt a more flexible peak identification approach. Novelty P3a peaks were first identified at all central and parietal sites. From the range of peak latencies obtained at central sites (C3, Cz, C4), minimum and maximum latencies were identified. By subtracting 50&#x02009;ms from the minimum and adding 50&#x02009;ms to the maximum, the search window for identification of P3a peaks at frontal sites was defined. Somewhat early latency cut-off (400&#x02009;ms) for auditory P300s was chosen to avoid picking the second late positive component, which peaked around 550&#x02009;ms (see Figure <xref ref-type="fig" rid="F1">1</xref>). Peak amplitudes and latencies for target P3b and novelty P3a were extracted from electrodes Fz, Cz, and Pz for statistical analyses.</p><fig id="F1" position="float"><label>Figure 1</label><caption><p><bold>Event-related brain potential grand average waveforms (left) and corresponding topographic maps (right) are shown for placebo (black), ketamine alone (red), nicotine alone (blue), and ketamine&#x02009;+&#x02009;nicotine (magenta) days</bold>. ERPs, overlaid for each test day, are shown to oddball targets at Pz (top row), to oddball novels at Cz (middle row), and to difference waveforms (deviants-standards) at Cz. The oddball target elicited a P3b, the oddball novel elicited a P3a, and the deviant elicited a MMN, with each peak denoted by an arrow on the ERP waveforms. Amplitude in microvolts is on the <italic>y</italic>-axis, and latency in milliseconds is on the <italic>x</italic>-axis. Stimulus onset is at 0&#x02009;ms. Negativity is plotted down. Scalp topography maps are shown for each test day for each stimulus, at the peak latency for P3b (top), P3a (middle), and MMN (bottom). Hot colors indicate positive voltage and cool colors, negative voltage.</p></caption><graphic xlink:href="fpsyt-05-00003-g001"/></fig><p>The same eye-movement correction and artifact rejection criteria used in the P300 data processing pipeline were applied to the MMN standard and deviant trials, but these data were segmented into 550&#x02009;ms epochs and baseline corrected using the 50-ms preceding tone onset. Standard and deviant trials remaining after artifact rejection were averaged separately, and the resulting ERP for the standard was subtracted from the deviant to create a difference wave. MMN was identified as the most negative peak between 90 and 270&#x02009;ms post-tone onset in the difference wave at electrodes Fz and Cz. Peak amplitudes and latencies were extracted for statistical analyses.</p></sec><sec id="S2-12"><title>Statistical analyses</title><sec id="S2-12-1"><title>Behavioral data</title><p>Initially, behavioral data were examined descriptively using means, standard deviations, and graphs. Each measure was tested for normality using Kolmogorov-Smirnov test statistics and normal probability plots. All PANSS, CADSS, and VAS measures were highly skewed. Thus, these non-normal behavioral data were first ranked and then fitted using a mixed-effects model with an unstructured variance-covariance matrix and <italic>p</italic>-values adjusted for Analysis of Variance (ANOVA)-type statistics (ATS). In these models, Ketamine (active vs. placebo), Nicotine (active vs. placebo), and Time (&#x02212;110, &#x02212;19, +35, +110, and +180&#x02009;min) were included as within-subjects explanatory factors, while Subject was the clustering factor. Time reflected the time point, in minutes, relative to Time 0 when the first intravenous infusion of active-nicotine or placebo-nicotine was initiated (see Table <xref ref-type="table" rid="T2">2</xref>). All two- and three-way interactions were modeled. Significant interactions were followed by appropriate <italic>post hoc</italic> tests and graphical displays to interpret the effects. All results were considered statistically significant at <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05. Bonferroni correction was applied within but not across domains. Thus, for example, a cut-off alpha level of 0.05/2&#x02009;=&#x02009;0.025 was used to declare effects significant for the two CADSS ratings (Subject- and Clinician-Rated).</p></sec><sec id="S2-12-2"><title>ERP data</title><p>For the ERP data, which were collected once per test day, repeated-measures ANOVAs were conducted with Ketamine (active vs. placebo) and Nicotine (active vs. placebo) as within-subjects factors. The ANOVA models assessing P300 amplitudes and latencies included two additional within-subjects factors: Deviant Type (target vs. novel) and Lead (Fz vs. Cz vs. Pz). The ANOVA model for MMN amplitude and latency included one additional within-subjects factor: Lead (Fz vs. Cz). Analyses proceeded in a hierarchical fashion, with higher order interactions being parsed by examining lower order simple main effects and interactions. Ultimately, condition comparisons were tested with single degree of freedom contrasts.</p></sec></sec></sec><sec id="S3"><title>Results</title><sec id="S3-13"><title>Behavioral data</title><p>Ketamine produced significant increases in PANSS Total, CADSS Subject-Rated and Clinician-Rated Perceptual Alterations, and VAS subjective &#x0201c;High&#x0201d; ratings (see Figure <xref ref-type="fig" rid="F2">2</xref>). All Ketamine main effects and Ketamine&#x02009;&#x000d7;&#x02009;Time interactions were significant at <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.0001 (Table <xref ref-type="table" rid="T3">3</xref>). <italic>Post hoc</italic> analyses showed significant effects of Ketamine at time points &#x02212;19, +35, and +110 (all <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05) for each of these measures. There were no significant main effects of Nicotine. Nor were there any significant Ketamine&#x02009;&#x000d7;&#x02009;Nicotine or Ketamine&#x02009;&#x000d7;&#x02009;Nicotine&#x02009;&#x000d7;&#x02009;Time interactions for any of these outcome measures.</p><fig id="F2" position="float"><label>Figure 2</label><caption><p><bold>Mean and standard errors are plotted for Positive and Negative Syndrome Scale (PANSS) total scores (upper left), Visual Analog Scale of subjective states (upper right), subject-rate (lower-left) and clinician-rated (lower-right) perceptual alterations using the Clinician Administered Dissociative Symptoms Scale (CADSS)</bold>. For each plot, values for each of the four test days are overlaid, for Placebo (black), Ketamine Alone (red), Nicotine Alone (blue), and Ketamine&#x02009;+&#x02009;Nicotine (magenta) days.</p></caption><graphic xlink:href="fpsyt-05-00003-g002"/></fig><table-wrap id="T3" position="float"><label>Table 3</label><caption><p><bold>Analysis of clinical scales</bold>.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Effect</th><th align="center" colspan="4" rowspan="1">Positive and Negative Syndrome Scale<hr/></th><th align="center" colspan="4" rowspan="1">Visual Analog Scale<hr/></th><th align="center" colspan="8" rowspan="1">CADSS perceptual alterations<hr/></th></tr><tr><th align="left" rowspan="1" colspan="1"/><th align="center" colspan="4" rowspan="1">Total score<hr/></th><th align="center" colspan="4" rowspan="1">&#x0201c;High&#x0201d;<hr/></th><th align="center" colspan="4" rowspan="1">Subject-rated<hr/></th><th align="center" colspan="4" rowspan="1">Clinician-rated<hr/></th></tr><tr><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">Num <italic>df</italic></th><th align="left" rowspan="1" colspan="1">ATS</th><th align="left" rowspan="1" colspan="1"><italic>p</italic>-Value</th><th align="left" rowspan="1" colspan="1">Direction of effect</th><th align="left" rowspan="1" colspan="1">Num <italic>df</italic></th><th align="left" rowspan="1" colspan="1">ATS</th><th align="left" rowspan="1" colspan="1"><italic>p</italic>-Value</th><th align="left" rowspan="1" colspan="1">Direction of effect</th><th align="left" rowspan="1" colspan="1">Num <italic>df</italic></th><th align="left" rowspan="1" colspan="1">ATS</th><th align="left" rowspan="1" colspan="1"><italic>p</italic>-Value</th><th align="left" rowspan="1" colspan="1">Direction of effect</th><th align="left" rowspan="1" colspan="1">Num <italic>df</italic></th><th align="left" rowspan="1" colspan="1">ATS</th><th align="left" rowspan="1" colspan="1"><italic>p</italic>-Value</th><th align="left" rowspan="1" colspan="1">Direction of effect</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Nicotine (nicotine vs. placebo-nicotine)</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">0.36</td><td align="left" rowspan="1" colspan="1">0.551</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">0.59</td><td align="left" rowspan="1" colspan="1">0.441</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">0.96</td><td align="left" rowspan="1" colspan="1">0.327</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">0.20</td><td align="left" rowspan="1" colspan="1">0.655</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Ketamine (ketamine vs. placebo-ketamine)</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">24.60</td><td align="left" rowspan="1" colspan="1"><bold>&#x0003c;0.0001</bold></td><td align="left" rowspan="1" colspan="1">Ketamine&#x02009;&#x0003e;&#x02009;placebo</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">77.01</td><td align="left" rowspan="1" colspan="1"><bold>&#x0003c;0.0001</bold></td><td align="left" rowspan="1" colspan="1">Ketamine&#x02009;&#x0003e;&#x02009;placebo</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">23.39</td><td align="left" rowspan="1" colspan="1"><bold>&#x0003c;0.0001</bold></td><td align="left" rowspan="1" colspan="1">Ketamine&#x02009;&#x0003e;&#x02009;placebo</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">43.32</td><td align="left" rowspan="1" colspan="1"><bold>&#x0003c;0.0001</bold></td><td align="left" rowspan="1" colspan="1">Ketamine&#x02009;&#x0003e;&#x02009;placebo</td></tr><tr><td align="left" rowspan="1" colspan="1">Time (&#x02212;110 vs. &#x02212;19 vs. 35 vs. 110 vs. 180&#x02009;min)</td><td align="left" rowspan="1" colspan="1">2.58</td><td align="left" rowspan="1" colspan="1">21.50</td><td align="left" rowspan="1" colspan="1"><bold>&#x0003c;0.0001</bold></td><td align="left" rowspan="1" colspan="1">(&#x02212;19, 35, 110)&#x02009;&#x0003e;&#x02009;(&#x02212;110, 180)</td><td align="left" rowspan="1" colspan="1">3.39</td><td align="left" rowspan="1" colspan="1">29.94</td><td align="left" rowspan="1" colspan="1"><bold>&#x0003c;0.0001</bold></td><td align="left" rowspan="1" colspan="1">(&#x02212;19, 35, 110)&#x02009;&#x0003e;&#x02009;(&#x02212;110, 180)</td><td align="left" rowspan="1" colspan="1">2.66</td><td align="left" rowspan="1" colspan="1">9.32</td><td align="left" rowspan="1" colspan="1"><bold>&#x0003c;0.0001</bold></td><td align="left" rowspan="1" colspan="1">(&#x02212;19, 35, 110)&#x02009;&#x0003e;&#x02009;(&#x02212;110, 180)</td><td align="left" rowspan="1" colspan="1">2.46</td><td align="left" rowspan="1" colspan="1">19.98</td><td align="left" rowspan="1" colspan="1"><bold>&#x0003c;0.0001</bold></td><td align="left" rowspan="1" colspan="1">(&#x02212;19, 35, 110)&#x02009;&#x0003e;&#x02009;(&#x02212;110, 180)</td></tr><tr><td align="left" rowspan="1" colspan="1">Nicotine&#x02009;&#x000d7;&#x02009;ketamine</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">0.020</td><td align="left" rowspan="1" colspan="1">0.892</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">0.190</td><td align="left" rowspan="1" colspan="1">0.660</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">0.050</td><td align="left" rowspan="1" colspan="1">0.829</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">0.100</td><td align="left" rowspan="1" colspan="1">0.751</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Nicotine&#x02009;&#x000d7;&#x02009;time</td><td align="left" rowspan="1" colspan="1">2.72</td><td align="left" rowspan="1" colspan="1">0.18</td><td align="left" rowspan="1" colspan="1">0.892</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">3.47</td><td align="left" rowspan="1" colspan="1">0.31</td><td align="left" rowspan="1" colspan="1">0.847</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">3.11</td><td align="left" rowspan="1" colspan="1">1.10</td><td align="left" rowspan="1" colspan="1">0.349</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">3.42</td><td align="left" rowspan="1" colspan="1">0.65</td><td align="left" rowspan="1" colspan="1">0.601</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Ketamine&#x02009;&#x000d7;&#x02009;time</td><td align="left" rowspan="1" colspan="1">3.12</td><td align="left" rowspan="1" colspan="1">22.12</td><td align="left" rowspan="1" colspan="1"><bold>&#x0003c;0.0001</bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">3.09</td><td align="left" rowspan="1" colspan="1">22.97</td><td align="left" rowspan="1" colspan="1"><bold>&#x0003c;0.0001</bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">3.15</td><td align="left" rowspan="1" colspan="1">16.39</td><td align="left" rowspan="1" colspan="1"><bold>&#x0003c;0.0001</bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">2.72</td><td align="left" rowspan="1" colspan="1">23.10</td><td align="left" rowspan="1" colspan="1"><bold>&#x0003c;0.0001</bold></td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;<italic>Ketamine effect at &#x02212;110&#x02009;min</italic></td><td align="left" rowspan="1" colspan="1"><italic>1</italic></td><td align="left" rowspan="1" colspan="1"><italic>2.99</italic></td><td align="left" rowspan="1" colspan="1"><italic>0.084</italic></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><italic>1</italic></td><td align="left" rowspan="1" colspan="1"><italic>0.00</italic></td><td align="left" rowspan="1" colspan="1"><italic>0.953</italic></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><italic>1</italic></td><td align="left" rowspan="1" colspan="1"><italic>0.18</italic></td><td align="left" rowspan="1" colspan="1"><italic>0.672</italic></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><italic>1</italic></td><td align="left" rowspan="1" colspan="1"><italic>0.00</italic></td><td align="left" rowspan="1" colspan="1"><italic>1.000</italic></td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;<italic>Ketamine effect at &#x02212;19&#x02009;min</italic></td><td align="left" rowspan="1" colspan="1"><italic>1</italic></td><td align="left" rowspan="1" colspan="1"><italic>38.06</italic></td><td align="left" rowspan="1" colspan="1"><bold>&#x0003c;<italic>0.0001</italic></bold></td><td align="left" rowspan="1" colspan="1"><italic>Ketamine</italic>&#x02009;&#x0003e;&#x02009;<italic>placebo</italic></td><td align="left" rowspan="1" colspan="1"><italic>1</italic></td><td align="left" rowspan="1" colspan="1"><italic>96.57</italic></td><td align="left" rowspan="1" colspan="1"><bold>&#x0003c;<italic>0.0001</italic></bold></td><td align="left" rowspan="1" colspan="1"><italic>Ketamine</italic>&#x02009;&#x0003e;&#x02009;<italic>placebo</italic></td><td align="left" rowspan="1" colspan="1"><italic>1</italic></td><td align="left" rowspan="1" colspan="1"><italic>27.32</italic></td><td align="left" rowspan="1" colspan="1"><bold>&#x0003c;<italic>0.0001</italic></bold></td><td align="left" rowspan="1" colspan="1"><italic>Ketamine</italic>&#x02009;&#x0003e;&#x02009;<italic>placebo</italic></td><td align="left" rowspan="1" colspan="1"><italic>1</italic></td><td align="left" rowspan="1" colspan="1"><italic>142.70</italic></td><td align="left" rowspan="1" colspan="1"><bold>&#x0003c;<italic>0.0001</italic></bold></td><td align="left" rowspan="1" colspan="1"><italic>Ketamine</italic>&#x02009;&#x0003e;&#x02009;<italic>placebo</italic></td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;<italic>Ketamine effect at 35&#x02009;min</italic></td><td align="left" rowspan="1" colspan="1"><italic>1</italic></td><td align="left" rowspan="1" colspan="1"><italic>41.12</italic></td><td align="left" rowspan="1" colspan="1"><bold>&#x0003c;<italic>0.0001</italic></bold></td><td align="left" rowspan="1" colspan="1"><italic>Ketamine</italic>&#x02009;&#x0003e;&#x02009;<italic>placebo</italic></td><td align="left" rowspan="1" colspan="1"><italic>1</italic></td><td align="left" rowspan="1" colspan="1"><italic>75.97</italic></td><td align="left" rowspan="1" colspan="1"><bold>&#x0003c;<italic>0.0001</italic></bold></td><td align="left" rowspan="1" colspan="1"><italic>Ketamine</italic>&#x02009;&#x0003e;&#x02009;<italic>placebo</italic></td><td align="left" rowspan="1" colspan="1"><italic>1</italic></td><td align="left" rowspan="1" colspan="1"><italic>33.83</italic></td><td align="left" rowspan="1" colspan="1"><bold>&#x0003c;<italic>0.0001</italic></bold></td><td align="left" rowspan="1" colspan="1"><italic>Ketamine</italic>&#x02009;&#x0003e;&#x02009;<italic>placebo</italic></td><td align="left" rowspan="1" colspan="1"><italic>1</italic></td><td align="left" rowspan="1" colspan="1"><italic>51.34</italic></td><td align="left" rowspan="1" colspan="1"><bold>&#x0003c;<italic>0.0001</italic></bold></td><td align="left" rowspan="1" colspan="1"><italic>Ketamine</italic>&#x02009;&#x0003e;&#x02009;<italic>placebo</italic></td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;<italic>Ketamine effect at 110&#x02009;min</italic></td><td align="left" rowspan="1" colspan="1"><italic>1</italic></td><td align="left" rowspan="1" colspan="1"><italic>26.90</italic></td><td align="left" rowspan="1" colspan="1"><bold>&#x0003c;<italic>0.0001</italic></bold></td><td align="left" rowspan="1" colspan="1"><italic>Ketamine</italic>&#x02009;&#x0003e;&#x02009;<italic>placebo</italic></td><td align="left" rowspan="1" colspan="1"><italic>1</italic></td><td align="left" rowspan="1" colspan="1"><italic>29.44</italic></td><td align="left" rowspan="1" colspan="1"><bold>&#x0003c;<italic>0.0001</italic></bold></td><td align="left" rowspan="1" colspan="1"><italic>Ketamine</italic>&#x02009;&#x0003e;&#x02009;<italic>placebo</italic></td><td align="left" rowspan="1" colspan="1"><italic>1</italic></td><td align="left" rowspan="1" colspan="1"><italic>12.09</italic></td><td align="left" rowspan="1" colspan="1"><bold><italic>0.0005</italic></bold></td><td align="left" rowspan="1" colspan="1"><italic>Ketamine</italic>&#x02009;&#x0003e;&#x02009;<italic>placebo</italic></td><td align="left" rowspan="1" colspan="1"><italic>1</italic></td><td align="left" rowspan="1" colspan="1"><italic>15.17</italic></td><td align="left" rowspan="1" colspan="1"><bold>&#x0003c;<italic>0.0001</italic></bold></td><td align="left" rowspan="1" colspan="1"><italic>Ketamine</italic>&#x02009;&#x0003e;&#x02009;<italic>placebo</italic></td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;<italic>Ketamine effect at 180&#x02009;min</italic></td><td align="left" rowspan="1" colspan="1"><italic>1</italic></td><td align="left" rowspan="1" colspan="1"><italic>0.57</italic></td><td align="left" rowspan="1" colspan="1"><italic>0.449</italic></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><italic>1</italic></td><td align="left" rowspan="1" colspan="1"><italic>3.40</italic></td><td align="left" rowspan="1" colspan="1"><italic>0.065</italic></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><italic>1</italic></td><td align="left" rowspan="1" colspan="1"><italic>0.00</italic></td><td align="left" rowspan="1" colspan="1"><italic>1.000</italic></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><italic>1</italic></td><td align="left" rowspan="1" colspan="1"><italic>0.34</italic></td><td align="left" rowspan="1" colspan="1"><italic>0.559</italic></td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Nicotine&#x02009;&#x000d7;&#x02009;ketamine&#x02009;&#x000d7;&#x02009;time</td><td align="left" rowspan="1" colspan="1">2.67</td><td align="left" rowspan="1" colspan="1">0.04</td><td align="left" rowspan="1" colspan="1">0.983</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">3.34</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">0.399</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">3.05</td><td align="left" rowspan="1" colspan="1">1.34</td><td align="left" rowspan="1" colspan="1">0.258</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">3.49</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">0.399</td><td align="left" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><p><italic>Results are based on a non-parametric mixed-effects model of ranked data with an unstructured variance-covariance matrix and <italic>p</italic>-values adjusted for ANOVA-type statistics (ATS). Follow-up test results are shown in italics. Significant p-values are shown in bold. Num <italic>df</italic>, numerator degrees of freedom</italic>.</p></table-wrap-foot></table-wrap></sec><sec id="S3-14"><title>P300 amplitude</title><p>Event-related brain potential overlays showing P300 waves and topographic maps are shown in Figure <xref ref-type="fig" rid="F1">1</xref>, P300 peak amplitude and latency means are presented in Table <xref ref-type="table" rid="T4">4</xref> and histograms showing the effects of the drug conditions on P3b and P3a are shown in Figure <xref ref-type="fig" rid="F3">3</xref>. Results of the Ketamine&#x02009;&#x000d7;&#x02009;Nicotine&#x02009;&#x000d7;&#x02009;Deviant Type&#x02009;&#x000d7;&#x02009;Lead repeated-measures ANOVA for P300 amplitude and latency are presented in Table <xref ref-type="table" rid="T5">5</xref>.</p><table-wrap id="T4" position="float"><label>Table 4</label><caption><p><bold>Means and standard errors for auditory oddball P300 amplitude and latency across the four test sessions</bold>.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Condition</th><th align="left" rowspan="1" colspan="1">Deviant type</th><th align="left" rowspan="1" colspan="1">Lead</th><th align="center" colspan="4" rowspan="1">P300 peak<hr/></th></tr><tr><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1"/><th align="center" colspan="2" rowspan="1">Amplitude (&#x003bc;V)<hr/></th><th align="center" colspan="2" rowspan="1">Latency (ms)<hr/></th></tr><tr><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">Mean</th><th align="center" rowspan="1" colspan="1">SE</th><th align="center" rowspan="1" colspan="1">Mean</th><th align="center" rowspan="1" colspan="1">SE</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Placebo</td><td align="left" rowspan="1" colspan="1">Target P3b</td><td align="left" rowspan="1" colspan="1">Fz</td><td align="char" char="." charoff="50" rowspan="1" colspan="1">4.232</td><td align="center" rowspan="1" colspan="1">0.961</td><td align="center" rowspan="1" colspan="1">283.625</td><td align="char" char="." charoff="50" rowspan="1" colspan="1">12.659</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Cz</td><td align="char" char="." charoff="50" rowspan="1" colspan="1">8.423</td><td align="center" rowspan="1" colspan="1">1.213</td><td align="center" rowspan="1" colspan="1">274.125</td><td align="char" char="." charoff="50" rowspan="1" colspan="1">9.003</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Pz</td><td align="char" char="." charoff="50" rowspan="1" colspan="1">10.981</td><td align="center" rowspan="1" colspan="1">0.713</td><td align="center" rowspan="1" colspan="1">288.500</td><td align="char" char="." charoff="50" rowspan="1" colspan="1">10.544</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Novelty P3a</td><td align="left" rowspan="1" colspan="1">Fz</td><td align="char" char="." charoff="50" rowspan="1" colspan="1">7.049</td><td align="center" rowspan="1" colspan="1">1.052</td><td align="center" rowspan="1" colspan="1">313.125</td><td align="char" char="." charoff="50" rowspan="1" colspan="1">17.845</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Cz</td><td align="char" char="." charoff="50" rowspan="1" colspan="1">11.409</td><td align="center" rowspan="1" colspan="1">0.727</td><td align="center" rowspan="1" colspan="1">277.000</td><td align="char" char="." charoff="50" rowspan="1" colspan="1">12.694</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Pz</td><td align="char" char="." charoff="50" rowspan="1" colspan="1">11.036</td><td align="center" rowspan="1" colspan="1">0.727</td><td align="center" rowspan="1" colspan="1">296.625</td><td align="char" char="." charoff="50" rowspan="1" colspan="1">14.493</td></tr><tr><td align="left" rowspan="1" colspan="1">Ketamine alone</td><td align="left" rowspan="1" colspan="1">Target P3b</td><td align="left" rowspan="1" colspan="1">Fz</td><td align="char" char="." charoff="50" rowspan="1" colspan="1">3.043</td><td align="center" rowspan="1" colspan="1">1.639</td><td align="center" rowspan="1" colspan="1">338.125</td><td align="char" char="." charoff="50" rowspan="1" colspan="1">20.994</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Cz</td><td align="char" char="." charoff="50" rowspan="1" colspan="1">5.490</td><td align="center" rowspan="1" colspan="1">2.337</td><td align="center" rowspan="1" colspan="1">333.750</td><td align="char" char="." charoff="50" rowspan="1" colspan="1">21.874</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Pz</td><td align="char" char="." charoff="50" rowspan="1" colspan="1">9.744</td><td align="center" rowspan="1" colspan="1">1.300</td><td align="center" rowspan="1" colspan="1">341.500</td><td align="char" char="." charoff="50" rowspan="1" colspan="1">19.991</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Novelty P3a</td><td align="left" rowspan="1" colspan="1">Fz</td><td align="char" char="." charoff="50" rowspan="1" colspan="1">7.356</td><td align="center" rowspan="1" colspan="1">0.935</td><td align="center" rowspan="1" colspan="1">311.125</td><td align="char" char="." charoff="50" rowspan="1" colspan="1">15.725</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Cz</td><td align="char" char="." charoff="50" rowspan="1" colspan="1">9.973</td><td align="center" rowspan="1" colspan="1">1.480</td><td align="center" rowspan="1" colspan="1">289.000</td><td align="char" char="." charoff="50" rowspan="1" colspan="1">17.537</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Pz</td><td align="char" char="." charoff="50" rowspan="1" colspan="1">8.882</td><td align="center" rowspan="1" colspan="1">0.886</td><td align="center" rowspan="1" colspan="1">311.375</td><td align="char" char="." charoff="50" rowspan="1" colspan="1">13.950</td></tr><tr><td align="left" rowspan="1" colspan="1">Nicotine alone</td><td align="left" rowspan="1" colspan="1">Target P3b</td><td align="left" rowspan="1" colspan="1">Fz</td><td align="char" char="." charoff="50" rowspan="1" colspan="1">4.698</td><td align="center" rowspan="1" colspan="1">1.120</td><td align="center" rowspan="1" colspan="1">292.375</td><td align="char" char="." charoff="50" rowspan="1" colspan="1">7.426</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Cz</td><td align="char" char="." charoff="50" rowspan="1" colspan="1">8.792</td><td align="center" rowspan="1" colspan="1">1.671</td><td align="center" rowspan="1" colspan="1">280.375</td><td align="char" char="." charoff="50" rowspan="1" colspan="1">9.653</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Pz</td><td align="char" char="." charoff="50" rowspan="1" colspan="1">10.990</td><td align="center" rowspan="1" colspan="1">1.695</td><td align="center" rowspan="1" colspan="1">284.000</td><td align="char" char="." charoff="50" rowspan="1" colspan="1">7.778</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Novelty P3a</td><td align="left" rowspan="1" colspan="1">Fz</td><td align="char" char="." charoff="50" rowspan="1" colspan="1">6.163</td><td align="center" rowspan="1" colspan="1">0.870</td><td align="center" rowspan="1" colspan="1">300.375</td><td align="char" char="." charoff="50" rowspan="1" colspan="1">14.645</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Cz</td><td align="char" char="." charoff="50" rowspan="1" colspan="1">9.142</td><td align="center" rowspan="1" colspan="1">1.471</td><td align="center" rowspan="1" colspan="1">269.125</td><td align="char" char="." charoff="50" rowspan="1" colspan="1">9.875</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Pz</td><td align="char" char="." charoff="50" rowspan="1" colspan="1">8.208</td><td align="center" rowspan="1" colspan="1">1.331</td><td align="center" rowspan="1" colspan="1">284.250</td><td align="char" char="." charoff="50" rowspan="1" colspan="1">13.080</td></tr><tr><td align="left" rowspan="1" colspan="1">Ketamine&#x02009;+&#x02009;nicotine</td><td align="left" rowspan="1" colspan="1">Target P3b</td><td align="left" rowspan="1" colspan="1">Fz</td><td align="char" char="." charoff="50" rowspan="1" colspan="1">4.126</td><td align="center" rowspan="1" colspan="1">0.719</td><td align="center" rowspan="1" colspan="1">311.625</td><td align="char" char="." charoff="50" rowspan="1" colspan="1">21.304</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Cz</td><td align="char" char="." charoff="50" rowspan="1" colspan="1">6.741</td><td align="center" rowspan="1" colspan="1">0.736</td><td align="center" rowspan="1" colspan="1">306.250</td><td align="char" char="." charoff="50" rowspan="1" colspan="1">21.445</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Pz</td><td align="char" char="." charoff="50" rowspan="1" colspan="1">9.790</td><td align="center" rowspan="1" colspan="1">1.119</td><td align="center" rowspan="1" colspan="1">315.000</td><td align="char" char="." charoff="50" rowspan="1" colspan="1">20.376</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Novelty P3a</td><td align="left" rowspan="1" colspan="1">Fz</td><td align="char" char="." charoff="50" rowspan="1" colspan="1">5.189</td><td align="center" rowspan="1" colspan="1">0.614</td><td align="center" rowspan="1" colspan="1">311.875</td><td align="char" char="." charoff="50" rowspan="1" colspan="1">10.419</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Cz</td><td align="char" char="." charoff="50" rowspan="1" colspan="1">6.364</td><td align="center" rowspan="1" colspan="1">1.108</td><td align="center" rowspan="1" colspan="1">280.500</td><td align="char" char="." charoff="50" rowspan="1" colspan="1">13.340</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Pz</td><td align="char" char="." charoff="50" rowspan="1" colspan="1">5.916</td><td align="center" rowspan="1" colspan="1">1.185</td><td align="center" rowspan="1" colspan="1">298.625</td><td align="char" char="." charoff="50" rowspan="1" colspan="1">13.143</td></tr></tbody></table></table-wrap><fig id="F3" position="float"><label>Figure 3</label><caption><p><bold>Mean P300 amplitude across four test days</bold>. <bold>(A)</bold> Mean target P3b amplitude for each test day. <bold>(B)</bold> Mean novelty P3a amplitude for each test day. Error bars indicate standard errors.</p></caption><graphic xlink:href="fpsyt-05-00003-g003"/></fig><table-wrap id="T5" position="float"><label>Table 5</label><caption><p><bold>Analysis of variance (ANOVA) of P300 peak amplitudes and latencies</bold>.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Effect</th><th align="center" colspan="4" rowspan="1">P300 peak amplitude<hr/></th><th align="center" colspan="3" rowspan="1">P300 peak latency<hr/></th></tr><tr><th align="left" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1"><italic>df</italic></th><th align="center" rowspan="1" colspan="1"><italic>F</italic></th><th align="center" rowspan="1" colspan="1"><italic>p</italic>-Value</th><th align="left" rowspan="1" colspan="1">Direction of effect</th><th align="center" rowspan="1" colspan="1"><italic>F</italic></th><th align="center" rowspan="1" colspan="1"><italic>p</italic>-Value</th><th align="left" rowspan="1" colspan="1">Direction of effect</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Deviant type (target vs. novel)</td><td align="center" rowspan="1" colspan="1">1.7</td><td align="center" rowspan="1" colspan="1">1.33</td><td align="center" rowspan="1" colspan="1">0.287</td><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">2.72</td><td align="center" rowspan="1" colspan="1">0.143</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Nicotine (nicotine vs. placebo-nicotine)</td><td align="center" rowspan="1" colspan="1">1.7</td><td align="center" rowspan="1" colspan="1">0.85</td><td align="center" rowspan="1" colspan="1">0.388</td><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">1.12</td><td align="center" rowspan="1" colspan="1">0.325</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Ketamine (ketamine vs. placebo-ketamine)</td><td align="center" rowspan="1" colspan="1">1.7</td><td align="center" rowspan="1" colspan="1">3.64</td><td align="center" rowspan="1" colspan="1">0.098</td><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">6.09</td><td align="center" rowspan="1" colspan="1"><bold>0.043</bold></td><td align="left" rowspan="1" colspan="1">Ketamine&#x02009;&#x0003e;&#x02009;placebo</td></tr><tr><td align="left" rowspan="1" colspan="1">Lead (Fz vs. Cz vs. Pz)</td><td align="center" rowspan="1" colspan="1">2.6</td><td align="center" rowspan="1" colspan="1">61.71</td><td align="center" rowspan="1" colspan="1"><bold>&#x0003c;0.001</bold></td><td align="left" rowspan="1" colspan="1">Fz&#x02009;&#x0003c;&#x02009;Cz&#x02009;=&#x02009;Pz</td><td align="center" rowspan="1" colspan="1">8.52</td><td align="center" rowspan="1" colspan="1"><bold>0.018</bold></td><td align="left" rowspan="1" colspan="1">Cz&#x02009;&#x0003c;&#x02009;Fz&#x02009;=&#x02009;Pz</td></tr><tr><td align="left" rowspan="1" colspan="1">Deviant type&#x02009;&#x000d7;&#x02009;ketamine</td><td align="center" rowspan="1" colspan="1">1.7</td><td align="center" rowspan="1" colspan="1">0.001</td><td align="center" rowspan="1" colspan="1">0.982</td><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">2.21</td><td align="center" rowspan="1" colspan="1">0.181</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Deviant type&#x02009;&#x000d7;&#x02009;nicotine</td><td align="center" rowspan="1" colspan="1">1.7</td><td align="center" rowspan="1" colspan="1">5.20</td><td align="center" rowspan="1" colspan="1">0.057</td><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.01</td><td align="center" rowspan="1" colspan="1">0.912</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;<italic>Nicotine effect for targets</italic></td><td align="center" rowspan="1" colspan="1"><italic>1.7</italic></td><td align="center" rowspan="1" colspan="1"><italic>0.12</italic></td><td align="center" rowspan="1" colspan="1"><italic>0.737</italic></td><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;<italic>Nicotine effect for novels</italic></td><td align="center" rowspan="1" colspan="1"><italic>1.7</italic></td><td align="center" rowspan="1" colspan="1"><italic>9.06</italic></td><td align="center" rowspan="1" colspan="1"><bold>0.020</bold></td><td align="left" rowspan="1" colspan="1"><italic>Nicotine</italic>&#x02009;&#x0003c;&#x02009;<italic>placebo</italic></td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Deviant type&#x02009;&#x000d7;&#x02009;lead</td><td align="center" rowspan="1" colspan="1">2.6</td><td align="center" rowspan="1" colspan="1">26.95</td><td align="center" rowspan="1" colspan="1"><bold>0.001</bold></td><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">4.59</td><td align="center" rowspan="1" colspan="1">0.062</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;<italic>Lead effect for targets</italic></td><td align="center" rowspan="1" colspan="1"><italic>2.6</italic></td><td align="center" rowspan="1" colspan="1"><italic>53.08</italic></td><td align="center" rowspan="1" colspan="1"><bold>&#x0003c;0.001</bold></td><td align="left" rowspan="1" colspan="1"><italic>Fz</italic>&#x02009;&#x0003c;&#x02009;<italic>Cz</italic>&#x02009;&#x0003c;&#x02009;<italic>Pz</italic></td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;<italic>Lead effect for novels</italic></td><td align="center" rowspan="1" colspan="1"><italic>1.7</italic></td><td align="center" rowspan="1" colspan="1"><italic>17.69</italic></td><td align="center" rowspan="1" colspan="1"><bold>0.001</bold></td><td align="left" rowspan="1" colspan="1"><italic>Fz</italic>&#x02009;&#x0003c;&#x02009;<italic>Cz</italic>&#x02009;=&#x02009;<italic>Pz</italic></td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Nicotine&#x02009;&#x000d7;&#x02009;ketamine</td><td align="center" rowspan="1" colspan="1">1.7</td><td align="center" rowspan="1" colspan="1">0.02</td><td align="center" rowspan="1" colspan="1">0.900</td><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.87</td><td align="center" rowspan="1" colspan="1">0.381</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Nicotine&#x02009;&#x000d7;&#x02009;lead</td><td align="center" rowspan="1" colspan="1">2.6</td><td align="center" rowspan="1" colspan="1">0.82</td><td align="center" rowspan="1" colspan="1">0.486</td><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">1.40</td><td align="center" rowspan="1" colspan="1">0.317</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Ketamine&#x02009;&#x000d7;&#x02009;lead</td><td align="center" rowspan="1" colspan="1">2.6</td><td align="center" rowspan="1" colspan="1">8.04</td><td align="center" rowspan="1" colspan="1"><bold>0.020</bold></td><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.34</td><td align="center" rowspan="1" colspan="1">0.723</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;<italic>Ketamine effect at Fz</italic></td><td align="center" rowspan="1" colspan="1"><italic>1.7</italic></td><td align="center" rowspan="1" colspan="1"><italic>0.86</italic></td><td align="center" rowspan="1" colspan="1"><italic>0.384</italic></td><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;<italic>Ketamine effect at Cz</italic></td><td align="center" rowspan="1" colspan="1"><italic>1.7</italic></td><td align="center" rowspan="1" colspan="1"><italic>5.87</italic></td><td align="center" rowspan="1" colspan="1"><bold>0.046</bold></td><td align="left" rowspan="1" colspan="1"><italic>Ketamine</italic>&#x02009;&#x0003c;&#x02009;<italic>placebo</italic></td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;<italic>Ketamine effect at Pz</italic></td><td align="center" rowspan="1" colspan="1"><italic>1.7</italic></td><td align="center" rowspan="1" colspan="1"><italic>3.34</italic></td><td align="center" rowspan="1" colspan="1"><italic>0.110</italic></td><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Deviant type&#x02009;&#x000d7;&#x02009;ketamine&#x02009;&#x000d7;&#x02009;lead</td><td align="center" rowspan="1" colspan="1">2.6</td><td align="center" rowspan="1" colspan="1">1.11</td><td align="center" rowspan="1" colspan="1">0.389</td><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.07</td><td align="center" rowspan="1" colspan="1">0.932</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Deviant type&#x02009;&#x000d7;&#x02009;nicotine&#x02009;&#x000d7;&#x02009;lead</td><td align="center" rowspan="1" colspan="1">2.6</td><td align="center" rowspan="1" colspan="1">2.01</td><td align="center" rowspan="1" colspan="1">0.215</td><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.00</td><td align="center" rowspan="1" colspan="1">1.000</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Deviant type&#x02009;&#x000d7;&#x02009;nicotine&#x02009;&#x000d7;&#x02009;ketamine</td><td align="center" rowspan="1" colspan="1">1.7</td><td align="center" rowspan="1" colspan="1">1.02</td><td align="center" rowspan="1" colspan="1">0.346</td><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.79</td><td align="center" rowspan="1" colspan="1">0.405</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Nicotine&#x02009;&#x000d7;&#x02009;ketamine&#x02009;&#x000d7;&#x02009;lead</td><td align="center" rowspan="1" colspan="1">2.6</td><td align="center" rowspan="1" colspan="1">0.04</td><td align="center" rowspan="1" colspan="1">0.958</td><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.33</td><td align="center" rowspan="1" colspan="1">0.729</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Deviant type&#x02009;&#x000d7;&#x02009;nicotine&#x02009;&#x000d7;&#x02009;ketamine&#x02009;&#x000d7;&#x02009;lead</td><td align="center" rowspan="1" colspan="1">2.6</td><td align="center" rowspan="1" colspan="1">3.16</td><td align="center" rowspan="1" colspan="1">0.116</td><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.21</td><td align="center" rowspan="1" colspan="1">0.818</td><td align="left" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><p><italic>ANOVA results are based on mutlivariate assumptions for repeated-measures, and all <italic>F</italic>-tests are based on Wilks&#x02019; Lambda. Follow-up ANOVA results are shown in italics. Significant p-values are shown in bold</italic>.</p></table-wrap-foot></table-wrap><p>In terms of main effects, only the effect of Lead was significant, with contrasts indicating equivalent P300 amplitudes at Pz and Cz that were both larger than P300 amplitude at Fz. In terms of two-way interactions, there were significant Ketamine&#x02009;&#x000d7;&#x02009;Lead (<italic>p</italic>&#x02009;=&#x02009;0.02) and Deviant Type&#x02009;&#x000d7;&#x02009;Lead (<italic>p</italic>&#x02009;=&#x02009;0.001) effects, with a trend (<italic>p</italic>&#x02009;=&#x02009;0.057) toward a Deviant Type&#x02009;&#x000d7;&#x02009;Nicotine effect. The Ketamine&#x02009;&#x000d7;&#x02009;Lead effect was parsed by examining the main effects of Ketamine separately for each of the three midline leads, with results showing ketamine to significantly reduce P300 amplitude at electrode Cz (<italic>p</italic>&#x02009;=&#x02009;0.046), but not at Fz (<italic>p</italic>&#x02009;=&#x02009;0.384) or Pz (<italic>p</italic>&#x02009;=&#x02009;0.11). This ketamine-induced reduction of midline vertex P300 amplitude did not significantly depend on Deviant Type (<italic>p</italic>&#x02009;=&#x02009;0.389). The Deviant Type&#x02009;&#x000d7;&#x02009;Lead effect was parsed by examining lead effects separately for targets and novels, both of which were significant. These Lead effects reflected the typical midline scalp topographies of target P3b amplitude (i.e., Fz&#x02009;&#x0003c;&#x02009;Cz&#x02009;&#x0003c;&#x02009;Pz) and novelty P3a amplitude (i.e., Fz&#x02009;&#x0003c;&#x02009;Cz&#x02009;=&#x02009;Pz). The Deviant Type&#x02009;&#x000d7;&#x02009;Nicotine trend was parsed by examining the main effect of Nicotine for each Deviant Type separately. Nicotine significantly reduced the amplitude of novelty P3a (<italic>p</italic>&#x02009;=&#x02009;0.02) but not target P3b (<italic>p</italic>&#x02009;=&#x02009;0.737). No other main effects or interactions were significant.</p></sec><sec id="S3-15"><title>P300 latency</title><p>There was a significant main effect of Ketamine (<italic>p</italic>&#x02009;=&#x02009;0.043) indicating that ketamine delayed P300 latency by 25.44&#x02009;ms relative to placebo (Tables <xref ref-type="table" rid="T4">4</xref> and <xref ref-type="table" rid="T5">5</xref>). There was also a significant main effect of Lead (<italic>p</italic>&#x02009;=&#x02009;0.018) indicating that P300&#x02019;s peak latency was significantly shorter at Cz than at Pz and Fz. No other main effects or interactions were significant (see Table <xref ref-type="table" rid="T5">5</xref>).</p></sec><sec id="S3-16"><title>Mismatch negativity amplitude</title><p>Event-related brain potential overlays showing MMN difference waves and topographic maps are shown in Figure <xref ref-type="fig" rid="F1">1</xref>, MMN peak amplitude and latency means are presented in Table <xref ref-type="table" rid="T6">6</xref>, and histograms showing the effects of the drug conditions on MMN are shown in Figure <xref ref-type="fig" rid="F4">4</xref>. The ANOVA results for MMN amplitude are presented in Table <xref ref-type="table" rid="T7">7</xref>. None of the main effects were significant, but there were significant Nicotine&#x02009;&#x000d7;&#x02009;Ketamine and Nicotine&#x02009;&#x000d7;&#x02009;Ketamine&#x02009;&#x000d7;&#x02009;Lead interactions. The Nicotine&#x02009;&#x000d7;&#x02009;Ketamine&#x02009;&#x000d7;&#x02009;Lead three-way interaction was parsed by examining the Nicotine&#x02009;&#x000d7;&#x02009;Ketamine effect separately for Fz and Cz. The Nicotine&#x02009;&#x000d7;&#x02009;Ketamine effect was significant at Cz (<italic>p</italic>&#x02009;=&#x02009;0.015) but not at Fz (<italic>p</italic>&#x02009;=&#x02009;0.347). The Nicotine&#x02009;&#x000d7;&#x02009;Ketamine effect at Cz and the overall Nicotine&#x02009;&#x000d7;&#x02009;Ketamine two-way interaction (averaged over leads) were parsed by examining the main effect of each drug condition separately for the active and placebo days of the other drug condition. Nicotine Alone produced a trend level reduction of MMN amplitude relative to Placebo (<italic>p</italic>&#x02009;=&#x02009;0.058 for Cz; <italic>p</italic>&#x02009;=&#x02009;0.084 for average of Fz and Cz), but this Nicotine effect was not evident when Nicotine&#x02009;+&#x02009;Ketamine was compared to Ketamine Alone. In contrast, Ketamine did not significantly affect MMN amplitude when administered alone or along with Nicotine. No other interaction effects were significant.</p><table-wrap id="T6" position="float"><label>Table 6</label><caption><p><bold>Means and standard errors for mismatch negativity amplitude and latency across the four test sessions</bold>.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Condition</th><th align="left" rowspan="1" colspan="1">Lead</th><th align="center" colspan="4" rowspan="1">MMN peak<hr/></th></tr><tr><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1"/><th align="center" colspan="2" rowspan="1">Amplitude (&#x003bc;V)<hr/></th><th align="center" colspan="2" rowspan="1">Latency (ms)<hr/></th></tr><tr><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">Mean</th><th align="center" rowspan="1" colspan="1">SE</th><th align="center" rowspan="1" colspan="1">Mean</th><th align="center" rowspan="1" colspan="1">SE</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Placebo</td><td align="left" rowspan="1" colspan="1">Fz</td><td align="center" rowspan="1" colspan="1">&#x02212;4.591</td><td align="center" rowspan="1" colspan="1">0.687</td><td align="center" rowspan="1" colspan="1">196.286</td><td align="char" char="." charoff="50" rowspan="1" colspan="1">8.216</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Cz</td><td align="center" rowspan="1" colspan="1">&#x02212;4.905</td><td align="center" rowspan="1" colspan="1">0.604</td><td align="center" rowspan="1" colspan="1">196.143</td><td align="char" char="." charoff="50" rowspan="1" colspan="1">7.802</td></tr><tr><td align="left" rowspan="1" colspan="1">Ketamine alone</td><td align="left" rowspan="1" colspan="1">Fz</td><td align="center" rowspan="1" colspan="1">&#x02212;4.216</td><td align="center" rowspan="1" colspan="1">0.949</td><td align="center" rowspan="1" colspan="1">179.429</td><td align="char" char="." charoff="50" rowspan="1" colspan="1">11.487</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Cz</td><td align="center" rowspan="1" colspan="1">&#x02212;4.286</td><td align="center" rowspan="1" colspan="1">1.083</td><td align="center" rowspan="1" colspan="1">180.143</td><td align="char" char="." charoff="50" rowspan="1" colspan="1">11.531</td></tr><tr><td align="left" rowspan="1" colspan="1">Nicotine alone</td><td align="left" rowspan="1" colspan="1">Fz</td><td align="center" rowspan="1" colspan="1">&#x02212;4.270</td><td align="center" rowspan="1" colspan="1">0.763</td><td align="center" rowspan="1" colspan="1">201.143</td><td align="char" char="." charoff="50" rowspan="1" colspan="1">7.561</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Cz</td><td align="center" rowspan="1" colspan="1">&#x02212;4.239</td><td align="center" rowspan="1" colspan="1">0.873</td><td align="center" rowspan="1" colspan="1">194.143</td><td align="char" char="." charoff="50" rowspan="1" colspan="1">11.754</td></tr><tr><td align="left" rowspan="1" colspan="1">Ketamine&#x02009;+&#x02009;nicotine</td><td align="left" rowspan="1" colspan="1">Fz</td><td align="center" rowspan="1" colspan="1">&#x02212;3.890</td><td align="center" rowspan="1" colspan="1">1.012</td><td align="center" rowspan="1" colspan="1">177.571</td><td align="char" char="." charoff="50" rowspan="1" colspan="1">10.040</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Cz</td><td align="center" rowspan="1" colspan="1">&#x02212;4.411</td><td align="center" rowspan="1" colspan="1">1.152</td><td align="center" rowspan="1" colspan="1">172.000</td><td align="char" char="." charoff="50" rowspan="1" colspan="1">11.103</td></tr></tbody></table></table-wrap><fig id="F4" position="float"><label>Figure 4</label><caption><p><bold>Mean and standard errors for MMN amplitudes recorded at Cz are plotted for the four test days</bold>.</p></caption><graphic xlink:href="fpsyt-05-00003-g004"/></fig><table-wrap id="T7" position="float"><label>Table 7</label><caption><p><bold>Analysis of variance (ANOVA) of MMN peak amplitudes and latencies</bold>.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Effect</th><th align="center" rowspan="1" colspan="1"><italic>df</italic></th><th align="center" colspan="3" rowspan="1">MMN peak amplitude<hr/></th><th align="center" colspan="3" rowspan="1">MMN peak latency<hr/></th></tr><tr><th align="left" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1"><italic>F</italic></th><th align="center" rowspan="1" colspan="1"><italic>p</italic>-Value</th><th align="left" rowspan="1" colspan="1">Direction of effect</th><th align="center" rowspan="1" colspan="1"><italic>F</italic></th><th align="center" rowspan="1" colspan="1"><italic>p</italic>-Value</th><th align="left" rowspan="1" colspan="1">Direction of effect</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Nicotine (active-nicotine vs. placebo-nicotine)</td><td align="center" rowspan="1" colspan="1">1.6</td><td align="center" rowspan="1" colspan="1">2.04</td><td align="center" rowspan="1" colspan="1">0.203</td><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.03</td><td align="center" rowspan="1" colspan="1">0.875</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Ketamine (active ketamine vs. placebo-ketamine)</td><td align="center" rowspan="1" colspan="1">1.6</td><td align="center" rowspan="1" colspan="1">0.20</td><td align="center" rowspan="1" colspan="1">0.668</td><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">8.77</td><td align="center" rowspan="1" colspan="1"><bold>0.025</bold></td><td align="left" rowspan="1" colspan="1">Ketamine&#x02009;&#x0003c;&#x02009;placebo</td></tr><tr><td align="left" rowspan="1" colspan="1">Lead (Fz vs. Cz)</td><td align="center" rowspan="1" colspan="1">1.6</td><td align="center" rowspan="1" colspan="1">1.27</td><td align="center" rowspan="1" colspan="1">0.302</td><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.27</td><td align="center" rowspan="1" colspan="1">0.624</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Nicotine&#x02009;&#x000d7;&#x02009;ketamine</td><td align="center" rowspan="1" colspan="1">1.6</td><td align="center" rowspan="1" colspan="1">7.04</td><td align="center" rowspan="1" colspan="1"><bold>0.038</bold></td><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.11</td><td align="center" rowspan="1" colspan="1">0.756</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;<italic>Nicotine effect during placebo-ketamine</italic></td><td align="center" rowspan="1" colspan="1"><italic>1.6</italic></td><td align="center" rowspan="1" colspan="1"><italic>4.27</italic></td><td align="center" rowspan="1" colspan="1"><italic>0.084</italic></td><td align="left" rowspan="1" colspan="1"><italic>Nicotine</italic>&#x02009;&#x0003c;&#x02009;<italic>placebo</italic></td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;<italic>Nicotine effect during active ketamine</italic></td><td align="center" rowspan="1" colspan="1"><italic>1.6</italic></td><td align="center" rowspan="1" colspan="1"><italic>0.26</italic></td><td align="center" rowspan="1" colspan="1"><italic>0.629</italic></td><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;<italic>Ketamine effect during placebo-nicotine</italic></td><td align="center" rowspan="1" colspan="1"><italic>1.6</italic></td><td align="center" rowspan="1" colspan="1"><italic>1.28</italic></td><td align="center" rowspan="1" colspan="1"><italic>0.301</italic></td><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;<italic>Ketamine effect during active-nicotine</italic></td><td align="center" rowspan="1" colspan="1"><italic>1.6</italic></td><td align="center" rowspan="1" colspan="1"><italic>0.47</italic></td><td align="center" rowspan="1" colspan="1"><italic>0.519</italic></td><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Nicotine&#x02009;&#x000d7;&#x02009;lead</td><td align="center" rowspan="1" colspan="1">1.6</td><td align="center" rowspan="1" colspan="1">0.01</td><td align="center" rowspan="1" colspan="1">0.914</td><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">1.81</td><td align="center" rowspan="1" colspan="1">0.227</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Ketamine&#x02009;&#x000d7;&#x02009;lead</td><td align="center" rowspan="1" colspan="1">1.6</td><td align="center" rowspan="1" colspan="1">0.26</td><td align="center" rowspan="1" colspan="1">0.627</td><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.04</td><td align="center" rowspan="1" colspan="1">0.854</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Nicotine&#x02009;&#x000d7;&#x02009;ketamine&#x02009;&#x000d7;&#x02009;lead</td><td align="center" rowspan="1" colspan="1">1.6</td><td align="center" rowspan="1" colspan="1">9.50</td><td align="center" rowspan="1" colspan="1"><bold>0.022</bold></td><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.00</td><td align="center" rowspan="1" colspan="1">0.972</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;<italic>Nicotine</italic>&#x02009;&#x000d7;&#x02009;<italic>ketamine at Fz</italic></td><td align="center" rowspan="1" colspan="1"><italic>1.6</italic></td><td align="center" rowspan="1" colspan="1"><italic>1.04</italic></td><td align="center" rowspan="1" colspan="1"><italic>0.347</italic></td><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;<italic>Nicotine</italic>&#x02009;&#x000d7;&#x02009;<italic>ketamine at Cz</italic></td><td align="center" rowspan="1" colspan="1"><italic>1.6</italic></td><td align="center" rowspan="1" colspan="1"><italic>11.38</italic></td><td align="center" rowspan="1" colspan="1"><bold><italic>0.015</italic></bold></td><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;<italic>Nicotine effect during placebo-ketamine</italic></td><td align="center" rowspan="1" colspan="1"><italic>1.6</italic></td><td align="center" rowspan="1" colspan="1"><italic>5.48</italic></td><td align="center" rowspan="1" colspan="1"><italic>0.058</italic></td><td align="left" rowspan="1" colspan="1"><italic>Nicotine</italic>&#x02009;&#x0003c;&#x02009;<italic>placebo</italic></td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;<italic>Nicotine effect during active ketamine</italic></td><td align="center" rowspan="1" colspan="1"><italic>1.6</italic></td><td align="center" rowspan="1" colspan="1"><italic>0.003</italic></td><td align="center" rowspan="1" colspan="1"><italic>0.960</italic></td><td align="left" rowspan="1" colspan="1"><italic>Nicotine&#x02009;&#x02265;&#x02009;placebo</italic></td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;<italic>Ketamine effect during placebo-nicotine</italic></td><td align="center" rowspan="1" colspan="1"><italic>1.6</italic></td><td align="center" rowspan="1" colspan="1"><italic>1.40</italic></td><td align="center" rowspan="1" colspan="1"><italic>0.281</italic></td><td align="left" rowspan="1" colspan="1"><italic>Ketamine&#x02009;&#x02264;&#x02009;placebo</italic></td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;<italic>Ketamine effect during active-nicotine</italic></td><td align="center" rowspan="1" colspan="1"><italic>1.6</italic></td><td align="center" rowspan="1" colspan="1"><italic>2.94</italic></td><td align="center" rowspan="1" colspan="1"><italic>0.137</italic></td><td align="left" rowspan="1" colspan="1"><italic>Ketamine&#x02009;&#x02265;&#x02009;placebo</italic></td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><p><italic>ANOVA results are based on mutlivariate assumptions for repeated-measures, and all <italic>F</italic>-tests are based on Wilks&#x02019; Lambda. Follow-up ANOVA results are shown in italics. Significant p-values are shown in bold</italic>.</p></table-wrap-foot></table-wrap></sec><sec id="S3-17"><title>Mismatch negativity latency</title><p>Analysis of variance results for MMN latency are presented in Table <xref ref-type="table" rid="T7">7</xref>. There was a significant main effect of ketamine (<italic>p</italic>&#x02009;=&#x02009;0.025) indicating that ketamine shortened MMN latency by 19.64&#x02009;ms relative to placebo. No other main effects or interactions were significant.</p></sec><sec id="S3-18"><title>Plasma drug levels</title><p>Mean plasma levels for ketamine, norketamine, dehydroketamine, and nicotine are presented in Table <xref ref-type="table" rid="T8">8</xref>. There were no significant differences in levels of plasma ketamine, norketamine, or dehydroketamine levels between the ketamine alone condition and the ketamine&#x02013;nicotine condition. In addition, there were no significant differences in plasma nicotine levels between the nicotine alone condition and the ketamine&#x02013;nicotine condition.</p><table-wrap id="T8" position="float"><label>Table 8</label><caption><p><bold>Plasma ketamine, norketamine, dehydroketamine and nicotine levels</bold>.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Blood level (ng/ml)</th><th align="center" rowspan="1" colspan="1">Time</th><th align="center" rowspan="1" colspan="1">Placebo</th><th align="center" rowspan="1" colspan="1">Ketamine alone</th><th align="center" rowspan="1" colspan="1">Nicotine alone</th><th align="center" rowspan="1" colspan="1">Ketamine&#x02009;+&#x02009;nicotine</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Ketamine</td><td align="center" rowspan="1" colspan="1">+35</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">174.91 (59.92)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">171.22 (62.21)</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">+98</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">222.40 (57.55)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">229.78 (64.52)</td></tr><tr><td align="left" rowspan="1" colspan="1">Norketamine</td><td align="center" rowspan="1" colspan="1">+35</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">70.82 (32.61)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">73.78 (40.92)</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">+98</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">147.20 (52.21)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">138.67 (45.92)</td></tr><tr><td align="left" rowspan="1" colspan="1">Dehydroketamine</td><td align="center" rowspan="1" colspan="1">+35</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">16.09 (9.86)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">17.78 (9.04)</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">+98</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">42.20 (19.77)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">42.33 (23.52)</td></tr><tr><td align="left" rowspan="1" colspan="1">Nicotine</td><td align="center" rowspan="1" colspan="1">+35</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">6.92 (3.23)</td><td align="center" rowspan="1" colspan="1">10.18 (4.31)</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">+98</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">6.65 (2.63)</td><td align="center" rowspan="1" colspan="1">12.93 (7.01)</td></tr></tbody></table><table-wrap-foot><p><italic>Ketamine levels were assayed only on the days that subjects received ketamine (ketamine alone and ketamine&#x02009;+&#x02009;nicotine) and nicotine was assayed only on the days that subjects received nicotine (nicotine alone and nicotine&#x02009;+&#x02009;ketamine)</italic>.</p></table-wrap-foot></table-wrap></sec></sec><sec sec-type="discussion" id="S4"><title>Discussion</title><p>The principal findings of the current study are the differential effects of ketamine and nicotine on MMN and P300, and their interactive effects on MMN.</p><sec id="S4-19"><title>Effects of ketamine</title><p>Consistent with previous studies (<xref ref-type="bibr" rid="B4">4</xref>, <xref ref-type="bibr" rid="B5">5</xref>, <xref ref-type="bibr" rid="B7">7</xref>&#x02013;<xref ref-type="bibr" rid="B13">13</xref>, <xref ref-type="bibr" rid="B120">120</xref>), ketamine induced transient schizophrenia-like behavioral effects in healthy subjects. In terms of the electrophysiological measures, ketamine decreased the amplitude and delayed the latency of P300, regardless of whether P300 was elicited by a target or novel stimulus. The decrease in amplitude is consistent with the other ERP studies showing ketamine to reduce P300 amplitude at parietal leads (<xref ref-type="bibr" rid="B46">46</xref>&#x02013;<xref ref-type="bibr" rid="B51">51</xref>), although we did not observe the previously reported increase in novelty P3a at frontal leads with ketamine (<xref ref-type="bibr" rid="B51">51</xref>). Our results are also consistent with a prior study showing ketamine to decrease the amplitude of the late positive potential in a working memory task (<xref ref-type="bibr" rid="B9">9</xref>). These results provide evidence that glutamatergic neurotransmission at NMDA receptors contribute to P300 generation, both in response to infrequent target stimuli (P3b) and infrequent novel stimuli (P3a). Moreover, inasmuch as P300 amplitude reduction and latency delay are well established in schizophrenia (<xref ref-type="bibr" rid="B42">42</xref>, <xref ref-type="bibr" rid="B43">43</xref>, <xref ref-type="bibr" rid="B121">121</xref>, <xref ref-type="bibr" rid="B122">122</xref>), our findings are consistent with the NMDA receptor hypofunction model of schizophrenia (<xref ref-type="bibr" rid="B1">1</xref>&#x02013;<xref ref-type="bibr" rid="B3">3</xref>, <xref ref-type="bibr" rid="B5">5</xref>, <xref ref-type="bibr" rid="B6">6</xref>, <xref ref-type="bibr" rid="B123">123</xref>, <xref ref-type="bibr" rid="B124">124</xref>) and its possible role in mediating P300 deficits.</p><p>The current study did not find ketamine to significantly reduce MMN amplitude. This conflicts with a number of previous studies (<xref ref-type="bibr" rid="B26">26</xref>, <xref ref-type="bibr" rid="B46">46</xref>, <xref ref-type="bibr" rid="B65">65</xref>&#x02013;<xref ref-type="bibr" rid="B68">68</xref>), but is consistent with some studies that either failed to show a ketamine effect on MMN (<xref ref-type="bibr" rid="B50">50</xref>) or showed the ketamine-induced MMN reduction to be limited to a subset of task conditions or cortical source locations (<xref ref-type="bibr" rid="B26">26</xref>, <xref ref-type="bibr" rid="B65">65</xref>, <xref ref-type="bibr" rid="B67">67</xref>), or to a subgroup of subjects (<xref ref-type="bibr" rid="B66">66</xref>). The discrepant results across these studies may be due to differences in the dosage and dosing schedule of ketamine. For example, the study with the most robust effects (<xref ref-type="bibr" rid="B26">26</xref>) used a high dose of ketamine (0.9&#x02009;mg/kg), while the study with a non-significant result (<xref ref-type="bibr" rid="B50">50</xref>) used a relatively low dose (0.3&#x02009;mg/kg). Heekeren and colleagues (<xref ref-type="bibr" rid="B65">65</xref>) also demonstrated dose-dependent changes in MMN amplitude using two different doses of ketamine (0.1&#x02013;0.15 and 0.15&#x02013;0.20&#x02009;mg/kg). The absence of a significant ketamine effect on MMN in our study may also have been related to the relatively small size of our subject sample, resulting in limited power to detect an effect. For the ketamine vs. placebo effect on MMN amplitude during the placebo-nicotine day, the effect size (Cohen&#x02019;s <italic>d</italic>) was estimated to be &#x02212;0.43. This effect size, which appears to be smaller than the effects reported in prior studies showing ketamine to reduce MMN, would reach significance (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05) with a sample of about 25 subjects. This underscores the limited power in our current study, and points to an effect of ketamine on MMN that may emerge with moderate sample sizes.</p><p>However, it is noteworthy that our sample size was sufficiently large to detect robust psychotomimetic effects of ketamine, as well as significant ketamine-induced reductions and delays in the P300 ERP component. Thus, consistent with the report of Oranje and colleagues (<xref ref-type="bibr" rid="B50">50</xref>), the P300 ERP component appears to be more sensitive to the effects of NMDA receptor blockade than the MMN component. In terms of MMN latency, ketamine reduced MMN latency by about 19&#x02009;ms. This effect has not been previously reported to our knowledge, and therefore should be regarded as preliminary pending replication in future studies.</p></sec><sec id="S4-20"><title>Effects of nicotine</title><p>To our knowledge, this is the first study to show nicotine to reduce the novelty P300 (P3a) in humans. This unexpected finding appears to conflict with the plethora of evidence showing nicotine to enhance cognitive functions, including attention (<xref ref-type="bibr" rid="B14">14</xref>&#x02013;<xref ref-type="bibr" rid="B16">16</xref>). It is possible to construe the novelty P3a reduction by nicotine as a reflection of enhanced focus on the target detection task and reduced susceptibility to distraction by non-target distractors. However, such an interpretation is not consistent with other evidence showing P3a reduction in patients with schizophrenia (<xref ref-type="bibr" rid="B43">43</xref>, <xref ref-type="bibr" rid="B121">121</xref>, <xref ref-type="bibr" rid="B125">125</xref>&#x02013;<xref ref-type="bibr" rid="B128">128</xref>) and patients with frontal lobe lesions (<xref ref-type="bibr" rid="B129">129</xref>&#x02013;<xref ref-type="bibr" rid="B131">131</xref>), two conditions known to be associated with attentional impairments and increased distractibility. Thus, nicotine&#x02019;s reduction of the P3a response to novel distractors is unlikely to be a reflection of its cognitive enhancing effects.</p><p>We did not observe significant effects of nicotine on target P300 (P3b), inconsistent with some prior reports showing nicotine to increase P300 amplitude (<xref ref-type="bibr" rid="B47">47</xref>, <xref ref-type="bibr" rid="B73">73</xref>, <xref ref-type="bibr" rid="B74">74</xref>) and decrease P300 latency (<xref ref-type="bibr" rid="B75">75</xref>, <xref ref-type="bibr" rid="B77">77</xref>) in smokers. However, our results are consistent with other studies reporting no effects of nicotine on P300 (<xref ref-type="bibr" rid="B76">76</xref>, <xref ref-type="bibr" rid="B78">78</xref>&#x02013;<xref ref-type="bibr" rid="B80">80</xref>). Our study was relatively unique in its use of the intravenous route for nicotine administration, which may partially account for inconsistencies between our results and some prior studies. More generally, inconsistencies among studies may also be related to differences in the type of nicotinic agonist and dosage used, differences in sensory modality of the oddball task used to elicit the P300, and different representations of smokers and non-smokers in the study samples.</p><p>The differential effects of nicotine on P3a and P3b in our study is consistent with other evidence that the neuroanatomical (<xref ref-type="bibr" rid="B33">33</xref>) and neurochemical (<xref ref-type="bibr" rid="B71">71</xref>) underpinnings of P3a and P3b are at least partially dissociable. Polich and Criado (<xref ref-type="bibr" rid="B71">71</xref>) proposed dopaminergic/frontal processes for P3a generation and locus coeruleus-mediated noradrenergic/parietal processes for P3b generation. Evidence for this includes demonstrations that chronic abuse of different street drugs are associated with differential effects on P3a and P3b amplitudes (<xref ref-type="bibr" rid="B71">71</xref>). Nonetheless, roles for nicotinic cholinergic neurotransmission, as well as glutamatergic neurotransmission, have not figured prominently in prior neurochemical models of P300 generation.</p><p>Nicotine alone produced a trend level reduction of MMN amplitude, but this effect was not evident when comparing the Nicotine&#x02009;+&#x02009;Ketamine condition to Ketamine alone. These results conflict with some prior studies showing nicotine or nicotinic agonists to enhance MMN amplitude in response to duration (<xref ref-type="bibr" rid="B85">85</xref>), frequency (<xref ref-type="bibr" rid="B86">86</xref>, <xref ref-type="bibr" rid="B87">87</xref>), or inter-stimulus interval (<xref ref-type="bibr" rid="B88">88</xref>) deviants in healthy volunteers, and similarly failed to corroborate studies showing nicotine to enhance duration-deviant MMN amplitude in schizophrenia patients (<xref ref-type="bibr" rid="B98">98</xref>). One possible reason for the discrepancy between our findings and those reported previously is that our study used an intravenous route of nicotine administration whereas prior studies used either gum (<xref ref-type="bibr" rid="B85">85</xref>, <xref ref-type="bibr" rid="B88">88</xref>, <xref ref-type="bibr" rid="B98">98</xref>) or a transdermal patch (<xref ref-type="bibr" rid="B87">87</xref>). While differences in the pharmacokinetics and pharmacodynamics between intravenous vs. gum and transdermal routes of administration have not been systematically studied&#x02019;, it is likely that time to onset of action and peak levels achieved would differ between these modes of nicotine delivery, and such differences could account for variability in the effects of nicotine on MMN. At the same time, it should be noted that a number of studies using gum (<xref ref-type="bibr" rid="B47">47</xref>, <xref ref-type="bibr" rid="B99">99</xref>) or transdermal patches (<xref ref-type="bibr" rid="B89">89</xref>, <xref ref-type="bibr" rid="B90">90</xref>) failed to demonstrate an enhancement of MMN amplitude by nicotine. Moreover, the fact that our study focused on duration-deviant MMN, in part because of evidence that it is more sensitive to schizophrenia than other types of MMN (<xref ref-type="bibr" rid="B58">58</xref>, <xref ref-type="bibr" rid="B60">60</xref>, <xref ref-type="bibr" rid="B61">61</xref>) cannot be the reason we failed to observe enhancement by nicotine, since at least two prior studies have shown the amplitude of the duration-deviant MMN to be increased by nicotine [Ref. (<xref ref-type="bibr" rid="B85">85</xref>, <xref ref-type="bibr" rid="B98">98</xref>); but, see Ref. (<xref ref-type="bibr" rid="B99">99</xref>)].</p></sec><sec id="S4-21"><title>Combined effect of ketamine and nicotine</title><p>Discordant with the study hypothesis, nicotine did not improve either the behavioral or neurophysiological abnormalities induced by ketamine. Of the many drugs tested in the ketamine model, few have been shown to reduce the schizophrenia-like behavioral and cognitive effects of ketamine in healthy human subjects. Lamotrigine, but not haloperidol or lorazepam, has been shown to reduce some of the behavioral and cognitive symptoms induced by ketamine in healthy volunteers (<xref ref-type="bibr" rid="B132">132</xref>&#x02013;<xref ref-type="bibr" rid="B134">134</xref>). With previous findings from animal and human studies documenting cognitive enhancing effects of nicotine in humans (<xref ref-type="bibr" rid="B135">135</xref>&#x02013;<xref ref-type="bibr" rid="B138">138</xref>) and animals (<xref ref-type="bibr" rid="B139">139</xref>, <xref ref-type="bibr" rid="B140">140</xref>), including animal data showing nicotine to ameliorate NMDA-antagonist induced cognitive deficits (<xref ref-type="bibr" rid="B106">106</xref>, <xref ref-type="bibr" rid="B107">107</xref>) or NMDA-antagonists to block cognitive enhancing effects of nicotine (<xref ref-type="bibr" rid="B108">108</xref>), it was surprising that nicotine did not show any tendency to reverse ketamine&#x02019;s psychotomimetic or cognitive ERP effects. Inconsistencies among studies may be due to differences in nicotine dose, rate, and route of nicotine administration, and the smoking status of the subjects tested. Importantly, our results are consistent with other studies showing that nicotine did not block ketamine&#x02019;s deleterious effects on P300 (<xref ref-type="bibr" rid="B47">47</xref>) or on neurocognitive test performance (<xref ref-type="bibr" rid="B141">141</xref>) in humans, suggesting that any pro-cognitive effects of nicotine may not be able to overcome the impairments produced by NMDA receptor blockade. However, our results were not consistent with a prior study that showed nicotine to prevent ketamine&#x02019;s reduction on MMN amplitude, an effect that was only observed in the subgroup of healthy volunteers with a high propensity to have hallucinatory experiences (<xref ref-type="bibr" rid="B66">66</xref>). However, this prior study used a substantially lower dose of ketamine than used in the current study, and nicotine was administered with chewing gum rather than the intravenous route employed here.</p></sec><sec id="S4-22"><title>Limitations</title><p>The main limitations of the current study include the small sample size, the high dropout rate, the heterogeneous smoking status of our sample, and the use of only one dose of nicotine. Future studies aimed at elucidating the effects of nicotine on patients with schizophrenia by using pharmacological models of psychosis in healthy volunteers must consider the fact that the large majority of schizophrenia patients are significantly dependent on nicotine. Accordingly, for studies about nAChR function to be relevant to schizophrenia, heavy smokers need to be included in the subject sample. However, the inclusion of nicotine-dependent heavy smokers in such studies raises the question of when to schedule the nicotine challenge relative to the timing of their last cigarette. Studying smokers who have been asked to abstain from smoking for several hours or more prior to study onset would mean studying them in a nicotine-withdrawal state. On the other hand, studying smokers who have smoked recently and are in a nicotine-satiated state may obscure the effects of intravenous nicotine. Further complicating this issue, studying non-smokers would result in high dropout routes because nicotine is generally unpleasant to non-smokers. Moreover, data from non-smokers may not generalize to schizophrenia patients, most of whom are heavy smokers.</p><p>In conclusion, the results of this study suggest that activation of nACH receptors does not influence ketamine&#x02019;s psychotomimetic effects or physiological effects on MMN and P300 in healthy human volunteers. However, ketamine and nicotine appear to have independent effects on P3a, P3b, and MMN suggesting differential effects of nACH and NMDA receptor systems on these ERP components. Moreover, this is the first study to report a significant reduction in P3a amplitude by nicotine.</p></sec></sec><sec id="S5"><title>Conflict of Interest Statement</title><p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></sec></body><back><ack><p>The authors also thank Angelina Genovese, R.N.C., M.B.A.; Elizabeth O&#x02019;Donnell, R.N.; Brenda Breault, R.N., B.S.N.; Sonah Yoo, R.Ph.; Robert Sturwold, R.Ph.; and Willie Ford of the Neurobiological Studies Unit at the VA Connecticut Healthcare System, West Haven Campus for their central contributions to the success of this project. The authors also acknowledge the contributions of John Krystal, MD for his role in providing the impetus in conducting the study. The Department of Veterans Affairs Schizophrenia Biological Research Center and a NARSAD Young Investigator Award to Hyun-Sang Cho supported this study.</p></ack><ref-list><title>References</title><ref id="B1"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coyle</surname><given-names>JT</given-names></name><name><surname>Tsai</surname><given-names>G</given-names></name><name><surname>Goff</surname><given-names>D</given-names></name></person-group>
<article-title>Converging evidence of NMDA receptor hypofunction in the pathophysiology of schizophrenia</article-title>. <source>Ann N Y Acad Sci</source> (<year>2003</year>) <volume>1003</volume>:<fpage>318</fpage>&#x02013;<lpage>27</lpage><pub-id pub-id-type="doi">10.1196/annals.1300.020</pub-id><pub-id pub-id-type="pmid">14684455</pub-id></mixed-citation></ref><ref id="B2"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Javitt</surname><given-names>DC</given-names></name><name><surname>Zukin</surname><given-names>SR</given-names></name></person-group>
<article-title>Recent advances in the phencyclidine model of schizophrenia</article-title>. <source>Am J Psychiatry</source> (<year>1991</year>) <volume>148</volume>:<fpage>1301</fpage>&#x02013;<lpage>8</lpage><pub-id pub-id-type="pmid">1654746</pub-id></mixed-citation></ref><ref id="B3"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Javitt</surname><given-names>DC</given-names></name><name><surname>Zukin</surname><given-names>SR</given-names></name><name><surname>Heresco-Levy</surname><given-names>U</given-names></name><name><surname>Umbricht</surname><given-names>D</given-names></name></person-group>
<article-title>Has an angel shown the way? Etiological and therapeutic implications of the PCP/NMDA model of schizophrenia</article-title>. <source>Schizophr Bull</source> (<year>2012</year>) <volume>38</volume>:<fpage>958</fpage>&#x02013;<lpage>66</lpage><pub-id pub-id-type="doi">10.1093/schbul/sbs069</pub-id><pub-id pub-id-type="pmid">22987851</pub-id></mixed-citation></ref><ref id="B4"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krystal</surname><given-names>JH</given-names></name><name><surname>Anand</surname><given-names>A</given-names></name><name><surname>Moghaddam</surname><given-names>B</given-names></name></person-group>
<article-title>Effects of NMDA receptor antagonists: implications for the pathophysiology of schizophrenia</article-title>. <source>Arch Gen Psychiatry</source> (<year>2002</year>) <volume>59</volume>:<fpage>663</fpage>&#x02013;<lpage>4</lpage><pub-id pub-id-type="doi">10.1001/archpsyc.59.7.663</pub-id><pub-id pub-id-type="pmid">12090822</pub-id></mixed-citation></ref><ref id="B5"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krystal</surname><given-names>JH</given-names></name><name><surname>D&#x02019;Souza</surname><given-names>DC</given-names></name><name><surname>Mathalon</surname><given-names>D</given-names></name><name><surname>Perry</surname><given-names>E</given-names></name><name><surname>Belger</surname><given-names>A</given-names></name><name><surname>Hoffman</surname><given-names>R</given-names></name></person-group>
<article-title>NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: toward a paradigm shift in medication development</article-title>. <source>Psychopharmacology (Berl)</source> (<year>2003</year>) <volume>169</volume>:<fpage>215</fpage>&#x02013;<lpage>33</lpage><pub-id pub-id-type="doi">10.1007/s00213-003-1582-z</pub-id><pub-id pub-id-type="pmid">12955285</pub-id></mixed-citation></ref><ref id="B6"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moghaddam</surname><given-names>B</given-names></name><name><surname>Javitt</surname><given-names>D</given-names></name></person-group>
<article-title>From revolution to evolution: the glutamate hypothesis of schizophrenia and its implication for treatment</article-title>. <source>Neuropsychopharmacology</source> (<year>2012</year>) <volume>37</volume>:<fpage>4</fpage>&#x02013;<lpage>15</lpage><pub-id pub-id-type="doi">10.1038/npp.2011.181</pub-id><pub-id pub-id-type="pmid">21956446</pub-id></mixed-citation></ref><ref id="B7"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moghaddam</surname><given-names>B</given-names></name><name><surname>Krystal</surname><given-names>JH</given-names></name></person-group>
<article-title>Capturing the angel in &#x0201c;angel dust&#x0201d;: twenty years of translational neuroscience studies of NMDA receptor antagonists in animals and humans</article-title>. <source>Schizophr Bull</source> (<year>2012</year>) <volume>38</volume>:<fpage>942</fpage>&#x02013;<lpage>9</lpage><pub-id pub-id-type="doi">10.1093/schbul/sbs075</pub-id><pub-id pub-id-type="pmid">22899397</pub-id></mixed-citation></ref><ref id="B8"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adler</surname><given-names>CM</given-names></name><name><surname>Goldberg</surname><given-names>TE</given-names></name><name><surname>Malhotra</surname><given-names>AK</given-names></name><name><surname>Pickar</surname><given-names>D</given-names></name><name><surname>Breier</surname><given-names>A</given-names></name></person-group>
<article-title>Effects of ketamine on thought disorder, working memory, and semantic memory in healthy volunteers</article-title>. <source>Biol Psychiatry</source> (<year>1998</year>) <volume>43</volume>:<fpage>811</fpage>&#x02013;<lpage>6</lpage><pub-id pub-id-type="doi">10.1016/S0006-3223(97)00556-8</pub-id><pub-id pub-id-type="pmid">9611670</pub-id></mixed-citation></ref><ref id="B9"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ahn</surname><given-names>KH</given-names></name><name><surname>Youn</surname><given-names>T</given-names></name><name><surname>Cho</surname><given-names>SS</given-names></name><name><surname>Ha</surname><given-names>TH</given-names></name><name><surname>Ha</surname><given-names>KS</given-names></name><name><surname>Kim</surname><given-names>MS</given-names></name><etal/></person-group>
<article-title>N-methyl-D-aspartate receptor in working memory impairments in schizophrenia: event-related potential study of late stage of working memory process</article-title>. <source>Prog Neuropsychopharmacol Biol Psychiatry</source> (<year>2003</year>) <volume>27</volume>:<fpage>993</fpage>&#x02013;<lpage>9</lpage><pub-id pub-id-type="doi">10.1016/S0278-5846(03)00159-3</pub-id><pub-id pub-id-type="pmid">14499316</pub-id></mixed-citation></ref><ref id="B10"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krystal</surname><given-names>JH</given-names></name><name><surname>Karper</surname><given-names>LP</given-names></name><name><surname>Seibyl</surname><given-names>JP</given-names></name><name><surname>Freeman</surname><given-names>GK</given-names></name><name><surname>Delaney</surname><given-names>R</given-names></name><name><surname>Bremner</surname><given-names>JD</given-names></name><etal/></person-group>
<article-title>Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses</article-title>. <source>Arch Gen Psychiatry</source> (<year>1994</year>) <volume>51</volume>:<fpage>199</fpage>&#x02013;<lpage>214</lpage><pub-id pub-id-type="doi">10.1001/archpsyc.1994.03950030035004</pub-id><pub-id pub-id-type="pmid">8122957</pub-id></mixed-citation></ref><ref id="B11"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lahti</surname><given-names>AC</given-names></name><name><surname>Weiler</surname><given-names>MA</given-names></name><name><surname>Tamara Michaelidis</surname><given-names>BA</given-names></name><name><surname>Parwani</surname><given-names>A</given-names></name><name><surname>Tamminga</surname><given-names>CA</given-names></name></person-group>
<article-title>Effects of ketamine in normal and schizophrenic volunteers</article-title>. <source>Neuropsychopharmacology</source> (<year>2001</year>) <volume>25</volume>:<fpage>455</fpage>&#x02013;<lpage>67</lpage><pub-id pub-id-type="doi">10.1016/S0893-133X(01)00243-3</pub-id><pub-id pub-id-type="pmid">11557159</pub-id></mixed-citation></ref><ref id="B12"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Malhotra</surname><given-names>AK</given-names></name><name><surname>Pinals</surname><given-names>DA</given-names></name><name><surname>Weingartner</surname><given-names>H</given-names></name><name><surname>Sirocco</surname><given-names>K</given-names></name><name><surname>Missar</surname><given-names>CD</given-names></name><name><surname>Pickar</surname><given-names>D</given-names></name><etal/></person-group>
<article-title>NMDA receptor function and human cognition: the effects of ketamine in healthy volunteers</article-title>. <source>Neuropsychopharmacology</source> (<year>1996</year>) <volume>14</volume>:<fpage>301</fpage>&#x02013;<lpage>7</lpage><pub-id pub-id-type="doi">10.1016/0893-133X(95)00137-3</pub-id><pub-id pub-id-type="pmid">8703299</pub-id></mixed-citation></ref><ref id="B13"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morgan</surname><given-names>CJ</given-names></name><name><surname>Mofeez</surname><given-names>A</given-names></name><name><surname>Brandner</surname><given-names>B</given-names></name><name><surname>Bromley</surname><given-names>L</given-names></name><name><surname>Curran</surname><given-names>HV</given-names></name></person-group>
<article-title>Acute effects of ketamine on memory systems and psychotic symptoms in healthy volunteers</article-title>. <source>Neuropsychopharmacology</source> (<year>2004</year>) <volume>29</volume>:<fpage>208</fpage>&#x02013;<lpage>18</lpage><pub-id pub-id-type="doi">10.1038/sj.npp.1300342</pub-id><pub-id pub-id-type="pmid">14603267</pub-id></mixed-citation></ref><ref id="B14"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Newhouse</surname><given-names>PA</given-names></name><name><surname>Potter</surname><given-names>A</given-names></name><name><surname>Singh</surname><given-names>A</given-names></name></person-group>
<article-title>Effects of nicotinic stimulation on cognitive performance</article-title>. <source>Curr Opin Pharmacol</source> (<year>2004</year>) <volume>4</volume>:<fpage>36</fpage>&#x02013;<lpage>46</lpage><pub-id pub-id-type="doi">10.1016/j.coph.2003.11.001</pub-id><pub-id pub-id-type="pmid">15018837</pub-id></mixed-citation></ref><ref id="B15"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rezvani</surname><given-names>AH</given-names></name><name><surname>Levin</surname><given-names>ED</given-names></name></person-group>
<article-title>Cognitive effects of nicotine</article-title>. <source>Biol Psychiatry</source> (<year>2001</year>) <volume>49</volume>:<fpage>258</fpage>&#x02013;<lpage>67</lpage><pub-id pub-id-type="doi">10.1016/S0006-3223(00)01094-5</pub-id><pub-id pub-id-type="pmid">11230877</pub-id></mixed-citation></ref><ref id="B16"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Swan</surname><given-names>GE</given-names></name><name><surname>Lessov-Schlaggar</surname><given-names>CN</given-names></name></person-group>
<article-title>The effects of tobacco smoke and nicotine on cognition and the brain</article-title>. <source>Neuropsychol Rev</source> (<year>2007</year>) <volume>17</volume>:<fpage>259</fpage>&#x02013;<lpage>73</lpage><pub-id pub-id-type="doi">10.1007/s11065-007-9035-9</pub-id><pub-id pub-id-type="pmid">17690985</pub-id></mixed-citation></ref><ref id="B17"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>S</given-names></name><name><surname>Knopick</surname><given-names>C</given-names></name><name><surname>McGurk</surname><given-names>S</given-names></name><name><surname>Meltzer</surname><given-names>HY</given-names></name></person-group>
<article-title>Nicotine impairs spatial working memory while leaving spatial attention intact</article-title>. <source>Neuropsychopharmacology</source> (<year>2000</year>) <volume>22</volume>:<fpage>200</fpage>&#x02013;<lpage>9</lpage><pub-id pub-id-type="doi">10.1016/S0893-133X(99)00098-6</pub-id><pub-id pub-id-type="pmid">10649832</pub-id></mixed-citation></ref><ref id="B18"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sakurai</surname><given-names>Y</given-names></name><name><surname>Kanazawa</surname><given-names>I</given-names></name></person-group>
<article-title>Acute effects of cigarettes in non-deprived smokers on memory, calculation and executive functions</article-title>. <source>Hum Psychopharmacol</source> (<year>2002</year>) <volume>17</volume>:<fpage>369</fpage>&#x02013;<lpage>73</lpage><pub-id pub-id-type="doi">10.1002/hup.424</pub-id><pub-id pub-id-type="pmid">12415558</pub-id></mixed-citation></ref><ref id="B19"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>George</surname><given-names>TP</given-names></name><name><surname>Vessicchio</surname><given-names>JC</given-names></name><name><surname>Termine</surname><given-names>A</given-names></name><name><surname>Sahady</surname><given-names>DM</given-names></name><name><surname>Head</surname><given-names>CA</given-names></name><name><surname>Pepper</surname><given-names>WT</given-names></name><etal/></person-group>
<article-title>Effects of smoking abstinence on visuospatial working memory function in schizophrenia</article-title>. <source>Neuropsychopharmacology</source> (<year>2002</year>) <volume>26</volume>:<fpage>75</fpage>&#x02013;<lpage>85</lpage><pub-id pub-id-type="doi">10.1016/S0893-133X(01)00296-2</pub-id><pub-id pub-id-type="pmid">11751034</pub-id></mixed-citation></ref><ref id="B20"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kumari</surname><given-names>V</given-names></name><name><surname>Postma</surname><given-names>P</given-names></name></person-group>
<article-title>Nicotine use in schizophrenia: the self medication hypotheses</article-title>. <source>Neurosci Biobehav Rev</source> (<year>2005</year>) <volume>29</volume>:<fpage>1021</fpage>&#x02013;<lpage>34</lpage><pub-id pub-id-type="doi">10.1016/j.neubiorev.2005.02.006</pub-id><pub-id pub-id-type="pmid">15964073</pub-id></mixed-citation></ref><ref id="B21"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sacco</surname><given-names>KA</given-names></name><name><surname>Bannon</surname><given-names>KL</given-names></name><name><surname>George</surname><given-names>TP</given-names></name></person-group>
<article-title>Nicotinic receptor mechanisms and cognition in normal states and neuropsychiatric disorders</article-title>. <source>J Psychopharmacol</source> (<year>2004</year>) <volume>18</volume>:<fpage>457</fpage>&#x02013;<lpage>74</lpage><pub-id pub-id-type="doi">10.1177/0269881104047273</pub-id><pub-id pub-id-type="pmid">15582913</pub-id></mixed-citation></ref><ref id="B22"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hetem</surname><given-names>LA</given-names></name><name><surname>Danion</surname><given-names>JM</given-names></name><name><surname>Diemunsch</surname><given-names>P</given-names></name><name><surname>Brandt</surname><given-names>C</given-names></name></person-group>
<article-title>Effect of a subanesthetic dose of ketamine on memory and conscious awareness in healthy volunteers</article-title>. <source>Psychopharmacology (Berl)</source> (<year>2000</year>) <volume>152</volume>:<fpage>283</fpage>&#x02013;<lpage>8</lpage><pub-id pub-id-type="doi">10.1007/s002130000511</pub-id><pub-id pub-id-type="pmid">11105938</pub-id></mixed-citation></ref><ref id="B23"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Honey</surname><given-names>RA</given-names></name><name><surname>Turner</surname><given-names>DC</given-names></name><name><surname>Honey</surname><given-names>GD</given-names></name><name><surname>Sharar</surname><given-names>SR</given-names></name><name><surname>Kumaran</surname><given-names>D</given-names></name><name><surname>Pomarol-Clotet</surname><given-names>E</given-names></name><etal/></person-group>
<article-title>Subdissociative dose ketamine produces a deficit in manipulation but not maintenance of the contents of working memory</article-title>. <source>Neuropsychopharmacology</source> (<year>2003</year>) <volume>28</volume>:<fpage>2037</fpage>&#x02013;<lpage>44</lpage><pub-id pub-id-type="doi">10.1038/sj.npp.1300272</pub-id><pub-id pub-id-type="pmid">12888783</pub-id></mixed-citation></ref><ref id="B24"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krystal</surname><given-names>JH</given-names></name><name><surname>Bennett</surname><given-names>A</given-names></name><name><surname>Abi-Saab</surname><given-names>D</given-names></name><name><surname>Belger</surname><given-names>A</given-names></name><name><surname>Karper</surname><given-names>LP</given-names></name><name><surname>D&#x02019;Souza</surname><given-names>DC</given-names></name><etal/></person-group>
<article-title>Dissociation of ketamine effects on rule acquisition and rule implementation: possible relevance to NMDA receptor contributions to executive cognitive functions</article-title>. <source>Biol Psychiatry</source> (<year>2000</year>) <volume>47</volume>:<fpage>137</fpage>&#x02013;<lpage>43</lpage><pub-id pub-id-type="doi">10.1016/S0006-3223(99)00097-9</pub-id><pub-id pub-id-type="pmid">10664830</pub-id></mixed-citation></ref><ref id="B25"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rowland</surname><given-names>LM</given-names></name><name><surname>Astur</surname><given-names>RS</given-names></name><name><surname>Jung</surname><given-names>RE</given-names></name><name><surname>Bustillo</surname><given-names>JR</given-names></name><name><surname>Lauriello</surname><given-names>J</given-names></name><name><surname>Yeo</surname><given-names>RA</given-names></name></person-group>
<article-title>Selective cognitive impairments associated with NMDA receptor blockade in humans</article-title>. <source>Neuropsychopharmacology</source> (<year>2005</year>) <volume>30</volume>:<fpage>633</fpage>&#x02013;<lpage>9</lpage><pub-id pub-id-type="doi">10.1038/sj.npp.1300642</pub-id><pub-id pub-id-type="pmid">15647751</pub-id></mixed-citation></ref><ref id="B26"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Umbricht</surname><given-names>D</given-names></name><name><surname>Schmid</surname><given-names>L</given-names></name><name><surname>Koller</surname><given-names>R</given-names></name><name><surname>Vollenweider</surname><given-names>FX</given-names></name><name><surname>Hell</surname><given-names>D</given-names></name><name><surname>Javitt</surname><given-names>DC</given-names></name></person-group>
<article-title>Ketamine-induced deficits in auditory and visual context-dependent processing in healthy volunteers: implications for models of cognitive deficits in schizophrenia</article-title>. <source>Arch Gen Psychiatry</source> (<year>2000</year>) <volume>57</volume>:<fpage>1139</fpage>&#x02013;<lpage>47</lpage><pub-id pub-id-type="doi">10.1001/archpsyc.57.12.1139</pub-id><pub-id pub-id-type="pmid">11115327</pub-id></mixed-citation></ref><ref id="B27"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Polich</surname><given-names>J</given-names></name></person-group>
<article-title>Updating P300: an integrative theory of P3a and P3b</article-title>. <source>Clin Neurophysiol</source> (<year>2007</year>) <volume>118</volume>:<fpage>2128</fpage>&#x02013;<lpage>48</lpage><pub-id pub-id-type="doi">10.1016/j.clinph.2007.04.019</pub-id><pub-id pub-id-type="pmid">17573239</pub-id></mixed-citation></ref><ref id="B28"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Isreal</surname><given-names>JB</given-names></name><name><surname>Chesney</surname><given-names>GL</given-names></name><name><surname>Wickens</surname><given-names>CD</given-names></name><name><surname>Donchin</surname><given-names>E</given-names></name></person-group>
<article-title>P300 and tracking difficulty: evidence for multiple resources in dual-task performance</article-title>. <source>Psychophysiology</source> (<year>1980</year>) <volume>17</volume>:<fpage>259</fpage>&#x02013;<lpage>73</lpage><pub-id pub-id-type="doi">10.1111/j.1469-8986.1980.tb00146.x</pub-id><pub-id pub-id-type="pmid">7384376</pub-id></mixed-citation></ref><ref id="B29"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kramer</surname><given-names>AF</given-names></name><name><surname>Strayer</surname><given-names>DL</given-names></name></person-group>
<article-title>Assessing the development of automatic processing: an application of dual-task and event-related brain potential methodologies</article-title>. <source>Biol Psychol</source> (<year>1988</year>) <volume>26</volume>:<fpage>231</fpage>&#x02013;<lpage>67</lpage><pub-id pub-id-type="doi">10.1016/0301-0511(88)90022-1</pub-id><pub-id pub-id-type="pmid">3207785</pub-id></mixed-citation></ref><ref id="B30"><label>30</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ravden</surname><given-names>D</given-names></name><name><surname>Polich</surname><given-names>J</given-names></name></person-group>
<article-title>Habituation of P300 from visual stimuli</article-title>. <source>Int J Psychophysiol</source> (<year>1998</year>) <volume>30</volume>:<fpage>359</fpage>&#x02013;<lpage>65</lpage><pub-id pub-id-type="doi">10.1016/S0167-8760(98)00039-7</pub-id><pub-id pub-id-type="pmid">9834892</pub-id></mixed-citation></ref><ref id="B31"><label>31</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johnson</surname><given-names>R</given-names><suffix>Jr</suffix></name><name><surname>Donchin</surname><given-names>E</given-names></name></person-group>
<article-title>P300 and stimulus categorization: two plus one is not so different from one plus one</article-title>. <source>Psychophysiology</source> (<year>1980</year>) <volume>17</volume>:<fpage>167</fpage>&#x02013;<lpage>78</lpage><pub-id pub-id-type="doi">10.1111/j.1469-8986.1980.tb00131.x</pub-id><pub-id pub-id-type="pmid">7375618</pub-id></mixed-citation></ref><ref id="B32"><label>32</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Donchin</surname><given-names>E</given-names></name><name><surname>Coles</surname><given-names>M</given-names></name></person-group>
<article-title>Is the P300 component a manifestation of context updating? (Commentary on Verleger&#x02019;s critique of the context updating model)</article-title>. <source>Behav Brain Sci</source> (<year>1988</year>) <volume>11</volume>:<fpage>357</fpage>&#x02013;<lpage>74</lpage><pub-id pub-id-type="doi">10.1017/S0140525X00058027</pub-id></mixed-citation></ref><ref id="B33"><label>33</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Halgren</surname><given-names>E</given-names></name><name><surname>Marinkovic</surname><given-names>K</given-names></name><name><surname>Chauvel</surname><given-names>P</given-names></name></person-group>
<article-title>Generators of the late cognitive potentials in auditory and visual oddball tasks</article-title>. <source>Electroencephalogr Clin Neurophysiol</source> (<year>1998</year>) <volume>106</volume>:<fpage>156</fpage>&#x02013;<lpage>64</lpage><pub-id pub-id-type="doi">10.1016/S0013-4694(97)00119-3</pub-id><pub-id pub-id-type="pmid">9741777</pub-id></mixed-citation></ref><ref id="B34"><label>34</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>ME</given-names></name><name><surname>Halgren</surname><given-names>E</given-names></name><name><surname>Sokolik</surname><given-names>M</given-names></name><name><surname>Baudena</surname><given-names>P</given-names></name><name><surname>Musolino</surname><given-names>A</given-names></name><name><surname>Liegeois-Chauvel</surname><given-names>C</given-names></name><etal/></person-group>
<article-title>The intracranial topography of the P3 event-related potential elicited during auditory oddball</article-title>. <source>Electroencephalogr Clin Neurophysiol</source> (<year>1990</year>) <volume>76</volume>:<fpage>235</fpage>&#x02013;<lpage>48</lpage><pub-id pub-id-type="doi">10.1016/0013-4694(90)90018-F</pub-id><pub-id pub-id-type="pmid">1697255</pub-id></mixed-citation></ref><ref id="B35"><label>35</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dien</surname><given-names>J</given-names></name><name><surname>Spencer</surname><given-names>KM</given-names></name><name><surname>Donchin</surname><given-names>E</given-names></name></person-group>
<article-title>Parsing the late positive complex: mental chronometry and the ERP components that inhabit the neighborhood of the P300</article-title>. <source>Psychophysiology</source> (<year>2004</year>) <volume>41</volume>:<fpage>665</fpage>&#x02013;<lpage>78</lpage><pub-id pub-id-type="doi">10.1111/j.1469-8986.2004.00193.x</pub-id><pub-id pub-id-type="pmid">15318873</pub-id></mixed-citation></ref><ref id="B36"><label>36</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Polich</surname><given-names>J</given-names></name><name><surname>Kok</surname><given-names>A</given-names></name></person-group>
<article-title>Cognitive and biological determinants of P300: an integrative review</article-title>. <source>Biol Psychol</source> (<year>1995</year>) <volume>41</volume>:<fpage>103</fpage>&#x02013;<lpage>46</lpage><pub-id pub-id-type="doi">10.1016/0301-0511(95)05130-9</pub-id><pub-id pub-id-type="pmid">8534788</pub-id></mixed-citation></ref><ref id="B37"><label>37</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spencer</surname><given-names>KM</given-names></name><name><surname>Dien</surname><given-names>J</given-names></name><name><surname>Donchin</surname><given-names>E</given-names></name></person-group>
<article-title>Spatiotemporal analysis of the late ERP responses to deviant stimuli</article-title>. <source>Psychophysiology</source> (<year>2001</year>) <volume>38</volume>:<fpage>343</fpage>&#x02013;<lpage>58</lpage><pub-id pub-id-type="doi">10.1111/1469-8986.3820343</pub-id><pub-id pub-id-type="pmid">11347879</pub-id></mixed-citation></ref><ref id="B38"><label>38</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Squires</surname><given-names>NK</given-names></name><name><surname>Squires</surname><given-names>KC</given-names></name><name><surname>Hillyard</surname><given-names>SA</given-names></name></person-group>
<article-title>Two varieties of long-latency positive waves evoked by unpredictable auditory stimuli in man</article-title>. <source>Electroencephalogr Clin Neuropysiol</source> (<year>1975</year>) <volume>38</volume>:<fpage>387</fpage>&#x02013;<lpage>401</lpage><pub-id pub-id-type="doi">10.1016/0013-4694(75)90263-1</pub-id></mixed-citation></ref><ref id="B39"><label>39</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Comerchero</surname><given-names>MD</given-names></name><name><surname>Polich</surname><given-names>J</given-names></name></person-group>
<article-title>P3a, perceptual distinctiveness, and stimulus modality</article-title>. <source>Brain Res Cogn Brain Res</source> (<year>1998</year>) <volume>7</volume>:<fpage>41</fpage>&#x02013;<lpage>8</lpage><pub-id pub-id-type="doi">10.1016/S0926-6410(98)00009-3</pub-id><pub-id pub-id-type="pmid">9714727</pub-id></mixed-citation></ref><ref id="B40"><label>40</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Courchesne</surname><given-names>E</given-names></name><name><surname>Hillyard</surname><given-names>S</given-names></name><name><surname>Galambos</surname><given-names>R</given-names></name></person-group>
<article-title>Stimulus novelty, task relevance and the visual evoked potential in man</article-title>. <source>Electroencephalogr Clin Neurophysiol</source> (<year>1975</year>) <volume>39</volume>:<fpage>131</fpage>&#x02013;<lpage>43</lpage><pub-id pub-id-type="doi">10.1016/0013-4694(75)90003-6</pub-id><pub-id pub-id-type="pmid">50210</pub-id></mixed-citation></ref><ref id="B41"><label>41</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goldstein</surname><given-names>A</given-names></name><name><surname>Spencer</surname><given-names>KM</given-names></name><name><surname>Donchin</surname><given-names>E</given-names></name></person-group>
<article-title>The influence of stimulus deviance and novelty on the P300 and novelty P3</article-title>. <source>Psychophysiology</source> (<year>2002</year>) <volume>39</volume>:<fpage>781</fpage>&#x02013;<lpage>90</lpage><pub-id pub-id-type="doi">10.1111/1469-8986.3960781</pub-id><pub-id pub-id-type="pmid">12462506</pub-id></mixed-citation></ref><ref id="B42"><label>42</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bramon</surname><given-names>E</given-names></name><name><surname>Rabe-Hesketh</surname><given-names>S</given-names></name><name><surname>Sham</surname><given-names>P</given-names></name><name><surname>Murray</surname><given-names>RM</given-names></name><name><surname>Frangou</surname><given-names>S</given-names></name></person-group>
<article-title>Meta-analysis of the P300 and P50 waveforms in schizophrenia</article-title>. <source>Schizophr Res</source> (<year>2004</year>) <volume>70</volume>:<fpage>315</fpage>&#x02013;<lpage>29</lpage><pub-id pub-id-type="doi">10.1016/j.schres.2004.01.004</pub-id><pub-id pub-id-type="pmid">15329307</pub-id></mixed-citation></ref><ref id="B43"><label>43</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jeon</surname><given-names>YW</given-names></name><name><surname>Polich</surname><given-names>J</given-names></name></person-group>
<article-title>Meta-analysis of P300 and schizophrenia: patients, paradigms, and practical implications</article-title>. <source>Psychophysiology</source> (<year>2003</year>) <volume>40</volume>:<fpage>684</fpage>&#x02013;<lpage>701</lpage><pub-id pub-id-type="doi">10.1111/1469-8986.00070</pub-id><pub-id pub-id-type="pmid">14696723</pub-id></mixed-citation></ref><ref id="B44"><label>44</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Charles</surname><given-names>G</given-names></name><name><surname>Hansenne</surname><given-names>M</given-names></name></person-group>
<article-title>P 300 slow potential. Clinical interest in 3 mental diseases and neurobiology: a review</article-title>. <source>Encephale</source> (<year>1992</year>) <volume>18</volume>:<fpage>225</fpage>&#x02013;<lpage>236</lpage><pub-id pub-id-type="pmid">1299592</pub-id></mixed-citation></ref><ref id="B45"><label>45</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hansenne</surname><given-names>M</given-names></name></person-group>
<article-title>The p300 cognitive event-related potential. II. Individual variability and clinical application in psychopathology</article-title>. <source>Neurophysiol Clin</source> (<year>2000</year>) <volume>30</volume>:<fpage>211</fpage>&#x02013;<lpage>31</lpage><pub-id pub-id-type="doi">10.1016/S0987-7053(00)00224-0</pub-id><pub-id pub-id-type="pmid">11013895</pub-id></mixed-citation></ref><ref id="B46"><label>46</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gunduz-Bruce</surname><given-names>H</given-names></name><name><surname>Reinhart</surname><given-names>RM</given-names></name><name><surname>Roach</surname><given-names>BJ</given-names></name><name><surname>Gueorguieva</surname><given-names>R</given-names></name><name><surname>Oliver</surname><given-names>S</given-names></name><name><surname>D&#x02019;Souza</surname><given-names>DC</given-names></name><etal/></person-group>
<article-title>Glutamatergic modulation of auditory information processing in the human brain</article-title>. <source>Biol Psychiatry</source> (<year>2012</year>) <volume>71</volume>:<fpage>969</fpage>&#x02013;<lpage>77</lpage><pub-id pub-id-type="doi">10.1016/j.biopsych.2011.09.031</pub-id><pub-id pub-id-type="pmid">22036036</pub-id></mixed-citation></ref><ref id="B47"><label>47</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Knott</surname><given-names>V</given-names></name><name><surname>Millar</surname><given-names>AM</given-names></name><name><surname>McIntosh</surname><given-names>JF</given-names></name><name><surname>Shah</surname><given-names>DK</given-names></name><name><surname>Fisher</surname><given-names>DJ</given-names></name><name><surname>Blais</surname><given-names>CM</given-names></name><etal/></person-group>
<article-title>Separate and combined effects of low dose ketamine and nicotine on behavioural and neural correlates of sustained attention</article-title>. <source>Biol Psychol</source> (<year>2011</year>) <volume>88</volume>:<fpage>83</fpage>&#x02013;<lpage>93</lpage><pub-id pub-id-type="doi">10.1016/j.biopsycho.2011.06.012</pub-id><pub-id pub-id-type="pmid">21742012</pub-id></mixed-citation></ref><ref id="B48"><label>48</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Musso</surname><given-names>F</given-names></name><name><surname>Brinkmeyer</surname><given-names>J</given-names></name><name><surname>Ecker</surname><given-names>D</given-names></name><name><surname>London</surname><given-names>MK</given-names></name><name><surname>Thieme</surname><given-names>G</given-names></name><name><surname>Warbrick</surname><given-names>T</given-names></name><etal/></person-group>
<article-title>Ketamine effects on brain function &#x02013; simultaneous fMRI/EEG during a visual oddball task</article-title>. <source>Neuroimage</source> (<year>2011</year>) <volume>58</volume>:<fpage>508</fpage>&#x02013;<lpage>25</lpage><pub-id pub-id-type="doi">10.1016/j.neuroimage.2011.06.045</pub-id><pub-id pub-id-type="pmid">21723949</pub-id></mixed-citation></ref><ref id="B49"><label>49</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oranje</surname><given-names>B</given-names></name><name><surname>Gispen-de Wied</surname><given-names>CC</given-names></name><name><surname>Westenberg</surname><given-names>HG</given-names></name><name><surname>Kemner</surname><given-names>C</given-names></name><name><surname>Verbaten</surname><given-names>MN</given-names></name><name><surname>Kahn</surname><given-names>RS</given-names></name></person-group>
<article-title>Haloperidol counteracts the ketamine-induced disruption of processing negativity, but not that of the P300 amplitude</article-title>. <source>Int J Neuropsychopharmacol</source> (<year>2009</year>) <volume>12</volume>:<fpage>823</fpage>&#x02013;<lpage>32</lpage><pub-id pub-id-type="doi">10.1017/S1461145708009814</pub-id><pub-id pub-id-type="pmid">19154656</pub-id></mixed-citation></ref><ref id="B50"><label>50</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oranje</surname><given-names>B</given-names></name><name><surname>van Berckel</surname><given-names>BN</given-names></name><name><surname>Kemner</surname><given-names>C</given-names></name><name><surname>van Ree</surname><given-names>JM</given-names></name><name><surname>Kahn</surname><given-names>RS</given-names></name><name><surname>Verbaten</surname><given-names>MN</given-names></name></person-group>
<article-title>The effects of a sub-anaesthetic dose of ketamine on human selective attention</article-title>. <source>Neuropsychopharmacology</source> (<year>2000</year>) <volume>22</volume>:<fpage>293</fpage>&#x02013;<lpage>302</lpage><pub-id pub-id-type="doi">10.1016/S0893-133X(99)00118-9</pub-id><pub-id pub-id-type="pmid">10693157</pub-id></mixed-citation></ref><ref id="B51"><label>51</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Watson</surname><given-names>TD</given-names></name><name><surname>Petrakis</surname><given-names>IL</given-names></name><name><surname>Edgecombe</surname><given-names>J</given-names></name><name><surname>Perrino</surname><given-names>A</given-names></name><name><surname>Krystal</surname><given-names>JH</given-names></name><name><surname>Mathalon</surname><given-names>DH</given-names></name></person-group>
<article-title>Modulation of the cortical processing of novel and target stimuli by drugs affecting glutamate and GABA neurotransmission</article-title>. <source>Int J Neuropsychopharmacol</source> (<year>2009</year>) <volume>12</volume>:<fpage>357</fpage>&#x02013;<lpage>70</lpage><pub-id pub-id-type="doi">10.1017/S1461145708009334</pub-id><pub-id pub-id-type="pmid">18771605</pub-id></mixed-citation></ref><ref id="B52"><label>52</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Naatanen</surname><given-names>R</given-names></name><name><surname>Alho</surname><given-names>K</given-names></name></person-group>
<article-title>Mismatch negativity &#x02013; a unique measure of sensory processing in audition</article-title>. <source>Int J Neurosci</source> (<year>1995</year>) <volume>80</volume>:<fpage>317</fpage>&#x02013;<lpage>37</lpage><pub-id pub-id-type="doi">10.3109/00207459508986107</pub-id><pub-id pub-id-type="pmid">7775056</pub-id></mixed-citation></ref><ref id="B53"><label>53</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Naatanen</surname><given-names>R</given-names></name><name><surname>Gaillard</surname><given-names>AW</given-names></name><name><surname>Mantysalo</surname><given-names>S</given-names></name></person-group>
<article-title>Early selective-attention effect on evoked potential reinterpreted</article-title>. <source>Acta Psychol (Amst)</source> (<year>1978</year>) <volume>42</volume>:<fpage>313</fpage>&#x02013;<lpage>29</lpage><pub-id pub-id-type="doi">10.1016/0001-6918(78)90006-9</pub-id><pub-id pub-id-type="pmid">685709</pub-id></mixed-citation></ref><ref id="B54"><label>54</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stephan</surname><given-names>KE</given-names></name><name><surname>Baldeweg</surname><given-names>T</given-names></name><name><surname>Friston</surname><given-names>KJ</given-names></name></person-group>
<article-title>Synaptic plasticity and dysconnection in schizophrenia</article-title>. <source>Biol Psychiatry</source> (<year>2006</year>) <volume>59</volume>:<fpage>929</fpage>&#x02013;<lpage>39</lpage><pub-id pub-id-type="doi">10.1016/j.biopsych.2005.10.005</pub-id><pub-id pub-id-type="pmid">16427028</pub-id></mixed-citation></ref><ref id="B55"><label>55</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stephan</surname><given-names>KE</given-names></name><name><surname>Friston</surname><given-names>KJ</given-names></name><name><surname>Frith</surname><given-names>CD</given-names></name></person-group>
<article-title>Dysconnection in schizophrenia: from abnormal synaptic plasticity to failures of self-monitoring</article-title>. <source>Schizophr Bull</source> (<year>2009</year>) <volume>35</volume>:<fpage>509</fpage>&#x02013;<lpage>27</lpage><pub-id pub-id-type="doi">10.1093/schbul/sbn176</pub-id><pub-id pub-id-type="pmid">19155345</pub-id></mixed-citation></ref><ref id="B56"><label>56</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garrido</surname><given-names>MI</given-names></name><name><surname>Kilner</surname><given-names>JM</given-names></name><name><surname>Stephan</surname><given-names>KE</given-names></name><name><surname>Friston</surname><given-names>KJ</given-names></name></person-group>
<article-title>The mismatch negativity: a review of underlying mechanisms</article-title>. <source>Neurophysiol Clin</source> (<year>2009</year>) <volume>120</volume>:<fpage>453</fpage>&#x02013;<lpage>63</lpage><pub-id pub-id-type="doi">10.1016/j.clinph.2008.11.029</pub-id><pub-id pub-id-type="pmid">19181570</pub-id></mixed-citation></ref><ref id="B57"><label>57</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Naatanen</surname><given-names>R</given-names></name><name><surname>Pakarinen</surname><given-names>S</given-names></name><name><surname>Rinne</surname><given-names>T</given-names></name><name><surname>Takegata</surname><given-names>R</given-names></name></person-group>
<article-title>The mismatch negativity (MMN): towards the optimal paradigm</article-title>. <source>Clin Neurophysiol</source> (<year>2004</year>) <volume>115</volume>:<fpage>140</fpage>&#x02013;<lpage>4</lpage><pub-id pub-id-type="doi">10.1016/j.clinph.2003.04.001</pub-id><pub-id pub-id-type="pmid">14706481</pub-id></mixed-citation></ref><ref id="B58"><label>58</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Michie</surname><given-names>PT</given-names></name></person-group>
<article-title>What has MMN revealed about the auditory system in schizophrenia?</article-title>
<source>Int J Psychophysiol</source> (<year>2001</year>) <volume>42</volume>:<fpage>177</fpage>&#x02013;<lpage>94</lpage><pub-id pub-id-type="doi">10.1016/S0167-8760(01)00166-0</pub-id><pub-id pub-id-type="pmid">11587775</pub-id></mixed-citation></ref><ref id="B59"><label>59</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Todd</surname><given-names>J</given-names></name><name><surname>Michie</surname><given-names>PT</given-names></name><name><surname>Schall</surname><given-names>U</given-names></name><name><surname>Karayanidis</surname><given-names>F</given-names></name><name><surname>Yabe</surname><given-names>H</given-names></name><name><surname>Naatanen</surname><given-names>R</given-names></name></person-group>
<article-title>Deviant matters: duration, frequency, and intensity deviants reveal different patterns of mismatch negativity reduction in early and late schizophrenia</article-title>. <source>Biol Psychiatry</source> (<year>2008</year>) <volume>63</volume>:<fpage>58</fpage>&#x02013;<lpage>64</lpage><pub-id pub-id-type="doi">10.1016/j.biopsych.2007.02.016</pub-id><pub-id pub-id-type="pmid">17585889</pub-id></mixed-citation></ref><ref id="B60"><label>60</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Umbricht</surname><given-names>D</given-names></name><name><surname>Krljes</surname><given-names>S</given-names></name></person-group>
<article-title>Mismatch negativity in schizophrenia: a meta-analysis</article-title>. <source>Schizophr Res</source> (<year>2005</year>) <volume>76</volume>:<fpage>1</fpage>&#x02013;<lpage>23</lpage><pub-id pub-id-type="doi">10.1016/j.schres.2004.12.002</pub-id><pub-id pub-id-type="pmid">15927795</pub-id></mixed-citation></ref><ref id="B61"><label>61</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Naatanen</surname><given-names>R</given-names></name><name><surname>Kahkonen</surname><given-names>S</given-names></name></person-group>
<article-title>Central auditory dysfunction in schizophrenia as revealed by the mismatch negativity (MMN) and its magnetic equivalent MMNm: a review</article-title>. <source>Int J Neuropsychopharmacol</source> (<year>2009</year>) <volume>12</volume>:<fpage>125</fpage>&#x02013;<lpage>35</lpage><pub-id pub-id-type="doi">10.1017/S1461145708009322</pub-id><pub-id pub-id-type="pmid">18771603</pub-id></mixed-citation></ref><ref id="B62"><label>62</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Umbricht</surname><given-names>D</given-names></name><name><surname>Koller</surname><given-names>R</given-names></name><name><surname>Schmid</surname><given-names>L</given-names></name><name><surname>Skrabo</surname><given-names>A</given-names></name><name><surname>Grubel</surname><given-names>C</given-names></name><name><surname>Huber</surname><given-names>T</given-names></name><etal/></person-group>
<article-title>How specific are deficits in mismatch negativity generation to schizophrenia?</article-title>
<source>Biol Psychiatry</source> (<year>2003</year>) <volume>53</volume>:<fpage>1120</fpage>&#x02013;<lpage>31</lpage><pub-id pub-id-type="doi">10.1016/S0006-3223(02)01642-6</pub-id><pub-id pub-id-type="pmid">12814863</pub-id></mixed-citation></ref><ref id="B63"><label>63</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Javitt</surname><given-names>DC</given-names></name><name><surname>Steinschneider</surname><given-names>M</given-names></name><name><surname>Schroeder</surname><given-names>CE</given-names></name><name><surname>Arezzo</surname><given-names>JC</given-names></name></person-group>
<article-title>Role of cortical N-methyl-D-aspartate receptors in auditory sensory memory and mismatch negativity generation: implications for schizophrenia</article-title>. <source>Proc Natl Acad Sci U S A</source> (<year>1996</year>) <volume>93</volume>:<fpage>11962</fpage>&#x02013;<lpage>7</lpage><pub-id pub-id-type="doi">10.1073/pnas.93.21.11962</pub-id><pub-id pub-id-type="pmid">8876245</pub-id></mixed-citation></ref><ref id="B64"><label>64</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Javitt</surname><given-names>DC</given-names></name><name><surname>Steinschneider</surname><given-names>M</given-names></name><name><surname>Schroeder</surname><given-names>CE</given-names></name><name><surname>Vaughan</surname><given-names>HG</given-names><suffix>Jr</suffix></name><name><surname>Arezzo</surname><given-names>JC</given-names></name></person-group>
<article-title>Detection of stimulus deviance within primate primary auditory cortex: intracortical mechanisms of mismatch negativity (MMN) generation</article-title>. <source>Brain Res</source> (<year>1994</year>) <volume>667</volume>:<fpage>192</fpage>&#x02013;<lpage>200</lpage><pub-id pub-id-type="doi">10.1016/0006-8993(94)91496-6</pub-id><pub-id pub-id-type="pmid">7697356</pub-id></mixed-citation></ref><ref id="B65"><label>65</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heekeren</surname><given-names>K</given-names></name><name><surname>Daumann</surname><given-names>J</given-names></name><name><surname>Neukirch</surname><given-names>A</given-names></name><name><surname>Stock</surname><given-names>C</given-names></name><name><surname>Kawohl</surname><given-names>W</given-names></name><name><surname>Norra</surname><given-names>C</given-names></name><etal/></person-group>
<article-title>Mismatch negativity generation in the human 5HT2A agonist and NMDA antagonist model of psychosis</article-title>. <source>Psychopharmacology (Berl)</source> (<year>2008</year>) <volume>199</volume>:<fpage>77</fpage>&#x02013;<lpage>88</lpage><pub-id pub-id-type="doi">10.1007/s00213-008-1129-4</pub-id><pub-id pub-id-type="pmid">18488201</pub-id></mixed-citation></ref><ref id="B66"><label>66</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Knott</surname><given-names>V</given-names></name><name><surname>Shah</surname><given-names>D</given-names></name><name><surname>Millar</surname><given-names>A</given-names></name><name><surname>McIntosh</surname><given-names>J</given-names></name><name><surname>Fisher</surname><given-names>D</given-names></name><name><surname>Blais</surname><given-names>C</given-names></name><etal/></person-group>
<article-title>Nicotine, auditory sensory memory, and sustained attention in a human ketamine model of schizophrenia: moderating influence of a hallucinatory trait</article-title>. <source>Front Pharmacol</source> (<year>2012</year>) <volume>3</volume>:<fpage>172</fpage><pub-id pub-id-type="doi">10.3389/fphar.2012.00172</pub-id><pub-id pub-id-type="pmid">23060793</pub-id></mixed-citation></ref><ref id="B67"><label>67</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kreitschmann-Andermahr</surname><given-names>I</given-names></name><name><surname>Rosburg</surname><given-names>T</given-names></name><name><surname>Demme</surname><given-names>U</given-names></name><name><surname>Gaser</surname><given-names>E</given-names></name><name><surname>Nowak</surname><given-names>H</given-names></name><name><surname>Sauer</surname><given-names>H</given-names></name></person-group>
<article-title>Effect of ketamine on the neuromagnetic mismatch field in healthy humans</article-title>. <source>Brain Res Cogn Brain Res</source> (<year>2001</year>) <volume>12</volume>:<fpage>109</fpage>&#x02013;<lpage>16</lpage><pub-id pub-id-type="doi">10.1016/S0926-6410(01)00043-X</pub-id><pub-id pub-id-type="pmid">11489614</pub-id></mixed-citation></ref><ref id="B68"><label>68</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schmidt</surname><given-names>A</given-names></name><name><surname>Bachmann</surname><given-names>R</given-names></name><name><surname>Kometer</surname><given-names>M</given-names></name><name><surname>Csomor</surname><given-names>PA</given-names></name><name><surname>Stephan</surname><given-names>KE</given-names></name><name><surname>Seifritz</surname><given-names>E</given-names></name><etal/></person-group>
<article-title>Mismatch negativity encoding of prediction errors predicts S-ketamine-induced cognitive impairments</article-title>. <source>Neuropsychopharmacology</source> (<year>2012</year>) <volume>37</volume>:<fpage>865</fpage>&#x02013;<lpage>75</lpage><pub-id pub-id-type="doi">10.1038/npp.2011.261</pub-id><pub-id pub-id-type="pmid">22030715</pub-id></mixed-citation></ref><ref id="B69"><label>69</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Froeliger</surname><given-names>B</given-names></name><name><surname>Gilbert</surname><given-names>DG</given-names></name><name><surname>McClernon</surname><given-names>FJ</given-names></name></person-group>
<article-title>Effects of nicotine on novelty detection and memory recognition performance: double-blind, placebo-controlled studies of smokers and nonsmokers</article-title>. <source>Psychopharmacology (Berl)</source> (<year>2009</year>) <volume>205</volume>:<fpage>625</fpage>&#x02013;<lpage>33</lpage><pub-id pub-id-type="doi">10.1007/s00213-009-1571-y</pub-id><pub-id pub-id-type="pmid">19488741</pub-id></mixed-citation></ref><ref id="B70"><label>70</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pineda</surname><given-names>JA</given-names></name><name><surname>Herrera</surname><given-names>C</given-names></name><name><surname>Kang</surname><given-names>C</given-names></name><name><surname>Sandler</surname><given-names>A</given-names></name></person-group>
<article-title>Effects of cigarette smoking and 12-h abstention on working memory during a serial-probe recognition task</article-title>. <source>Psychopharmacology (Berl)</source> (<year>1998</year>) <volume>139</volume>:<fpage>311</fpage>&#x02013;<lpage>21</lpage><pub-id pub-id-type="doi">10.1007/s002130050722</pub-id><pub-id pub-id-type="pmid">9809852</pub-id></mixed-citation></ref><ref id="B71"><label>71</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Polich</surname><given-names>J</given-names></name><name><surname>Criado</surname><given-names>JR</given-names></name></person-group>
<article-title>Neuropsychology and neuropharmacology of P3a and P3b</article-title>. <source>Int J Psychophysiol</source> (<year>2006</year>) <volume>60</volume>:<fpage>172</fpage>&#x02013;<lpage>85</lpage><pub-id pub-id-type="doi">10.1016/j.ijpsycho.2005.12.012</pub-id><pub-id pub-id-type="pmid">16510201</pub-id></mixed-citation></ref><ref id="B72"><label>72</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pritchard</surname><given-names>W</given-names></name><name><surname>Sokhadze</surname><given-names>E</given-names></name><name><surname>Houlihan</surname><given-names>M</given-names></name></person-group>
<article-title>Effects of nicotine and smoking on event-related potentials: a review</article-title>. <source>Nicotine Tob Res</source> (<year>2004</year>) <volume>6</volume>:<fpage>961</fpage>&#x02013;<lpage>84</lpage><pub-id pub-id-type="doi">10.1080/14622200412331324848</pub-id><pub-id pub-id-type="pmid">15801570</pub-id></mixed-citation></ref><ref id="B73"><label>73</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Houlihan</surname><given-names>ME</given-names></name><name><surname>Pritchard</surname><given-names>WS</given-names></name><name><surname>Robinson</surname><given-names>JH</given-names></name></person-group>
<article-title>Effects of smoking/nicotine on performance and event-related potentials during a short-term memory scanning task</article-title>. <source>Psychopharmacology (Berl)</source> (<year>2001</year>) <volume>156</volume>:<fpage>388</fpage>&#x02013;<lpage>96</lpage><pub-id pub-id-type="doi">10.1007/s002130100751</pub-id><pub-id pub-id-type="pmid">11498715</pub-id></mixed-citation></ref><ref id="B74"><label>74</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Knott</surname><given-names>V</given-names></name><name><surname>Bosman</surname><given-names>M</given-names></name><name><surname>Mahoney</surname><given-names>C</given-names></name><name><surname>Ilivitsky</surname><given-names>V</given-names></name><name><surname>Quirt</surname><given-names>K</given-names></name></person-group>
<article-title>Transdermal nicotine: single dose effects on mood, EEG, performance, and event-related potentials</article-title>. <source>Pharmacol Biochem Behav</source> (<year>1999</year>) <volume>63</volume>:<fpage>253</fpage>&#x02013;<lpage>61</lpage><pub-id pub-id-type="doi">10.1016/S0091-3057(99)00006-4</pub-id><pub-id pub-id-type="pmid">10371654</pub-id></mixed-citation></ref><ref id="B75"><label>75</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kodama</surname><given-names>E</given-names></name><name><surname>Morita</surname><given-names>K</given-names></name><name><surname>Kinoshita</surname><given-names>S</given-names></name><name><surname>Miyahira</surname><given-names>A</given-names></name><name><surname>Nakamura</surname><given-names>J</given-names></name><name><surname>Maeda</surname><given-names>H</given-names></name></person-group>
<article-title>Inhibitory effect of smoking on event-related potentials in schizophrenic patients: comparison with healthy subjects</article-title>. <source>Prog Neuropsychopharmacol Biol Psychiatry</source> (<year>1998</year>) <volume>22</volume>:<fpage>1275</fpage>&#x02013;<lpage>88</lpage><pub-id pub-id-type="doi">10.1016/S0278-5846(98)00082-7</pub-id></mixed-citation></ref><ref id="B76"><label>76</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Edwards</surname><given-names>JA</given-names></name><name><surname>Wesnes</surname><given-names>K</given-names></name><name><surname>Warburton</surname><given-names>DM</given-names></name><name><surname>Gale</surname><given-names>A</given-names></name></person-group>
<article-title>Evidence of more rapid stimulus evaluation following cigarette smoking</article-title>. <source>Addict Behav</source> (<year>1985</year>) <volume>10</volume>:<fpage>113</fpage>&#x02013;<lpage>26</lpage><pub-id pub-id-type="doi">10.1016/0306-4603(85)90017-6</pub-id><pub-id pub-id-type="pmid">4013861</pub-id></mixed-citation></ref><ref id="B77"><label>77</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Houlihan</surname><given-names>ME</given-names></name><name><surname>Pritchard</surname><given-names>WS</given-names></name><name><surname>Robinson</surname><given-names>JH</given-names></name></person-group>
<article-title>Faster P300 latency after smoking in visual but not auditory oddball tasks</article-title>. <source>Psychopharmacology (Berl)</source> (<year>1996</year>) <volume>123</volume>:<fpage>231</fpage>&#x02013;<lpage>8</lpage><pub-id pub-id-type="doi">10.1007/BF02246577</pub-id><pub-id pub-id-type="pmid">8833416</pub-id></mixed-citation></ref><ref id="B78"><label>78</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Knott</surname><given-names>V</given-names></name><name><surname>McIntosh</surname><given-names>J</given-names></name><name><surname>Millar</surname><given-names>A</given-names></name><name><surname>Fisher</surname><given-names>D</given-names></name><name><surname>Villeneuve</surname><given-names>C</given-names></name><name><surname>Ilivitsky</surname><given-names>V</given-names></name><etal/></person-group>
<article-title>Nicotine and smoker status moderate brain electric and mood activation induced by ketamine, an N-methyl-D-aspartate (NMDA) receptor antagonist</article-title>. <source>Pharmacol Biochem Behav</source> (<year>2006</year>) <volume>85</volume>:<fpage>228</fpage>&#x02013;<lpage>42</lpage><pub-id pub-id-type="doi">10.1016/j.pbb.2006.08.005</pub-id><pub-id pub-id-type="pmid">17023037</pub-id></mixed-citation></ref><ref id="B79"><label>79</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lindgren</surname><given-names>M</given-names></name><name><surname>Molander</surname><given-names>L</given-names></name><name><surname>Verbaan</surname><given-names>C</given-names></name><name><surname>Lunell</surname><given-names>E</given-names></name><name><surname>Rosen</surname><given-names>I</given-names></name></person-group>
<article-title>Electroencephalographic effects of intravenous nicotine &#x02013; a dose-response study</article-title>. <source>Psychopharmacology (Berl)</source> (<year>1999</year>) <volume>145</volume>:<fpage>342</fpage>&#x02013;<lpage>50</lpage><pub-id pub-id-type="doi">10.1007/s002130051067</pub-id><pub-id pub-id-type="pmid">10494584</pub-id></mixed-citation></ref><ref id="B80"><label>80</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lindgren</surname><given-names>M</given-names></name><name><surname>Stenberg</surname><given-names>G</given-names></name><name><surname>Rosen</surname><given-names>I</given-names></name></person-group>
<article-title>Effects of nicotine in a bimodal attention task</article-title>. <source>Neuropsychobiology</source> (<year>1998</year>) <volume>38</volume>:<fpage>42</fpage>&#x02013;<lpage>9</lpage><pub-id pub-id-type="doi">10.1159/000026515</pub-id><pub-id pub-id-type="pmid">9701721</pub-id></mixed-citation></ref><ref id="B81"><label>81</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Michel</surname><given-names>C</given-names></name><name><surname>Hasenfratz</surname><given-names>M</given-names></name><name><surname>Nil</surname><given-names>R</given-names></name><name><surname>Battig</surname><given-names>K</given-names></name></person-group>
<article-title>Cardiovascular, electrocortical, and behavioral effects of nicotine chewing gum</article-title>. <source>Klin Wochenschr</source> (<year>1988</year>) <volume>66</volume>(<issue>Suppl 11</issue>):<fpage>72</fpage>&#x02013;<lpage>9</lpage><pub-id pub-id-type="pmid">3184782</pub-id></mixed-citation></ref><ref id="B82"><label>82</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anokhin</surname><given-names>AP</given-names></name><name><surname>Vedeniapin</surname><given-names>AB</given-names></name><name><surname>Sirevaag</surname><given-names>EJ</given-names></name><name><surname>Bauer</surname><given-names>LO</given-names></name><name><surname>O&#x02019;Connor</surname><given-names>SJ</given-names></name><name><surname>Kuperman</surname><given-names>S</given-names></name><etal/></person-group>
<article-title>The P300 brain potential is reduced in smokers</article-title>. <source>Psychopharmacology (Berl)</source> (<year>2000</year>) <volume>149</volume>:<fpage>409</fpage>&#x02013;<lpage>13</lpage><pub-id pub-id-type="doi">10.1007/s002130000387</pub-id><pub-id pub-id-type="pmid">10867969</pub-id></mixed-citation></ref><ref id="B83"><label>83</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Neuhaus</surname><given-names>A</given-names></name><name><surname>Bajbouj</surname><given-names>M</given-names></name><name><surname>Kienast</surname><given-names>T</given-names></name><name><surname>Kalus</surname><given-names>P</given-names></name><name><surname>von Haebler</surname><given-names>D</given-names></name><name><surname>Winterer</surname><given-names>G</given-names></name><etal/></person-group>
<article-title>Persistent dysfunctional frontal lobe activation in former smokers</article-title>. <source>Psychopharmacology (Berl)</source> (<year>2006</year>) <volume>186</volume>:<fpage>191</fpage>&#x02013;<lpage>200</lpage><pub-id pub-id-type="doi">10.1007/s00213-006-0366-7</pub-id><pub-id pub-id-type="pmid">16612617</pub-id></mixed-citation></ref><ref id="B84"><label>84</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ascioglu</surname><given-names>M</given-names></name><name><surname>Dolu</surname><given-names>N</given-names></name><name><surname>Golgeli</surname><given-names>A</given-names></name><name><surname>Suer</surname><given-names>C</given-names></name><name><surname>Ozesmi</surname><given-names>C</given-names></name></person-group>
<article-title>Effects of cigarette smoking on cognitive processing</article-title>. <source>Int J Neurosci</source> (<year>2004</year>) <volume>114</volume>:<fpage>381</fpage>&#x02013;<lpage>90</lpage><pub-id pub-id-type="doi">10.1080/00207450490270668</pub-id><pub-id pub-id-type="pmid">14754662</pub-id></mixed-citation></ref><ref id="B85"><label>85</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baldeweg</surname><given-names>T</given-names></name><name><surname>Wong</surname><given-names>D</given-names></name><name><surname>Stephan</surname><given-names>KE</given-names></name></person-group>
<article-title>Nicotinic modulation of human auditory sensory memory: evidence from mismatch negativity potentials</article-title>. <source>Int J Psychophysiol</source> (<year>2006</year>) <volume>59</volume>:<fpage>49</fpage>&#x02013;<lpage>58</lpage><pub-id pub-id-type="doi">10.1016/j.ijpsycho.2005.07.014</pub-id><pub-id pub-id-type="pmid">16313986</pub-id></mixed-citation></ref><ref id="B86"><label>86</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dunbar</surname><given-names>G</given-names></name><name><surname>Boeijinga</surname><given-names>PH</given-names></name><name><surname>Demazieres</surname><given-names>A</given-names></name><name><surname>Cisterni</surname><given-names>C</given-names></name><name><surname>Kuchibhatla</surname><given-names>R</given-names></name><name><surname>Wesnes</surname><given-names>K</given-names></name><etal/></person-group>
<article-title>Effects of TC-1734 (AZD3480), a selective neuronal nicotinic receptor agonist, on cognitive performance and the EEG of young healthy male volunteers</article-title>. <source>Psychopharmacology</source> (<year>2007</year>) <volume>191</volume>:<fpage>919</fpage>&#x02013;<lpage>29</lpage><pub-id pub-id-type="doi">10.1007/s00213-006-0675-x</pub-id><pub-id pub-id-type="pmid">17225162</pub-id></mixed-citation></ref><ref id="B87"><label>87</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harkrider</surname><given-names>AW</given-names></name><name><surname>Hedrick</surname><given-names>MS</given-names></name></person-group>
<article-title>Acute effect of nicotine on auditory gating in smokers and non-smokers</article-title>. <source>Hear Res</source> (<year>2005</year>) <volume>202</volume>:<fpage>114</fpage>&#x02013;<lpage>28</lpage><pub-id pub-id-type="doi">10.1016/j.heares.2004.11.009</pub-id><pub-id pub-id-type="pmid">15811704</pub-id></mixed-citation></ref><ref id="B88"><label>88</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martin</surname><given-names>LF</given-names></name><name><surname>Davalos</surname><given-names>DB</given-names></name><name><surname>Kisley</surname><given-names>MA</given-names></name></person-group>
<article-title>Nicotine enhances automatic temporal processing as measured by the mismatch negativity waveform</article-title>. <source>Nicotine Tob Res</source> (<year>2009</year>) <volume>11</volume>:<fpage>698</fpage>&#x02013;<lpage>706</lpage><pub-id pub-id-type="doi">10.1093/ntr/ntp052</pub-id><pub-id pub-id-type="pmid">19436039</pub-id></mixed-citation></ref><ref id="B89"><label>89</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Inami</surname><given-names>R</given-names></name><name><surname>Kirino</surname><given-names>E</given-names></name><name><surname>Inoue</surname><given-names>R</given-names></name><name><surname>Arai</surname><given-names>H</given-names></name></person-group>
<article-title>Transdermal nicotine administration enhances automatic auditory processing reflected by mismatch negativity</article-title>. <source>Pharmacol Biochem Behav</source> (<year>2005</year>) <volume>80</volume>:<fpage>453</fpage>&#x02013;<lpage>61</lpage><pub-id pub-id-type="doi">10.1016/j.pbb.2005.01.001</pub-id><pub-id pub-id-type="pmid">15740788</pub-id></mixed-citation></ref><ref id="B90"><label>90</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Inami</surname><given-names>R</given-names></name><name><surname>Kirino</surname><given-names>E</given-names></name><name><surname>Inoue</surname><given-names>R</given-names></name><name><surname>Suzuki</surname><given-names>T</given-names></name><name><surname>Arai</surname><given-names>H</given-names></name></person-group>
<article-title>Nicotine effects on mismatch negativity in nonsmoking schizophrenic patients</article-title>. <source>Neuropsychobiology</source> (<year>2007</year>) <volume>56</volume>:<fpage>64</fpage>&#x02013;<lpage>72</lpage><pub-id pub-id-type="doi">10.1159/000111536</pub-id><pub-id pub-id-type="pmid">18037816</pub-id></mixed-citation></ref><ref id="B91"><label>91</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Knott</surname><given-names>V</given-names></name><name><surname>Heenan</surname><given-names>A</given-names></name><name><surname>Shah</surname><given-names>D</given-names></name><name><surname>Bolton</surname><given-names>K</given-names></name><name><surname>Fisher</surname><given-names>D</given-names></name><name><surname>Villeneuve</surname><given-names>C</given-names></name></person-group>
<article-title>Electrophysiological evidence of nicotine&#x02019;s distracter-filtering properties in non-smokers</article-title>. <source>J Psychopharmacol</source> (<year>2011</year>) <volume>25</volume>:<fpage>239</fpage>&#x02013;<lpage>48</lpage><pub-id pub-id-type="doi">10.1177/0269881109348158</pub-id><pub-id pub-id-type="pmid">19939874</pub-id></mixed-citation></ref><ref id="B92"><label>92</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dalack</surname><given-names>GW</given-names></name><name><surname>Healy</surname><given-names>DJ</given-names></name><name><surname>Meador-Woodruff</surname><given-names>JH</given-names></name></person-group>
<article-title>Nicotine dependence in schizophrenia: clinical phenomena and laboratory findings</article-title>. <source>Am J Psychiatry</source> (<year>1998</year>) <volume>155</volume>:<fpage>1490</fpage>&#x02013;<lpage>501</lpage><pub-id pub-id-type="pmid">9812108</pub-id></mixed-citation></ref><ref id="B93"><label>93</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Leon</surname><given-names>J</given-names></name><name><surname>Diaz</surname><given-names>FJ</given-names></name></person-group>
<article-title>A meta-analysis of worldwide studies demonstrates an association between schizophrenia and tobacco smoking behaviors</article-title>. <source>Schizophr Res</source> (<year>2005</year>) <volume>76</volume>:<fpage>135</fpage>&#x02013;<lpage>57</lpage><pub-id pub-id-type="doi">10.1016/j.schres.2005.02.010</pub-id><pub-id pub-id-type="pmid">15949648</pub-id></mixed-citation></ref><ref id="B94"><label>94</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hughes</surname><given-names>JR</given-names></name><name><surname>Hatsukami</surname><given-names>DK</given-names></name><name><surname>Mitchell</surname><given-names>JE</given-names></name><name><surname>Dahlgren</surname><given-names>LA</given-names></name></person-group>
<article-title>Prevalence of smoking among psychiatric outpatients</article-title>. <source>Am J Psychiatry</source> (<year>1986</year>) <volume>143</volume>:<fpage>993</fpage>&#x02013;<lpage>7</lpage><pub-id pub-id-type="pmid">3487983</pub-id></mixed-citation></ref><ref id="B95"><label>95</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ziedonis</surname><given-names>DM</given-names></name><name><surname>George</surname><given-names>TP</given-names></name></person-group>
<article-title>Schizophrenia and nicotine use: report of a pilot smoking cessation program and review of neurobiological and clinical issues</article-title>. <source>Schizophr Bull</source> (<year>1997</year>) <volume>23</volume>:<fpage>247</fpage>&#x02013;<lpage>54</lpage><pub-id pub-id-type="doi">10.1093/schbul/23.2.247</pub-id><pub-id pub-id-type="pmid">9165635</pub-id></mixed-citation></ref><ref id="B96"><label>96</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adler</surname><given-names>LE</given-names></name><name><surname>Hoffer</surname><given-names>LD</given-names></name><name><surname>Wiser</surname><given-names>A</given-names></name><name><surname>Freedman</surname><given-names>R</given-names></name></person-group>
<article-title>Normalization of auditory physiology by cigarette smoking in schizophrenic patients</article-title>. <source>Am J Psychiatry</source> (<year>1993</year>) <volume>150</volume>:<fpage>1856</fpage>&#x02013;<lpage>61</lpage><pub-id pub-id-type="pmid">8238642</pub-id></mixed-citation></ref><ref id="B97"><label>97</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Olincy</surname><given-names>A</given-names></name><name><surname>Harris</surname><given-names>JG</given-names></name><name><surname>Johnson</surname><given-names>LL</given-names></name><name><surname>Pender</surname><given-names>V</given-names></name><name><surname>Kongs</surname><given-names>S</given-names></name><name><surname>Allensworth</surname><given-names>D</given-names></name><etal/></person-group>
<article-title>Proof-of-concept trial of an alpha7 nicotinic agonist in schizophrenia</article-title>. <source>Arch Gen Psychiatry</source> (<year>2006</year>) <volume>63</volume>:<fpage>630</fpage>&#x02013;<lpage>8</lpage><pub-id pub-id-type="doi">10.1001/archpsyc.63.6.630</pub-id><pub-id pub-id-type="pmid">16754836</pub-id></mixed-citation></ref><ref id="B98"><label>98</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dulude</surname><given-names>L</given-names></name><name><surname>Labelle</surname><given-names>A</given-names></name><name><surname>Knott</surname><given-names>VJ</given-names></name></person-group>
<article-title>Acute nicotine alteration of sensory memory impairment in smokers with schizophrenia</article-title>. <source>J Clin Psychopharmacol</source> (<year>2010</year>) <volume>30</volume>:<fpage>541</fpage>&#x02013;<lpage>8</lpage><pub-id pub-id-type="doi">10.1097/JCP.0b013e3181f0c9c6</pub-id><pub-id pub-id-type="pmid">20814324</pub-id></mixed-citation></ref><ref id="B99"><label>99</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fisher</surname><given-names>DJ</given-names></name><name><surname>Grant</surname><given-names>B</given-names></name><name><surname>Smith</surname><given-names>DM</given-names></name><name><surname>Borracci</surname><given-names>G</given-names></name><name><surname>Labelle</surname><given-names>A</given-names></name><name><surname>Knott</surname><given-names>VJ</given-names></name></person-group>
<article-title>Nicotine and the hallucinating brain: effects on mismatch negativity (MMN) in schizophrenia</article-title>. <source>Psychiatry Res</source> (<year>2012</year>) <volume>196</volume>:<fpage>181</fpage>&#x02013;<lpage>7</lpage><pub-id pub-id-type="doi">10.1016/j.psychres.2012.01.026</pub-id><pub-id pub-id-type="pmid">22425471</pub-id></mixed-citation></ref><ref id="B100"><label>100</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McGehee</surname><given-names>DS</given-names></name><name><surname>Heath</surname><given-names>MJ</given-names></name><name><surname>Gelber</surname><given-names>S</given-names></name><name><surname>Devay</surname><given-names>P</given-names></name><name><surname>Role</surname><given-names>LW</given-names></name></person-group>
<article-title>Nicotine enhancement of fast excitatory synaptic transmission in CNS by presynaptic receptors</article-title>. <source>Science</source> (<year>1995</year>) <volume>269</volume>:<fpage>1692</fpage>&#x02013;<lpage>6</lpage><pub-id pub-id-type="doi">10.1126/science.7569895</pub-id><pub-id pub-id-type="pmid">7569895</pub-id></mixed-citation></ref><ref id="B101"><label>101</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alkondon</surname><given-names>M</given-names></name><name><surname>Pereira</surname><given-names>EF</given-names></name><name><surname>Eisenberg</surname><given-names>HM</given-names></name><name><surname>Albuquerque</surname><given-names>EX</given-names></name></person-group>
<article-title>Nicotinic receptor activation in human cerebral cortical interneurons: a mechanism for inhibition and disinhibition of neuronal networks</article-title>. <source>J Neurosci</source> (<year>2000</year>) <volume>20</volume>:<fpage>66</fpage>&#x02013;<lpage>75</lpage><pub-id pub-id-type="pmid">10627582</pub-id></mixed-citation></ref><ref id="B102"><label>102</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ji</surname><given-names>D</given-names></name><name><surname>Dani</surname><given-names>JA</given-names></name></person-group>
<article-title>Inhibition and disinhibition of pyramidal neurons by activation of nicotinic receptors on hippocampal interneurons</article-title>. <source>J Neurophysiol</source> (<year>2000</year>) <volume>83</volume>:<fpage>2682</fpage>&#x02013;<lpage>90</lpage><pub-id pub-id-type="pmid">10805668</pub-id></mixed-citation></ref><ref id="B103"><label>103</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gioanni</surname><given-names>Y</given-names></name><name><surname>Rougeot</surname><given-names>C</given-names></name><name><surname>Clarke</surname><given-names>PB</given-names></name><name><surname>Lepouse</surname><given-names>C</given-names></name><name><surname>Thierry</surname><given-names>AM</given-names></name><name><surname>Vidal</surname><given-names>C</given-names></name></person-group>
<article-title>Nicotinic receptors in the rat prefrontal cortex: increase in glutamate release and facilitation of mediodorsal thalamo-cortical transmission</article-title>. <source>Eur J Neurosci</source> (<year>1999</year>) <volume>11</volume>:<fpage>18</fpage>&#x02013;<lpage>30</lpage><pub-id pub-id-type="doi">10.1046/j.1460-9568.1999.00403.x</pub-id><pub-id pub-id-type="pmid">9987008</pub-id></mixed-citation></ref><ref id="B104"><label>104</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lambe</surname><given-names>EK</given-names></name><name><surname>Picciotto</surname><given-names>MR</given-names></name><name><surname>Aghajanian</surname><given-names>GK</given-names></name></person-group>
<article-title>Nicotine induces glutamate release from thalamocortical terminals in prefrontal cortex</article-title>. <source>Neuropsychopharmacology</source> (<year>2003</year>) <volume>28</volume>:<fpage>216</fpage>&#x02013;<lpage>25</lpage><pub-id pub-id-type="doi">10.1038/sj.npp.1300032</pub-id><pub-id pub-id-type="pmid">12589374</pub-id></mixed-citation></ref><ref id="B105"><label>105</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Radcliffe</surname><given-names>KA</given-names></name><name><surname>Fisher</surname><given-names>JL</given-names></name><name><surname>Gray</surname><given-names>R</given-names></name><name><surname>Dani</surname><given-names>JA</given-names></name></person-group>
<article-title>Nicotinic modulation of glutamate and GABA synaptic transmission of hippocampal neurons</article-title>. <source>Ann N Y Acad Sci</source> (<year>1999</year>) <volume>868</volume>:<fpage>591</fpage>&#x02013;<lpage>610</lpage><pub-id pub-id-type="doi">10.1111/j.1749-6632.1999.tb11332.x</pub-id><pub-id pub-id-type="pmid">10414340</pub-id></mixed-citation></ref><ref id="B106"><label>106</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Levin</surname><given-names>ED</given-names></name><name><surname>Bettegowda</surname><given-names>C</given-names></name><name><surname>Weaver</surname><given-names>T</given-names></name><name><surname>Christopher</surname><given-names>NC</given-names></name></person-group>
<article-title>Nicotine-dizocilpine interactions and working and reference memory performance of rats in the radial-arm maze</article-title>. <source>Pharmacol Biochem Behav</source> (<year>1998</year>) <volume>61</volume>:<fpage>335</fpage>&#x02013;<lpage>40</lpage><pub-id pub-id-type="doi">10.1016/S0091-3057(98)00109-9</pub-id><pub-id pub-id-type="pmid">9768569</pub-id></mixed-citation></ref><ref id="B107"><label>107</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rezvani</surname><given-names>AH</given-names></name><name><surname>Levin</surname><given-names>ED</given-names></name></person-group>
<article-title>Nicotinic-glutamatergic interactions and attentional performance on an operant visual signal detection task in female rats</article-title>. <source>Eur J Pharmacol</source> (<year>2003</year>) <volume>465</volume>:<fpage>83</fpage>&#x02013;<lpage>90</lpage><pub-id pub-id-type="doi">10.1016/S0014-2999(03)01439-0</pub-id><pub-id pub-id-type="pmid">12650836</pub-id></mixed-citation></ref><ref id="B108"><label>108</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ciamei</surname><given-names>A</given-names></name><name><surname>Aversano</surname><given-names>M</given-names></name><name><surname>Cestari</surname><given-names>V</given-names></name><name><surname>Castellano</surname><given-names>C</given-names></name></person-group>
<article-title>Effects of MK-801 and nicotine combinations on memory consolidation in CD1 mice</article-title>. <source>Psychopharmacology (Berl)</source> (<year>2001</year>) <volume>154</volume>:<fpage>126</fpage>&#x02013;<lpage>30</lpage><pub-id pub-id-type="doi">10.1007/s002130000584</pub-id><pub-id pub-id-type="pmid">11314674</pub-id></mixed-citation></ref><ref id="B109"><label>109</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Spitzer</surname><given-names>RL</given-names></name><name><surname>Williams</surname><given-names>JB</given-names></name><name><surname>Gibbon</surname><given-names>M</given-names></name><name><surname>First</surname><given-names>MB</given-names></name></person-group>
<source>Structured Clinical Interview for DSM-III-R &#x02013; Non-Patient Edition (SCID-NP, Version 1.0 with Supplement for DSM-IV)</source>. <publisher-loc>Washington, DC</publisher-loc>: <publisher-name>American Psychiatric Press</publisher-name> (<year>1990</year>).</mixed-citation></ref><ref id="B110"><label>110</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Wechsler</surname><given-names>D</given-names></name></person-group>
<source>Manual for the Wechsler Adult Intelligence Scale</source>. <publisher-loc>New York</publisher-loc>: <publisher-name>Psychological Corporation</publisher-name> (<year>1955</year>). <fpage>110</fpage> p.</mixed-citation></ref><ref id="B111"><label>111</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heatherton</surname><given-names>T</given-names></name><name><surname>Kozlowski</surname><given-names>L</given-names></name><name><surname>Frecker</surname><given-names>R</given-names></name><name><surname>Fagerstrom</surname><given-names>K</given-names></name></person-group>
<article-title>The Fagerstrom test for nicotine dependence: a revision of the Fagerstrom tolerance questionnaire</article-title>. <source>Br J Addict</source> (<year>1991</year>) <volume>86</volume>:<fpage>1119</fpage>&#x02013;<lpage>27</lpage><pub-id pub-id-type="doi">10.1111/j.1360-0443.1991.tb01879.x</pub-id><pub-id pub-id-type="pmid">1932883</pub-id></mixed-citation></ref><ref id="B112"><label>112</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kay</surname><given-names>S</given-names></name><name><surname>Fiszbein</surname><given-names>A</given-names></name><name><surname>Opler</surname><given-names>L</given-names></name></person-group>
<article-title>The Positive and Negative Syndrome Scale (PANSS) for schizophrenia</article-title>. <source>Schizophr Bull</source> (<year>1987</year>) <volume>13</volume>:<fpage>261</fpage>&#x02013;<lpage>76</lpage><pub-id pub-id-type="doi">10.1093/schbul/13.2.261</pub-id><pub-id pub-id-type="pmid">3616518</pub-id></mixed-citation></ref><ref id="B113"><label>113</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bremner</surname><given-names>JD</given-names></name><name><surname>Krystal</surname><given-names>JH</given-names></name><name><surname>Putnam</surname><given-names>FW</given-names></name><name><surname>Southwick</surname><given-names>SM</given-names></name><name><surname>Marmar</surname><given-names>C</given-names></name><name><surname>Charney</surname><given-names>DS</given-names></name><etal/></person-group>
<article-title>Measurement of dissociative states with the Clinician-Administered Dissociative States Scale (CADSS)</article-title>. <source>J Trauma Stress</source> (<year>1998</year>) <volume>11</volume>:<fpage>125</fpage>&#x02013;<lpage>36</lpage><pub-id pub-id-type="doi">10.1023/A:1024465317902</pub-id><pub-id pub-id-type="pmid">9479681</pub-id></mixed-citation></ref><ref id="B114"><label>114</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krystal</surname><given-names>JH</given-names></name><name><surname>Perry</surname><given-names>EB</given-names><suffix>Jr</suffix></name><name><surname>Gueorguieva</surname><given-names>R</given-names></name><name><surname>Belger</surname><given-names>A</given-names></name><name><surname>Madonick</surname><given-names>SH</given-names></name><name><surname>Abi-Dargham</surname><given-names>A</given-names></name><etal/></person-group>
<article-title>Comparative and interactive human psychopharmacologic effects of ketamine and amphetamine: implications for glutamatergic and dopaminergic model psychoses and cognitive function</article-title>. <source>Arch Gen Psychiatry</source> (<year>2005</year>) <volume>62</volume>:<fpage>985</fpage>&#x02013;<lpage>94</lpage><pub-id pub-id-type="doi">10.1001/archpsyc.62.9.985</pub-id><pub-id pub-id-type="pmid">16143730</pub-id></mixed-citation></ref><ref id="B115"><label>115</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hariharan</surname><given-names>M</given-names></name><name><surname>VanNoord</surname><given-names>T</given-names></name><name><surname>Greden</surname><given-names>JF</given-names></name></person-group>
<article-title>A high-performance liquid-chromatographic method for routine simultaneous determination of nicotine and cotinine in plasma</article-title>. <source>Clin Chem</source> (<year>1988</year>) <volume>34</volume>:<fpage>724</fpage>&#x02013;<lpage>9</lpage><pub-id pub-id-type="pmid">3359608</pub-id></mixed-citation></ref><ref id="B116"><label>116</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Staley</surname><given-names>JK</given-names></name><name><surname>Krishnan-Sarin</surname><given-names>S</given-names></name><name><surname>Cosgrove</surname><given-names>KP</given-names></name><name><surname>Krantzler</surname><given-names>E</given-names></name><name><surname>Frohlich</surname><given-names>E</given-names></name><name><surname>Perry</surname><given-names>E</given-names></name><etal/></person-group>
<article-title>Human tobacco smokers in early abstinence have higher levels of beta2* nicotinic acetylcholine receptors than nonsmokers</article-title>. <source>J Neurosci</source> (<year>2006</year>) <volume>26</volume>:<fpage>8707</fpage>&#x02013;<lpage>14</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.0546-06.2006</pub-id><pub-id pub-id-type="pmid">16928859</pub-id></mixed-citation></ref><ref id="B117"><label>117</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Friedman</surname><given-names>D</given-names></name><name><surname>Simpson</surname><given-names>G</given-names></name><name><surname>Hamberger</surname><given-names>M</given-names></name></person-group>
<article-title>Age-related changes in scalp topography to novel and target stimuli</article-title>. <source>Psychophysiology</source> (<year>1993</year>) <volume>30</volume>:<fpage>383</fpage>&#x02013;<lpage>96</lpage><pub-id pub-id-type="doi">10.1111/j.1469-8986.1993.tb02060.x</pub-id><pub-id pub-id-type="pmid">8327624</pub-id></mixed-citation></ref><ref id="B118"><label>118</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cohen</surname><given-names>JD</given-names></name><name><surname>Barch</surname><given-names>DM</given-names></name><name><surname>Carter</surname><given-names>C</given-names></name><name><surname>Servan-Schreiber</surname><given-names>D</given-names></name></person-group>
<article-title>Context-processing deficits in schizophrenia: converging evidence from three theoretically motivated cognitive tasks</article-title>. <source>J Abnorm Psychol</source> (<year>1999</year>) <volume>108</volume>:<fpage>120</fpage>&#x02013;<lpage>33</lpage><pub-id pub-id-type="doi">10.1037/0021-843X.108.1.120</pub-id><pub-id pub-id-type="pmid">10066998</pub-id></mixed-citation></ref><ref id="B119"><label>119</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gratton</surname><given-names>G</given-names></name><name><surname>Coles</surname><given-names>MG</given-names></name><name><surname>Donchin</surname><given-names>E</given-names></name></person-group>
<article-title>A new method for off-line removal of ocular artifact</article-title>. <source>Electroencephalogr Clin Neurophysiol</source> (<year>1983</year>) <volume>55</volume>:<fpage>468</fpage>&#x02013;<lpage>84</lpage><pub-id pub-id-type="doi">10.1016/0013-4694(83)90135-9</pub-id><pub-id pub-id-type="pmid">6187540</pub-id></mixed-citation></ref><ref id="B120"><label>120</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Cho</surname><given-names>HS</given-names></name><name><surname>Perry</surname><given-names>EB</given-names></name><name><surname>Gunduz-Bruce</surname><given-names>H</given-names></name><name><surname>D&#x02019;Souza</surname><given-names>DC</given-names></name></person-group>
<article-title>The ketamine paradigm in humans: relevance to psychotic disorders</article-title>. In: <person-group person-group-type="editor"><name><surname>Heresco-Levy</surname><given-names>U</given-names></name><name><surname>Daniel</surname><given-names>C</given-names></name><name><surname>Javitt</surname><given-names>DC</given-names></name></person-group>, editors. <source>Glutamate in Neuropsychiatric Disorders Trivandrum</source>. <publisher-loc>Kerala, India</publisher-loc>: <publisher-name>Research Signpost</publisher-name> (<year>2008</year>). p. <fpage>99</fpage>&#x02013;<lpage>131</lpage></mixed-citation></ref><ref id="B121"><label>121</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mathalon</surname><given-names>DH</given-names></name><name><surname>Ford</surname><given-names>JM</given-names></name><name><surname>Pfefferbaum</surname><given-names>A</given-names></name></person-group>
<article-title>Trait and state aspects of P300 amplitude reduction in schizophrenia: a retrospective longitudinal study</article-title>. <source>Biol Psychiatry</source> (<year>2000</year>) <volume>47</volume>:<fpage>434</fpage>&#x02013;<lpage>49</lpage><pub-id pub-id-type="doi">10.1016/S0006-3223(99)00277-2</pub-id><pub-id pub-id-type="pmid">10704955</pub-id></mixed-citation></ref><ref id="B122"><label>122</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mathalon</surname><given-names>DH</given-names></name><name><surname>Ford</surname><given-names>JM</given-names></name><name><surname>Rosenbloom</surname><given-names>M</given-names></name><name><surname>Pfefferbaum</surname><given-names>A</given-names></name></person-group>
<article-title>P300 reduction and prolongation with illness duration in schizophrenia</article-title>. <source>Biol Psychiatry</source> (<year>2000</year>) <volume>47</volume>:<fpage>413</fpage>&#x02013;<lpage>27</lpage><pub-id pub-id-type="doi">10.1016/S0006-3223(99)00151-1</pub-id><pub-id pub-id-type="pmid">10704953</pub-id></mixed-citation></ref><ref id="B123"><label>123</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abi-Saab</surname><given-names>WM</given-names></name><name><surname>D&#x02019;Souza</surname><given-names>DC</given-names></name><name><surname>Moghaddam</surname><given-names>B</given-names></name><name><surname>Krystal</surname><given-names>JH</given-names></name></person-group>
<article-title>The NMDA antagonist model for schizophrenia: promise and pitfalls</article-title>. <source>Pharmacopsychiatry</source> (<year>1998</year>) <volume>31</volume>(<issue>Suppl 2</issue>):<fpage>104</fpage>&#x02013;<lpage>9</lpage><pub-id pub-id-type="doi">10.1055/s-2007-979354</pub-id><pub-id pub-id-type="pmid">9754841</pub-id></mixed-citation></ref><ref id="B124"><label>124</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coyle</surname><given-names>JT</given-names></name></person-group>
<article-title>NMDA receptor and schizophrenia: a brief history</article-title>. <source>Schizophr Bull</source> (<year>2012</year>) <volume>38</volume>:<fpage>920</fpage>&#x02013;<lpage>6</lpage><pub-id pub-id-type="doi">10.1093/schbul/sbs076</pub-id><pub-id pub-id-type="pmid">22987850</pub-id></mixed-citation></ref><ref id="B125"><label>125</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alain</surname><given-names>C</given-names></name><name><surname>Bernstein</surname><given-names>LJ</given-names></name><name><surname>Cortese</surname><given-names>F</given-names></name><name><surname>Yu</surname><given-names>H</given-names></name><name><surname>Zipursky</surname><given-names>RB</given-names></name></person-group>
<article-title>Deficits in automatically detecting changes in conjunction of auditory features in patients with schizophrenia</article-title>. <source>Psychophysiology</source> (<year>2002</year>) <volume>39</volume>:<fpage>599</fpage>&#x02013;<lpage>606</lpage><pub-id pub-id-type="doi">10.1111/1469-8986.3950599</pub-id><pub-id pub-id-type="pmid">12236326</pub-id></mixed-citation></ref><ref id="B126"><label>126</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Devrim-Ucok</surname><given-names>M</given-names></name><name><surname>Keskin-Ergen</surname><given-names>HY</given-names></name><name><surname>Ucok</surname><given-names>A</given-names></name></person-group>
<article-title>Novelty P3 and P3b in first-episode schizophrenia and chronic schizophrenia</article-title>. <source>Prog Neuropsychopharmacol Biol Psychiatry</source> (<year>2006</year>) <volume>30</volume>:<fpage>1426</fpage>&#x02013;<lpage>34</lpage><pub-id pub-id-type="doi">10.1016/j.pnpbp.2006.05.019</pub-id><pub-id pub-id-type="pmid">16828218</pub-id></mixed-citation></ref><ref id="B127"><label>127</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grillon</surname><given-names>C</given-names></name><name><surname>Courchesne</surname><given-names>E</given-names></name><name><surname>Ameli</surname><given-names>R</given-names></name><name><surname>Geyer</surname><given-names>MA</given-names></name><name><surname>Braff</surname><given-names>DL</given-names></name></person-group>
<article-title>Increased distractibility in schizophrenic patients. Electrophysiologic and behavioral evidence</article-title>. <source>Arch Gen Psychiatry</source> (<year>1990</year>) <volume>47</volume>:<fpage>171</fpage>&#x02013;<lpage>9</lpage><pub-id pub-id-type="doi">10.1001/archpsyc.1990.01810140071010</pub-id><pub-id pub-id-type="pmid">2302027</pub-id></mixed-citation></ref><ref id="B128"><label>128</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Merrin</surname><given-names>EL</given-names></name><name><surname>Floyd</surname><given-names>TC</given-names></name></person-group>
<article-title>P300 responses to novel auditory stimuli in hospitalized schizophrenic patients</article-title>. <source>Biol Psychiatry</source> (<year>1994</year>) <volume>36</volume>:<fpage>527</fpage>&#x02013;<lpage>42</lpage><pub-id pub-id-type="doi">10.1016/0006-3223(94)90617-3</pub-id><pub-id pub-id-type="pmid">7827216</pub-id></mixed-citation></ref><ref id="B129"><label>129</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Daffner</surname><given-names>KR</given-names></name><name><surname>Mesulam</surname><given-names>MM</given-names></name><name><surname>Holcomb</surname><given-names>PJ</given-names></name><name><surname>Calvo</surname><given-names>V</given-names></name><name><surname>Acar</surname><given-names>D</given-names></name><name><surname>Chabrerie</surname><given-names>A</given-names></name><etal/></person-group>
<article-title>Disruption of attention to novel events after frontal lobe injury in humans</article-title>. <source>J Neurol Neurosurg Psychiatry</source> (<year>2000</year>) <volume>68</volume>:<fpage>18</fpage>&#x02013;<lpage>24</lpage><pub-id pub-id-type="doi">10.1136/jnnp.68.1.18</pub-id><pub-id pub-id-type="pmid">10601395</pub-id></mixed-citation></ref><ref id="B130"><label>130</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Daffner</surname><given-names>KR</given-names></name><name><surname>Mesulam</surname><given-names>MM</given-names></name><name><surname>Scinto</surname><given-names>LF</given-names></name><name><surname>Acar</surname><given-names>D</given-names></name><name><surname>Calvo</surname><given-names>V</given-names></name><name><surname>Faust</surname><given-names>R</given-names></name><etal/></person-group>
<article-title>The central role of the prefrontal cortex in directing attention to novel events</article-title>. <source>Brain</source> (<year>2000</year>) <volume>123</volume>(<issue>Pt 5</issue>):<fpage>927</fpage>&#x02013;<lpage>39</lpage><pub-id pub-id-type="doi">10.1093/brain/123.5.927</pub-id><pub-id pub-id-type="pmid">10775538</pub-id></mixed-citation></ref><ref id="B131"><label>131</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Woods</surname><given-names>DL</given-names></name><name><surname>Knight</surname><given-names>RT</given-names></name></person-group>
<article-title>Electrophysiologic evidence of increased distractibility after dorsolateral prefrontal lesions</article-title>. <source>Neurology</source> (<year>1986</year>) <volume>36</volume>:<fpage>212</fpage>&#x02013;<lpage>6</lpage><pub-id pub-id-type="doi">10.1212/WNL.36.2.212</pub-id><pub-id pub-id-type="pmid">3945393</pub-id></mixed-citation></ref><ref id="B132"><label>132</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anand</surname><given-names>A</given-names></name><name><surname>Charney</surname><given-names>DS</given-names></name><name><surname>Oren</surname><given-names>DA</given-names></name><name><surname>Berman</surname><given-names>RM</given-names></name><name><surname>Hu</surname><given-names>XS</given-names></name><name><surname>Cappiello</surname><given-names>A</given-names></name><etal/></person-group>
<article-title>Attenuation of the neuropsychiatric effects of ketamine with lamotrigine: support for hyperglutamatergic effects of N-methyl-D-aspartate receptor antagonists</article-title>. <source>Arch Gen Psychiatry</source> (<year>2000</year>) <volume>57</volume>:<fpage>270</fpage>&#x02013;<lpage>6</lpage><pub-id pub-id-type="doi">10.1001/archpsyc.57.3.270</pub-id><pub-id pub-id-type="pmid">10711913</pub-id></mixed-citation></ref><ref id="B133"><label>133</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krystal</surname><given-names>JH</given-names></name><name><surname>D&#x02019;Souza</surname><given-names>DC</given-names></name><name><surname>Karper</surname><given-names>LP</given-names></name><name><surname>Bennett</surname><given-names>A</given-names></name><name><surname>Abi-Dargham</surname><given-names>A</given-names></name><name><surname>Abi-Saab</surname><given-names>D</given-names></name><etal/></person-group>
<article-title>Interactive effects of subanesthetic ketamine and haloperidol in healthy humans</article-title>. <source>Psychopharmacology (Berl)</source> (<year>1999</year>) <volume>145</volume>:<fpage>193</fpage>&#x02013;<lpage>204</lpage><pub-id pub-id-type="doi">10.1007/s002130051049</pub-id><pub-id pub-id-type="pmid">10463321</pub-id></mixed-citation></ref><ref id="B134"><label>134</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krystal</surname><given-names>JH</given-names></name><name><surname>Karper</surname><given-names>LP</given-names></name><name><surname>Bennett</surname><given-names>A</given-names></name><name><surname>D&#x02019;Souza</surname><given-names>DC</given-names></name><name><surname>Abi-Dargham</surname><given-names>A</given-names></name><name><surname>Morrissey</surname><given-names>K</given-names></name><etal/></person-group>
<article-title>Interactive effects of subanesthetic ketamine and subhypnotic lorazepam in humans</article-title>. <source>Psychopharmacology (Berl)</source> (<year>1998</year>) <volume>135</volume>:<fpage>213</fpage>&#x02013;<lpage>29</lpage><pub-id pub-id-type="doi">10.1007/s002130050503</pub-id><pub-id pub-id-type="pmid">9498724</pub-id></mixed-citation></ref><ref id="B135"><label>135</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ernst</surname><given-names>M</given-names></name><name><surname>Heishman</surname><given-names>SJ</given-names></name><name><surname>Spurgeon</surname><given-names>L</given-names></name><name><surname>London</surname><given-names>ED</given-names></name></person-group>
<article-title>Smoking history and nicotine effects on cognitive performance</article-title>. <source>Neuropsychopharmacology</source> (<year>2001</year>) <volume>25</volume>:<fpage>313</fpage>&#x02013;<lpage>9</lpage><pub-id pub-id-type="doi">10.1016/S0893-133X(01)00257-3</pub-id><pub-id pub-id-type="pmid">11522460</pub-id></mixed-citation></ref><ref id="B136"><label>136</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lawrence</surname><given-names>NS</given-names></name><name><surname>Ross</surname><given-names>TJ</given-names></name><name><surname>Stein</surname><given-names>EA</given-names></name></person-group>
<article-title>Cognitive mechanisms of nicotine on visual attention</article-title>. <source>Neuron</source> (<year>2002</year>) <volume>36</volume>:<fpage>539</fpage>&#x02013;<lpage>48</lpage><pub-id pub-id-type="doi">10.1016/S0896-6273(02)01004-8</pub-id><pub-id pub-id-type="pmid">12408855</pub-id></mixed-citation></ref><ref id="B137"><label>137</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mancuso</surname><given-names>G</given-names></name><name><surname>Andres</surname><given-names>P</given-names></name><name><surname>Ansseau</surname><given-names>M</given-names></name><name><surname>Tirelli</surname><given-names>E</given-names></name></person-group>
<article-title>Effects of nicotine administered via a transdermal delivery system on vigilance: a repeated measure study</article-title>. <source>Psychopharmacology (Berl)</source> (<year>1999</year>) <volume>142</volume>:<fpage>18</fpage>&#x02013;<lpage>23</lpage><pub-id pub-id-type="doi">10.1007/s002130050857</pub-id><pub-id pub-id-type="pmid">10102778</pub-id></mixed-citation></ref><ref id="B138"><label>138</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McClernon</surname><given-names>FJ</given-names></name><name><surname>Gilbert</surname><given-names>DG</given-names></name><name><surname>Radtke</surname><given-names>R</given-names></name></person-group>
<article-title>Effects of transdermal nicotine on lateralized identification and memory interference</article-title>. <source>Hum Psychopharmacol</source> (<year>2003</year>) <volume>18</volume>:<fpage>339</fpage>&#x02013;<lpage>43</lpage><pub-id pub-id-type="doi">10.1002/hup.488</pub-id><pub-id pub-id-type="pmid">12858319</pub-id></mixed-citation></ref><ref id="B139"><label>139</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arendash</surname><given-names>GW</given-names></name><name><surname>Sanberg</surname><given-names>PR</given-names></name><name><surname>Sengstock</surname><given-names>GJ</given-names></name></person-group>
<article-title>Nicotine enhances the learning and memory of aged rats</article-title>. <source>Pharmacol Biochem Behav</source> (<year>1995</year>) <volume>52</volume>:<fpage>517</fpage>&#x02013;<lpage>23</lpage><pub-id pub-id-type="doi">10.1016/0091-3057(95)00119-H</pub-id><pub-id pub-id-type="pmid">8545468</pub-id></mixed-citation></ref><ref id="B140"><label>140</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Levin</surname><given-names>ED</given-names></name><name><surname>Simon</surname><given-names>BB</given-names></name></person-group>
<article-title>Nicotinic acetylcholine involvement in cognitive function in animals</article-title>. <source>Psychopharmacology (Berl)</source> (<year>1998</year>) <volume>138</volume>:<fpage>217</fpage>&#x02013;<lpage>30</lpage><pub-id pub-id-type="doi">10.1007/s002130050667</pub-id><pub-id pub-id-type="pmid">9725745</pub-id></mixed-citation></ref><ref id="B141"><label>141</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>D&#x02019;Souza</surname><given-names>DC</given-names></name><name><surname>Ahn</surname><given-names>K</given-names></name><name><surname>Bhakta</surname><given-names>S</given-names></name><name><surname>Elander</surname><given-names>J</given-names></name><name><surname>Singh</surname><given-names>N</given-names></name><name><surname>Nadim</surname><given-names>H</given-names></name><etal/></person-group>
<article-title>Nicotine fails to attenuate ketamine-induced cognitive deficits and negative and positive symptoms in humans: implications for schizophrenia</article-title>. <source>Biol Psychiatry</source> (<year>2012</year>) <volume>72</volume>:<fpage>785</fpage>&#x02013;<lpage>94</lpage><pub-id pub-id-type="doi">10.1016/j.biopsych.2012.05.009</pub-id><pub-id pub-id-type="pmid">22717030</pub-id></mixed-citation></ref></ref-list></back></article>